Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Influenza

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 1753 articles:
HTML format



Single Articles


    July 2024
  1. JIMENEZ-SEPULVEDA N, Gras-Valenti P, Chico-Sanchez P, Castro-Garcia JM, et al
    Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain.
    Vaccine. 2024;42:4011-4021.
    PubMed     Abstract available


  2. SANTIBANEZ TA, Black CL, Zhou T, Srivastav A, et al
    Parental hesitancy about COVID-19, influenza, HPV, and other childhood vaccines.
    Vaccine. 2024 Jul 16:S0264-410X(24)00802-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  3. LIU G, Pang Y, Lv M, Lu M, et al
    Effectiveness of influenza vaccination on hospitalization outcomes among older patients with diabetes.
    Vaccine. 2024 Jul 16:S0264-410X(24)00806-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  4. ERIKSSON M, Nylen S, Gronvik KO
    Passive immunization of mice with IgY anti-H5N1 protects against experimental influenza virus infection and allows development of protective immunity.
    Vaccine. 2024 Jul 16:S0264-410X(24)00796-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  5. LI J, Gong L, Li J, Gong Z, et al
    Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster.
    Vaccine. 2024;42:3751-3755.
    PubMed     Abstract available


  6. BANG JY, Kim YJ, Seo YJ, Hong SH, et al
    Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination.
    Vaccine. 2024 Jul 8:S0264-410X(24)00757-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  7. NOWALK MP, Smith KJ, Raviotta JM, Wateska A, et al
    Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18-64 years of age.
    Vaccine. 2024 Jul 5:S0264-410X(24)00748-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    June 2024
  8. COULIBALY D, Douba A, N'Guessan K, N'Gattia AK, et al
    Intent to receive flu vaccine and influenza vaccination coverage among health professionals during 2019, 2020 and 2021 campaigns in Cote d'Ivoire.
    Vaccine. 2024 Jun 25:S0264-410X(24)00717-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  9. YOO YM, Katz MA, Greenberg D, Marcenac P, et al
    Knowledge, attitudes, and practices associated with influenza vaccine uptake among healthcare personnel in Israel during three influenza seasons, 2016-2019.
    Vaccine. 2024 Jun 25:S0264-410X(24)00705-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  10. CHATZILENA A, Hyams C, Challen R, Marlow R, et al
    Winter 2022-23 influenza vaccine effectiveness against influenza-related hospitalised aLRTD: A test-negative, case-control study.
    Vaccine. 2024 Jun 24:S0264-410X(24)00713-8. doi: 10.1016/j.vaccine.2024.
    PubMed    


  11. LE GARS M, Sadoff J, Cardenas V, Heerwegh D, et al
    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.
    Vaccine. 2024 Jun 24:S0264-410X(24)00401-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  12. MCDERMID P, Abdi I, Mustafa K, Blazek K, et al
    Examining the influence of community leaders and other community actors on immunisation practices in Australia: A national cross-sectional study.
    Vaccine. 2024;42:3647-3654.
    PubMed     Abstract available


  13. CHENG TM, Chen YS, Wei KC, Chang YC, et al
    Assessment of the herpes zoster risk among renal transplant recipients administered the influenza vaccine.
    Vaccine. 2024 Jun 18:S0264-410X(24)00716-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  14. CARDENAS V, Le Gars M, Truyers C, Ruiz-Guinazu J, et al
    Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
    Vaccine. 2024;42:3536-3546.
    PubMed     Abstract available


  15. GOBIN S, Sahakyan G, Kusi Appiah M, Manukyan A, et al
    Costs of in- and outpatient respiratory disease and the seasonal influenza vaccination program in Armenia - 2020-2021.
    Vaccine. 2024 Jun 4:S0264-410X(24)00623-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  16. LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al
    Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
    Vaccine. 2024 Jun 4:S0264-410X(24)00644-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  17. FENG J, Du Y, Chen L, Su W, et al
    A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models.
    Vaccine. 2024 Jun 3:S0264-410X(24)00624-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    May 2024
  18. KUPEK E
    Avoidable COVID-19-related deaths and hospitalizations in Brazil, 2020-2023.
    Vaccine. 2024;42:3437-3444.
    PubMed     Abstract available


  19. MARANTOS T, Kyriazopoulou E, Angelakis E, Kitsos D, et al
    Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: A single-center prospective study.
    Vaccine. 2024 May 24:S0264-410X(24)00617-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  20. BAK J, Hasan Q, Kissa J, Mere MO, et al
    Deployment of COVID-19 vaccine in the WHO Eastern Mediterranean Region 2021-23: How do we switch to a life course approach?
    Vaccine. 2024 May 24:S0264-410X(24)00560-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  21. BENEDICT KPOZEHOUEN E, Raina Macintyre C, Tan TC
    Coverage of influenza, pneumococcal and zoster vaccination and determinants of influenza and pneumococcal vaccination among adults with cardiovascular diseases in community.
    Vaccine. 2024 May 23:S0264-410X(24)00619-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  22. EIBERG MF, Rezahosseini O, Bukan KB, Charlotte Arp B, et al
    Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis.
    Vaccine. 2024 May 23:S0264-410X(24)00566-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  23. CARNALLA M, Stern D, Arantxa Colchero M, Rangel-Moreno K, et al
    Who is getting COVID-19 boosters? A latent class analysis in a nationally representative sample of Mexican adults 60 years and over.
    Vaccine. 2024;42:3273-3276.
    PubMed     Abstract available


  24. RAMOS-DUARTE VA, Orlowski A, Jaquenod de Giusti C, Corigliano MG, et al
    Safe plant Hsp90 adjuvants elicit an effective immune response against SARS-CoV2-derived RBD antigen.
    Vaccine. 2024;42:3355-3364.
    PubMed     Abstract available


  25. ZHANG WX, Zhang Y, Du J, Shi W, et al
    Effectiveness of momentary intervention on influenza vaccination among the elderly in China: From willingness to action.
    Vaccine. 2024 May 22:S0264-410X(24)00591-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  26. PROSPER P, Rodriguez Puertas R, Guerin DMA, Branda MM, et al
    Computational method for designing vaccines applied to virus-like particles (VLPs) as epitope carriers.
    Vaccine. 2024 May 22:S0264-410X(24)00584-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  27. ZHOU H, Zhao W, Ma R, Zheng Y, et al
    Mixed methods examination of risk perception on vaccination intentions: The perspective of doctor-patient communication.
    Vaccine. 2024 May 22:S0264-410X(24)00565-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  28. VAN DER PLAS JL, Haijema BJ, Leenhouts K, Paul Zoeteweij J, et al
    Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM): A randomized, double-blind, controlled, ascending dose study in healthy adults and elderly.
    Vaccine. 2024 May 20:S0264-410X(24)00370-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  29. KARIMI-SHAHRBABAK E, Di Chiara C, Farrar DS, Abu Fadaleh SM, et al
    COVID-19 vaccine acceptance and uptake among caregivers of children aged 5-11?years in Ontario, Canada: A cross-sectional survey.
    Vaccine. 2024 May 20:S0264-410X(24)00553-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  30. YANG T, Tong F, Tang L, Li P, et al
    Repeated vaccination does not appear to significantly weaken the protective effect of influenza vaccine in the elderly: A test-negative case-control study in China.
    Vaccine. 2024 May 17:S0264-410X(24)00593-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  31. ANN COSTA CLEMENS S, Weckx L, Milan EP, Smolenov I, et al
    Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice.
    Vaccine. 2024 May 17:S0264-410X(24)00555-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  32. URQUIDI C, Sepulveda-Penaloza A, Valenzuela MT, Ponce A, et al
    Vaccine effectiveness in reducing COVID-19-related hospitalization after a risk-age-based mass vaccination program in a Chilean municipality: A comparison of observational study designs.
    Vaccine. 2024 May 14:S0264-410X(24)00538-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  33. MUANGNOICHAROEN S, Wiangcharoen R, Lawpoolsri S, Nanthapisal S, et al
    Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
    Vaccine. 2024 May 13:S0264-410X(24)00556-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  34. EJNAR HANSEN M, David Pickering S
    The role of religion and COVID-19 vaccine uptake in England.
    Vaccine. 2024;42:3215-3219.
    PubMed     Abstract available


  35. DINH THIEM V, Van Anh PT, Van Men C, Hung DT, et al
    A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial.
    Vaccine. 2024 May 10:S0264-410X(24)00523-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  36. MALTEZOU HC, Gamaletsou MN, Giannouchos TV, Koukou DM, et al
    Effectiveness of COVID-19 booster vaccination, morbidity and absenteeism among healthcare personnel during the 2022-2023 season dominated by Omicron BA.5 and BA.2 subvariants.
    Vaccine. 2024 May 9:S0264-410X(24)00522-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  37. SHANI M, Hermesh I, Feldhamer I, Reges O, et al
    The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities.
    Vaccine. 2024 May 9:S0264-410X(24)00536-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  38. LEE KY, Song KH, Lee KH, Baek JY, et al
    Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection.
    Vaccine. 2024 May 9:S0264-410X(24)00539-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  39. KIM DH, Lee SH, Kim J, Lee J, et al
    Efficacy of live and inactivated recombinant Newcastle disease virus vaccines expressing clade 2.3.4.4b H5 hemagglutinin against H5N1 highly pathogenic avian influenza in SPF chickens, Broilers, and domestic ducks.
    Vaccine. 2024 May 8:S0264-410X(24)00527-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  40. KIM J, Chang J
    Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2.
    Vaccine. 2024 May 6:S0264-410X(24)00481-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  41. CAO A, Ueta M, Uchibori M, Murakami M, et al
    Trust in governments, public health institutions, and other information sources as determinants of COVID-19 vaccine uptake behavior in Japan.
    Vaccine. 2024 May 6:S0264-410X(24)00520-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  42. JEARANAIWITAYAKUL T, Sunintaboon P, Kittiayuwat A, Limthongkul J, et al
    Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development.
    Vaccine. 2024 May 6:S0264-410X(24)00519-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  43. SOE P, Wong H, Naus M, Muller MP, et al
    mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network.
    Vaccine. 2024 May 6:S0264-410X(24)00535-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  44. SHI XC, Gruber JF, Ondari M, Lloyd PC, et al
    Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older.
    Vaccine. 2024 May 3:S0264-410X(24)00478-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  45. MAUREL M, Mazagatos C, Goerlitz L, Oroszi B, et al
    Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe.
    Vaccine. 2024 May 3:S0264-410X(24)00497-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  46. BENEDICT KPOZEHOUEN E, Macintyre CR, Tan TC
    Determinants of uptake of influenza, zoster and pneumococcal vaccines in patients with cardiovascular diseases.
    Vaccine. 2024 May 3:S0264-410X(24)00445-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  47. HU H, Ma F, Gong L, Wang Y, et al
    Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults.
    Vaccine. 2024 May 3:S0264-410X(24)00495-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  48. ADINUGROHO I, Stafford T, Bentall RP
    The correlation between conspiracy mentality and vaccine intentions is moderated by social events: Evidence from longitudinal data during COVID-19 pandemic in the UK.
    Vaccine. 2024 May 3:S0264-410X(24)00510-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  49. CHRISTOU-ERGOS M, Bleicher K, Leask J
    Factors associated with vaccination intention and uptake over time in a sample of older Australians.
    Vaccine. 2024 May 3:S0264-410X(24)00508-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  50. BAGLIVO F, De Angelis L, Magri M, De Nicola I, et al
    The impact of COVID-19 vaccination campaign on pediatric vaccine uptake based on parents' attitudes towards mandatory and recommended vaccination in Southern Italy.
    Vaccine. 2024 May 3:S0264-410X(24)00513-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  51. MARINTHE G, Brown G, Cristea M, Kutlaca M, et al
    Predicting vaccination hesitancy: The role of basic needs satisfaction and institutional trust.
    Vaccine. 2024 May 3:S0264-410X(24)00507-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  52. EHRLICH KB, Lyle SM, Corallo KL, Lavner JA, et al
    Changes in depressive symptoms and antibody production following influenza vaccination in adolescents and adults.
    Vaccine. 2024 May 2:S0264-410X(24)00505-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    April 2024
  53. FLEARY SA, Shahn Z, Teasdale CA
    Effects of parental childhood cultural health environment on children's influenza and COVID-19 vaccination status.
    Vaccine. 2024 Apr 29:S0264-410X(24)00515-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  54. NIESSEN FA, Bruijning-Verhagen PCJL, Bonten MJM, Knol MJ, et al
    Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands by medical risk condition: A test-negative case-control study.
    Vaccine. 2024 Apr 29:S0264-410X(24)00432-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  55. GUDOORU K, Nguyen K, Le K, Sarabu V, et al
    Collective good and individual choice: Perceptions on COVID-19 vaccine mandate among COVID-19 vaccinated individuals.
    Vaccine. 2024 Apr 27:S0264-410X(24)00479-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  56. DORJEE K, Namdon T, Topgyal S, Gyatso U, et al
    Association between Covishield vaccine and menstrual disturbance. Findings from a cross-sectional study among participants of Zero TB cohort in India.
    Vaccine. 2024 Apr 27:S0264-410X(24)00500-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  57. LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al
    Authors' reply: Excess mortality in Cyprus during the COVID-19 vaccination campaign.
    Vaccine. 2024 Apr 25:S0264-410X(24)00506-1. doi: 10.1016/j.vaccine.2024.
    PubMed    


  58. XIE Z, Stallings-Smith S, Patel S, Case S, et al
    COVID-19 booster vaccine uptake and reduced risks for long-COVID: A cross-sectional study of a U.S. adult population.
    Vaccine. 2024 Apr 25:S0264-410X(24)00509-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  59. FUJITA DM, da Silva Nali LH, da Costa RR, de Andrade Junior HF, et al
    Low vaccine coverage and varicella outbreaks in Brazil - 2019-2022.
    Vaccine. 2024 Apr 24:S0264-410X(24)00435-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  60. SELLIES AJ, Knol MJ, de Melker HE, Bruijning-Verhagen PCJL, et al
    Non-specific effects of the inactivated influenza vaccine. A test-negative study: The inactivated influenza vaccine and SARS-CoV-2 infections.
    Vaccine. 2024 Apr 23:S0264-410X(24)00468-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  61. SONG S, Madewell ZJ, Liu M, Miao Y, et al
    A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants.
    Vaccine. 2024 Apr 22:S0264-410X(24)00476-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  62. MUSA S, Merdrignac L, Skocibusic S, Nedic R, et al
    BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study.
    Vaccine. 2024 Apr 20:S0264-410X(24)00471-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  63. LIEVRE G, Sicsic J, Galmiche S, Charmet T, et al
    Are the 7C psychological antecedents associated with COVID-19 vaccine behaviours beyond intentions? A cross-sectional study on at-least-one-dose and up-to-date vaccination status, and uptake speed among adults in France.
    Vaccine. 2024 Apr 19:S0264-410X(24)00438-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  64. INGRAO F, Ngabirano E, Rauw F, Dauphin G, et al
    Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken.
    Vaccine. 2024 Apr 18:S0264-410X(24)00452-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  65. WON H, Kim JA, Jeong NY, Choi NK, et al
    Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly.
    Vaccine. 2024 Apr 18:S0264-410X(24)00400-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  66. RICKE IJ, Spaulding AB, Rajtar NN, Benton EM, et al
    Predictors of willingness to receive updated 2023-2024 COVID-19 booster vaccines among a convenience sample in Minnesota.
    Vaccine. 2024 Apr 18:S0264-410X(24)00480-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  67. ORANGZEB S, Desalegn A, Trinh NTH, Zhao J, et al
    COVID-19 vaccine uptake among children and adolescents in Norway: A comprehensive registry-based cohort study of over 800,000 individuals.
    Vaccine. 2024 Apr 18:S0264-410X(24)00464-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  68. TRINITE B, Durr E, Pons-Grifols A, O'Donnell G, et al
    VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
    Vaccine. 2024 Apr 18:S0264-410X(24)00473-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  69. VAN DER POL S, Zeevat F, Postma MJ, Boersma C, et al
    Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations.
    Vaccine. 2024 Apr 17:S0264-410X(24)00465-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  70. PEREIRA ET, Iasulaitis S, Greco BC
    Analysis of causal relations between vaccine hesitancy for COVID-19 vaccines and ideological orientations in Brazil.
    Vaccine. 2024 Apr 16:S0264-410X(24)00436-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  71. LEE N, Hong Y, Kirkpatrick CE, Hu S, et al
    COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants.
    Vaccine. 2024 Apr 16:S0264-410X(24)00402-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  72. DEAL A, Crawshaw AF, Salloum M, Hayward SE, et al
    Understanding the views of adult migrants around catch-up vaccination for missed routine immunisations to define strategies to improve coverage: A UK in-depth interview study.
    Vaccine. 2024 Apr 16:S0264-410X(24)00406-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  73. MARTINEZ JL, Lemus N, Lai TY, Mishra M, et al
    The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex.
    Vaccine. 2024 Apr 15:S0264-410X(24)00451-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  74. MELNIKOW J, Padovani A, Zhang J, Miller M, et al
    Patient concerns and physician strategies for addressing COVID-19 vaccine hesitancy.
    Vaccine. 2024 Apr 15:S0264-410X(24)00437-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  75. WONG IOL, Wong C, Mak N, Dai A, et al
    Assessment of the impact of the vaccine pass policy on COVID-19 vaccine hesitancy and uptake among Chinese adults in Hong Kong.
    Vaccine. 2024 Apr 15:S0264-410X(24)00449-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  76. BAKER J, Aliabadi N, Munjal I, Jiang Q, et al
    Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
    Vaccine. 2024 Apr 13:S0264-410X(24)00387-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  77. SUKIK L, Chemaitelly H, Ayoub HH, Coyle P, et al
    Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient.
    Vaccine. 2024 Apr 13:S0264-410X(24)00440-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  78. NOLAN MB, Chrenka E, Walker P, Steiner A, et al
    COVID-19 vaccine uptake among non-US-born populations in the United States, 2020-2022.
    Vaccine. 2024 Apr 11:S0264-410X(24)00443-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  79. KAINTH MK, Sembajwe GN, Ahn H, Qian M, et al
    Despite mandated primary series, health care personnel still hesitant about COVID-19 vaccine and immunizing children.
    Vaccine. 2024 Apr 11:S0264-410X(24)00442-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  80. LEE JS, Choi H, Shin SH, Hwang MJ, et al
    Characterization of Brighton Collaboration criteria for myocarditis and pericarditis following COVID-19 vaccine in Korean adolescents.
    Vaccine. 2024 Apr 11:S0264-410X(24)00446-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  81. PITTS PJ, Poland GA
    Addressing vaccine hesitancy: Learning from the successes and failures of the COVID-19 pandemic.
    Vaccine. 2024 Apr 10:S0264-410X(24)00396-7. doi: 10.1016/j.vaccine.2024.
    PubMed    


  82. AKMATOVA R, Ebama MS, Temirbekov S, Alymkulova V, et al
    A comparative analysis of knowledge, attitude, and practice (KAP) towards influenza and influenza vaccination among healthcare workers in Kyrgyzstan prior to and during the COVID-19 pandemic.
    Vaccine. 2024 Apr 9:S0264-410X(24)00420-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  83. THAI H, Audet EC, Koestner R
    Motivation for COVID-19 Vaccination: Applying a Self-Determination Theory Perspective to a Global Health Crisis.
    Vaccine. 2024 Apr 9:S0264-410X(24)00439-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available



  84. Immunization agenda 2030: A global strategy to leave no one behind.
    Vaccine. 2024;42 Suppl 1:S5-S14.
    PubMed    


  85. ZHU J, Cole CB, Fihman J, Adjagba A, et al
    Opportunities to accelerate immunization progress in middle-income countries.
    Vaccine. 2024;42 Suppl 1:S98-S106.
    PubMed     Abstract available


  86. BLANC DC, Grundy J, Sodha SV, O'Connell TS, et al
    Immunization programs to support primary health care and achieve universal health coverage.
    Vaccine. 2024;42 Suppl 1:S38-S42.
    PubMed     Abstract available


  87. SAXENIAN H, Alkenbrack S, Freitas Attaran M, Barcarolo J, et al
    Sustainable financing for Immunization Agenda 2030.
    Vaccine. 2024;42 Suppl 1:S73-S81.
    PubMed     Abstract available


  88. CERNUSCHI T, Malvolti S, Hall S, Debruyne L, et al
    The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.
    Vaccine. 2024;42 Suppl 1:S64-S72.
    PubMed     Abstract available


  89. CHARD AN, Machingaidze C, Loayza S, Gharpure R, et al
    Estimating averted illnesses from influenza vaccination for children and pregnant women - El Salvador, Panama, and Peru, 2011-2018.
    Vaccine. 2024 Apr 6:S0264-410X(24)00419-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  90. ARCHER H, McCoy SI, Sears D, Kwan A, et al
    Indirect vaccine effectiveness in an outbreak of Alpha B.1.1.7 variant in a California state Prison, May 2021.
    Vaccine. 2024 Apr 6:S0264-410X(24)00368-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  91. SCHULTZE A, Martin I, Messina D, Bots S, et al
    A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases.
    Vaccine. 2024 Apr 5:S0264-410X(24)00330-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  92. BAUM HE, Thirard R, Halliday A, Baos S, et al
    Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial.
    Vaccine. 2024 Apr 4:S0264-410X(24)00367-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  93. NURDIN A, Movieta Nency Y, Maddeppungeng M, Sekartini R, et al
    Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial.
    Vaccine. 2024 Apr 3:S0264-410X(24)00399-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  94. WU CY, Kao SE, Tseng YC, Hou JT, et al
    Pilot-scale production of a highly efficacious and stable monoglycosylated influenza split virus vaccine.
    Vaccine. 2024;42:2220-2228.
    PubMed     Abstract available


  95. LASRADO N, Rossler A, Rowe M, Collier AY, et al
    Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1.
    Vaccine. 2024;42:2117-2121.
    PubMed     Abstract available


    March 2024
  96. GONG JD, Barnboym E, O'Mara M, Gurevich N, et al
    Self-reported determinants of COVID-19 vaccine acceptance among persons with and without autoimmune disease.
    Vaccine. 2024 Mar 30:S0264-410X(24)00373-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  97. MALTEZOU HC, Kontogianni S, Michailidou E, Vergadi E, et al
    Effectiveness of COVID-19 vaccination against school absenteeism in children and adolescents hospitalized with COVID-19.
    Vaccine. 2024 Mar 30:S0264-410X(24)00397-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  98. HUF SW, Grailey K, Crespo RF, Woldmann L, et al
    Testing the impact of differing behavioural science informed text message content in COVID-19 vaccination invitations on vaccine uptake: A randomised clinical trial.
    Vaccine. 2024 Mar 28:S0264-410X(24)00365-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  99. DALEY MF, Reifler LM, Shoup JA, Glanz JM, et al
    Influenza vaccination accuracy among adults: Self-report compared with electronic health record data.
    Vaccine. 2024 Mar 25:S0264-410X(24)00339-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  100. BIEGUS J, Szenborn L, Zymlinski R, Zakliczynski M, et al
    The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure.
    Vaccine. 2024 Mar 25:S0264-410X(24)00366-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  101. VOLKMANN AM, Goldin S, McMurren B, Gapare C, et al
    Leveraging seasonal influenza health worker vaccination programmes for COVID-19 vaccine Introduction: A global qualitative analysis.
    Vaccine. 2024 Mar 25:S0264-410X(23)01490-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  102. MORGAN G, Casalino S, Chowdhary S, Frangione E, et al
    COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00317-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  103. CONDIE J, Northstone K, Major-Smith D, Halstead I, et al
    Exploring associations between the Big Five personality traits and cognitive ability with COVID-19 vaccination hesitancy and uptake among mothers and offspring in a UK prospective cohort study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00305-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  104. KLUWER B, Gleditsch R, Rydland KM, Mamelund SE, et al
    Higher educational attainment associated with higher confidence in influenza vaccination in Norway.
    Vaccine. 2024 Mar 21:S0264-410X(24)00338-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  105. PRICE O, Dietze P, Maher L, Dore GJ, et al
    High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs.
    Vaccine. 2024 Mar 21:S0264-410X(24)00337-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  106. MOFFETT KW, Seserman K, Margolis KA, Kranzler EC, et al
    Differences in social media use by COVID-19 vaccination status.
    Vaccine. 2024 Mar 20:S0264-410X(24)00318-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  107. SASI A, Dandotiya J, Kaushal J, Ganguly S, et al
    Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort study.
    Vaccine. 2024 Mar 20:S0264-410X(24)00329-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  108. HILL-BATORSKI L, Bowen R, Bielefeldt-Ohmann H, Moser MJ, et al
    Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge.
    Vaccine. 2024 Mar 19:S0264-410X(24)00327-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  109. KRASILNIKOV I, Isaev A, Djonovic M, Ivanov A, et al
    Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity.
    Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  110. LLOYD PC, Lufkin B, Moll K, Ogilvie RP, et al
    Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020.
    Vaccine. 2024;42:2004-2010.
    PubMed     Abstract available


  111. LANG JC, Kura K, Garba SM, Elbasha EH, et al
    Comparison of a static cohort model and dynamic transmission model for respiratory syncytial virus intervention programs for infants in England and Wales.
    Vaccine. 2024;42:1918-1927.
    PubMed     Abstract available


  112. SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y, et al
    CHO cells for virus-like particle and subunit vaccine manufacturing.
    Vaccine. 2024 Mar 18:S0264-410X(24)00321-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  113. CAMPAGNA R, Dominelli F, Zingaropoli MA, Ciurluini F, et al
    COVID-19 vaccination in cancer patients: Immune responses one year after the third dose.
    Vaccine. 2024 Mar 17:S0264-410X(24)00304-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  114. FIX J, Christopher Mast T, Smith K, Baker N, et al
    Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
    Vaccine. 2024 Mar 16:S0264-410X(24)00323-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  115. COTTON SA, Subramanian A, Hughes TD, Huang Y, et al
    The effect of SARS-COV-2 variant on non-respiratory features and mortality among vaccinated and non-fully vaccinated patients.
    Vaccine. 2024 Mar 14:S0264-410X(24)00195-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  116. CAMERON DB, Grage L, Van Wyck R, Edwards A, et al
    Identifying trusted local sources and predicting behavior change pathways according to COVID-19 vaccination status: Results of a 2022 statewide survey of Alaskan adults.
    Vaccine. 2024 Mar 14:S0264-410X(24)00314-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  117. EL SALIBI N, Abdulrahim S, El Haddad M, Abi Zeid B, et al
    Predicting intention to vaccinate against COVID-19 in older Syrian refugees in Lebanon: Findings from a multi-wave study.
    Vaccine. 2024 Mar 13:S0264-410X(24)00213-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  118. MCCOSKER LK, Ware RS, Seale H, Hooshmand D, et al
    The effect of a financial incentive on COVID-19 vaccination uptake, and predictors of uptake, in people experiencing homelessness: A randomized controlled trial.
    Vaccine. 2024 Mar 13:S0264-410X(24)00307-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  119. RUSS S, Myers C, Licherdell E, Bowden A, et al
    Sociodemographic and Occupational Characteristics Associated with Early and Continued COVID-19 Vaccine Uptake Among Healthcare Personnel: Monroe County, NY.
    Vaccine. 2024 Mar 12:S0264-410X(24)00306-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  120. SHIJIA YAN A, Jay Sehgal N
    Partisan divide and Racial/Ethnic disparities in COVID-19 vaccine hesitancy among Parents/Guardians and vaccine uptake among children in the U.S.
    Vaccine. 2024 Mar 11:S0264-410X(24)00309-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  121. MORO PL, Carlock G, Fifadara N, Habenicht T, et al
    Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
    Vaccine. 2024 Mar 9:S0264-410X(24)00262-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  122. LUISI M, Geana MV, Pei J
    Pandemic antecedents - Exploring predictivity and relationships between COVID-19 vaccine uptake and influenza, shingles, and HPV vaccination.
    Vaccine. 2024 Mar 8:S0264-410X(24)00275-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  123. ST-LOUIS P, Martin C, Khatri V, Bourgault S, et al
    Intranasal delivery of a self-adjuvanted nanovaccine composed of the curli filaments and the highly conserved M2e epitope confers protection against influenza a virus in mice.
    Vaccine. 2024 Mar 8:S0264-410X(24)00222-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  124. SU YW, Qiu YZ, Wang YH, Xu Y, et al
    Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
    Vaccine. 2024 Mar 8:S0264-410X(24)00277-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available



  125. Expression of Concern: "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine [33/1], 1 January 2015, Pages 108-116].
    Vaccine. 2024;42:1851.
    PubMed    


  126. MENG L, Harris L, Shaw L, Lymon H, et al
    Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged >/= 12 years, United States, August 2021-October 2
    Vaccine. 2024 Mar 6:S0264-410X(24)00271-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  127. KARRAS J, Harrison M, Steffens M, Abdi I, et al
    "COVID is a huge jigsaw puzzle that I am trying to make sense of myself": Exploring the perceptions towards the COVID-19 vaccine communication strategy in Australia amongst unvaccinated Australian adults.
    Vaccine. 2024 Mar 6:S0264-410X(24)00276-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  128. WONG WHS, Leung DL, Yip KM, So HK, et al
    Effectiveness of inactivated COVID-19 vaccine CoronaVac in children aged less than 3 years old during Omicron wave in Hong Kong.
    Vaccine. 2024 Mar 6:S0264-410X(24)00226-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  129. RAETHKE M, van Hunsel F, Luxi N, Lieber T, et al
    Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study.
    Vaccine. 2024 Mar 6:S0264-410X(24)00273-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  130. CHEN D, Cowling BJ, Ainslie KEC, Lin Y, et al
    Association of COVID-19 vaccination with duration of hospitalization in older adults in Hong Kong.
    Vaccine. 2024 Mar 5:S0264-410X(24)00252-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  131. YASHAR-GERSHMAN SG, Rosenberg AT, Sawhney M, Fernanda Machicao M, et al
    Developing a novel screening tool to address pediatric COVID-19 vaccine hesitancy at point of care.
    Vaccine. 2024 Mar 1:S0264-410X(24)00228-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    February 2024
  132. YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
    Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial.
    Vaccine. 2024 Feb 29:S0264-410X(24)00249-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  133. KOHLI M, Maschio M, Lee A, Igarashi A, et al
    Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine.
    Vaccine. 2024 Feb 29:S0264-410X(24)00117-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  134. GUO J, Chen X, Guo Y, Liu M, et al
    Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies.
    Vaccine. 2024 Feb 28:S0264-410X(24)00218-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  135. MARINDA E, Mathentamo Q, Coulson N, Parker S, et al
    Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake in Kwazulu-Natal, South Africa.
    Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  136. YANG XY, Liu T, Jiang SC, Zhang ZW, et al
    Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human muscle cells and neuroglial cells.
    Vaccine. 2024;42:1259-1267.
    PubMed     Abstract available


  137. JABBAR F, Kadhim KA, Alhilfi RA, Chitheer A, et al
    Intensification of integrated immunization services to recover routine vaccination coverage and bring COVID-19 vaccine to the population of Iraq in 2022.
    Vaccine. 2024 Feb 27:S0264-410X(24)00197-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  138. KRISTINSDOTTIR I, Haraldsson A, Thors V
    Influenza vaccination in pregnant women in Iceland 2010-2020 and the burden of influenza in pregnant women and their infants.
    Vaccine. 2024 Feb 26:S0264-410X(24)00205-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  139. MUNDO ORTIZ A, Nasri B
    Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring differences across the Health Region model.
    Vaccine. 2024 Feb 26:S0264-410X(24)00204-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  140. NEWALL AT, Nazareno AL, Muscatello DJ, Boettiger D, et al
    The association between influenza vaccination uptake and influenza and pneumonia-associated deaths in the United States.
    Vaccine. 2024 Feb 24:S0264-410X(24)00113-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  141. MURPHY C, Kwan MYW, Chan ELY, Wong JSC, et al
    Influenza vaccine effectiveness against hospitalizations associated with influenza A(H3N2) in Hong Kong children aged 9 months to 17 years, June-November 2023.
    Vaccine. 2024 Feb 22:S0264-410X(24)00215-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  142. SHETTY AN, Morgan HJ, Phuong LK, Mallard J, et al
    Audiovestibular adverse events following COVID-19 vaccinations.
    Vaccine. 2024 Feb 22:S0264-410X(24)00210-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  143. XU S, Sy LS, Hong V, Farrington P, et al
    Mortality risk after COVID-19 vaccination: A self-controlled case series study.
    Vaccine. 2024 Feb 21:S0264-410X(24)00191-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  144. SHOUKAT A, Bawden CE, Rost G, LeBlanc JJ, et al
    Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2024 Feb 16:S0264-410X(24)00200-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  145. CHERRY N, Adisesh A, Burstyn I, Charlton C, et al
    Determinants of SARS-CoV-2 IgG response and decay in Canadian healthcare workers: A prospective cohort study.
    Vaccine. 2024;42:1168-1178.
    PubMed     Abstract available


  146. JIN F, Qiu Y, Wu Z, Wang YH, et al
    Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.
    Vaccine. 2024 Feb 15:S0264-410X(24)00124-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  147. MZIOU E, Hchaichi A, Letaief H, Dhaouadi S, et al
    Vaccine effectiveness against COVID-19: A test negative case-control study in Tunisia, August 2021.
    Vaccine. 2024 Feb 15:S0264-410X(24)00174-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  148. ROCKSON ADJEI M, Longsignikuu A, Saeed Iddris I, Nang Suuri T, et al
    Trend of measles-rubella vaccination coverage and impact on measles epidemiology in the Savannah Region, Ghana; 2018-2022: A secondary data analysis.
    Vaccine. 2024 Feb 15:S0264-410X(24)00170-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  149. KIM HK, Park SK, Choe SA, Gwak ES, et al
    Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean Adults: A population-based observational study.
    Vaccine. 2024 Feb 15:S0264-410X(24)00168-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  150. KUTER BJ, Brien K, Anderson S, Bass SB, et al
    COVID-19 vaccine perspectives and uptake among university students three years into the pandemic.
    Vaccine. 2024 Feb 15:S0264-410X(24)00162-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  151. OKOLI GN, Righolt CH, Zhang G, Van Caeseele P, et al
    A population-based, province-wide, record-linkage interrupted time series analysis of impact of the universal seasonal influenza vaccination policy on seasonal influenza vaccine uptake among 5-64-year-olds in the province of Manitoba, Canada.
    Vaccine. 2024 Feb 14:S0264-410X(24)00104-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  152. BATHEJA A, Balkrishnan R
    Rhode Island as a model for promoting flu vaccination in the United States.
    Vaccine. 2024 Feb 14:S0264-410X(24)00161-0. doi: 10.1016/j.vaccine.2024.
    PubMed    


  153. KLASSEN AC, Lee G, Chiang S, Murray R, et al
    Did the COVID-19 experience change U.S. parents' attitudes towards HPV vaccination? Results from a national survey.
    Vaccine. 2024 Feb 14:S0264-410X(24)00142-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  154. DONATO F, Pilotto A, Foca E, Tresoldi M, et al
    The impact of time since SARS-Cov-2 vaccination, age, sex and comorbidities on COVID-19 outcome in hospitalized patients with SARS-CoV-2 infection.
    Vaccine. 2024 Feb 13:S0264-410X(24)00147-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  155. HEARN EB, Kehinde G, Sambamoorthi U
    Food insecurity and COVID-19 vaccine hesitancy among adults in the United States (US).
    Vaccine. 2024 Feb 13:S0264-410X(24)00102-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  156. AMDISEN L, Pedersen L, Abildgaard N, Benn CS, et al
    The coverage of influenza vaccination and predictors of influenza non-vaccination in Danish cancer patients: A nationwide register-based cohort study.
    Vaccine. 2024 Feb 12:S0264-410X(24)00155-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  157. VALENTIN J, Ingrao F, Rauw F, Lambrecht B, et al
    Protection conferred by an H5 DNA vaccine against highly pathogenic avian influenza in chickens: The effect of vaccination schedules.
    Vaccine. 2024 Feb 12:S0264-410X(23)01422-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  158. MORGAN HJ, Clothier HJ, Sepulveda Kattan G, Boyd JH, et al
    Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination - A self-controlled case series analysis.
    Vaccine. 2024 Feb 12:S0264-410X(24)00126-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  159. FAKSOVA K, Walsh D, Jiang Y, Griffin J, et al
    COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
    Vaccine. 2024 Feb 12:S0264-410X(24)00127-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  160. WHITAKER HJ, Hassell K, Hoschler K, Power L, et al
    Influenza vaccination during the 2021/22 season: A data-linkage test-negative case-control study of effectiveness against influenza requiring emergency care in England and serological analysis of primary care patients.
    Vaccine. 2024 Feb 10:S0264-410X(24)00150-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  161. LIJESKIC O, Bauman N, Markovic M, Srbljanovic J, et al
    SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Vaccine. 2024 Feb 10:S0264-410X(24)00110-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  162. WEI J, Tan TC, Moa AM, MacIntyre CR, et al
    Cost-benefit of influenza vaccination in preventing sudden cardiac arrest amongst Australian adults.
    Vaccine. 2024 Feb 9:S0264-410X(24)00154-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  163. BUEKENS P, Berrueta M, Ciapponi A, Bardach A, et al
    Safe in pregnancy: A global living systematic review and meta-analysis of COVID-19 vaccines in pregnancy.
    Vaccine. 2024 Feb 9:S0264-410X(24)00158-0. doi: 10.1016/j.vaccine.2024.
    PubMed    


  164. WADAPURKAR R, Singh S, Singh A
    Leveraging the immunoinformatics approach for designing the SARS-CoV-2 omicron-specific antigenic cassette of mRNA vaccine.
    Vaccine. 2024 Feb 8:S0264-410X(24)00111-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  165. RANDELL M, Sheel M, Dynes M, Li M, et al
    Influence of the COVID-19 pandemic on caregiver beliefs and experiences of routine childhood immunisation in Indonesia.
    Vaccine. 2024;42:812-818.
    PubMed     Abstract available


  166. KOLANDAI K, Milne B, von Randow M, Bullen C, et al
    Public opinion on global COVID-19 vaccine procurement and distribution policies: A nationally representative survey in Aotearoa New Zealand 2022.
    Vaccine. 2024 Feb 6:S0264-410X(24)00115-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  167. MAEDA M, Murata F, Fukuda H
    The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study.
    Vaccine. 2024 Feb 5:S0264-410X(24)00106-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  168. MIYAMOTO S, Suzuki T
    Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
    Vaccine. 2024 Feb 2:S0264-410X(24)00112-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  169. RIVERS P, Porter C, LeClair LB, Jeddy Z, et al
    Longitudinal parental perception of COVID-19 vaccines for children in a multi-site, cohort study.
    Vaccine. 2024 Feb 2:S0264-410X(24)00010-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  170. BENNETT JC, Luiten KG, O'Hanlon J, Han PD, et al
    Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection.
    Vaccine. 2024 Feb 1:S0264-410X(24)00103-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  171. DATTA S, Vattiato G, Maclaren OJ, Hua N, et al
    The impact of Covid-19 vaccination in Aotearoa New Zealand: A modelling study.
    Vaccine. 2024 Feb 1:S0264-410X(24)00128-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    January 2024
  172. SOOD S, Matar MM, Kim J, Kinsella M, et al
    Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer.
    Vaccine. 2024 Jan 31:S0264-410X(24)00077-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  173. HUANG Y, Shi H, Forgacs D, Ross TM, et al
    Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection.
    Vaccine. 2024 Jan 30:S0264-410X(23)01543-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  174. JI Y, Sui X, Miao W, Wang C, et al
    Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
    Vaccine. 2024 Jan 30:S0264-410X(24)00097-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  175. SHAPIRO BEN DAVID S, Baruch Gez S, Adler L, Kovatch R, et al
    Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey.
    Vaccine. 2024 Jan 27:S0264-410X(24)00067-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  176. BALSELLS E, Vicente M, Reyes S, Figueroa M, et al
    Impact of the 'Health on Wheels' (HoW) strategy on COVID-19 vaccination coverage in hard-to-reach communities in Alta Verapaz, Guatemala, 2022.
    Vaccine. 2024 Jan 27:S0264-410X(24)00033-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  177. OKPANI AI, Adu P, Paetkau T, Lockhart K, et al
    Are COVID-19 vaccination mandates for healthcare workers effective? A systematic review of the impact of mandates on increasing vaccination, alleviating staff shortages and decreasing staff illness.
    Vaccine. 2024 Jan 27:S0264-410X(24)00052-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  178. FILIPAS DK, Labban M, Beatrici E, Stone BV, et al
    Exploring preventive care practices among unvaccinated individuals in the United States during the COVID-19 pandemic.
    Vaccine. 2024;42:441-447.
    PubMed     Abstract available


  179. TAKALANI A, Robinson M, Jonas P, Bodenstein A, et al
    Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
    Vaccine. 2024 Jan 25:S0264-410X(24)00078-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  180. RUSS S, Bennett N, van Wijngaarden E, Hill E, et al
    Influence of Community Determinants on Barriers and Facilitators to COVID-19 Vaccine Uptake: Regional Stakeholders' Perspectives.
    Vaccine. 2024 Jan 24:S0264-410X(24)00051-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  181. LIU R, Fan Y, Patel A, Liu H, et al
    The association between influenza vaccination, cardiovascular mortality and hospitalization: A living systematic review and prospective meta-analysis.
    Vaccine. 2024 Jan 23:S0264-410X(24)00053-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  182. HAMAD SAIED M, van Straalen JW, de Roock S, Verduyn Lunel FM, et al
    Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study.
    Vaccine. 2024 Jan 22:S0264-410X(24)00059-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  183. PAL R, Ferrari MG, Honda-Okubo Y, Wattay L, et al
    Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
    Vaccine. 2024 Jan 22:S0264-410X(24)00034-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  184. GEINITZ H, Silberberger E, Spiegl K, Feichtinger J, et al
    SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients.
    Vaccine. 2024 Jan 20:S0264-410X(24)00004-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  185. HILL PL, Morstead T, Pfund GN, Burrow AL, et al
    Examining changes in sense of purpose before, during, and after COVID-19 vaccination.
    Vaccine. 2024 Jan 20:S0264-410X(24)00027-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  186. MITCHELL MM, Klott A, Scholtes J, Braden BB, et al
    Mixed-methods examination of attitudes and behaviors related to COVID-19 vaccines among parents of children with autism and autistic adults.
    Vaccine. 2024 Jan 19:S0264-410X(24)00013-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  187. HICKEN A, Jones P, Menon A, Rozek LS, et al
    Can endorsement by religious leaders move the needle on vaccine hesitancy?
    Vaccine. 2024 Jan 18:S0264-410X(24)00006-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  188. MEMEDOVICH A, Orr T, Hollis A, Salmon C, et al
    Social network risk factors and COVID-19 vaccination: A cross-sectional survey study.
    Vaccine. 2024 Jan 18:S0264-410X(24)00005-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  189. GRIMA AA, Kwong JC, Richard L, Reid J, et al
    The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
    Vaccine. 2024 Jan 17:S0264-410X(24)00023-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  190. LEMMER Y, Chapman R, Abolnik C, Smith T, et al
    Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters.
    Vaccine. 2024 Jan 17:S0264-410X(24)00036-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  191. FAN J, Song Y, Cong S, Millman AJ, et al
    Assessing interventions to encourage primary care health workers to recommend influenza vaccination and the impact on vaccination uptake for persons with Non-Communicable diseases in China.
    Vaccine. 2024 Jan 16:S0264-410X(24)00011-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  192. HARALAMBIEVA IH, Monroe JM, Ovsyannikova IG, Warner ND, et al
    Restricted Omicron-specific cross-variant memory B-cell immunity after a 3rd dose/booster of monovalent Wuhan-Hu-1-containing COVID-19 mRNA vaccine.
    Vaccine. 2024 Jan 16:S0264-410X(24)00032-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  193. KING ML
    How manufacturing won or lost the COVID-19 vaccine race.
    Vaccine. 2024 Jan 15:S0264-410X(23)01477-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  194. MCADAM E, Hayashi K, Barker B, Reddon H, et al
    COVID-19 vaccination among young people who use drugs in Vancouver, Canada.
    Vaccine. 2024 Jan 14:S0264-410X(24)00009-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  195. NAUTA J
    Estimand for non-inferiority influenza vaccine immunogenicity trials.
    Vaccine. 2024 Jan 13:S0264-410X(24)00014-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  196. RATISHVILI T, Quach HQ, Haralambieva IH, Suryawanshi YR, et al
    A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides.
    Vaccine. 2024;42:162-174.
    PubMed     Abstract available


  197. VAN ROEKEL C, Labuschagne L, Pijpers J, van Roon A, et al
    Factors associated with COVID-19 autumn 2022 booster uptake in the Netherlands among older adults aged >/= 60 years and younger adults with chronic conditions.
    Vaccine. 2024;42:146-155.
    PubMed     Abstract available


  198. PARK SI, Park S, Lee K, Kwak HW, et al
    Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.
    Vaccine. 2024;42:69-74.
    PubMed     Abstract available


  199. REN S, Chen Q, Zhang Y, Yi L, et al
    Modeling the optimal seasonal monoclonal antibody administration strategy for respiratory syncytial virus (RSV) prevention based on age-season specific hospitalization rate of RSV in Suzhou, China, 2016-2022.
    Vaccine. 2024;42:352-361.
    PubMed     Abstract available


  200. QURESHI NS, Miller LG, Judge SP, Tran NDT, et al
    Characterizing predictors of COVID-19 vaccine refusal in an urban southern California jail population.
    Vaccine. 2024 Jan 9:S0264-410X(24)00017-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  201. HINSON-ENSLIN AM, Espinoza LE
    The mental health symptoms of individuals with sensory disabilities and the reasons that lead to COVID-19 vaccine refusal and hesitancy.
    Vaccine. 2024 Jan 9:S0264-410X(24)00012-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  202. STELETOU E, Giannouchos T, Dimitriou G, Karatza A, et al
    Parental concerns and vaccine hesitancy against COVID-19 vaccination for children in Greece: A cross-sectional survey.
    Vaccine. 2024 Jan 6:S0264-410X(24)00003-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  203. KRANZLER EC, Ihongbe TO, Marshall MC, Denison B, et al
    Racial and ethnic differences in COVID-19 vaccine readiness among adults in the United States, January 2021-April 2023.
    Vaccine. 2024 Jan 4:S0264-410X(23)01537-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  204. BUHL C, Jacobsen R, Almarsdottir AB, Abtahi S, et al
    Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A cross-sectional study in six EU member states.
    Vaccine. 2024 Jan 4:S0264-410X(23)01511-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  205. CHARPIGNON ML, Gupta S, Shahnaz Majumder M
    Massachusetts companion program bolsters COVID-19 vaccine rates among seniors.
    Vaccine. 2024 Jan 3:S0264-410X(23)01494-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  206. DAVIDSON AM, Burns S, White LA, Perlman M, et al
    "I shall not poison my child with your human experiment": Investigating predictors of parents' hesitancy about vaccinating younger children (<12) in Canada.
    Vaccine. 2024 Jan 2:S0264-410X(23)01519-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  207. AGASSE E, Rodriguez GF, Vilarino V, Galli JH, et al
    Social determinants of health and vaccine uptake in pregnancy: Disparities in a diverse, predominately foreign-born population.
    Vaccine. 2024 Jan 2:S0264-410X(23)01515-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  208. VASHI MD, Watkins M
    Missed opportunities: Reducing zero dose children amongthe urban poor after COVID, Mumbai India, 2022.
    Vaccine. 2024;42:59-63.
    PubMed     Abstract available


    December 2023
  209. RUBIO-CASILLAS A, Rodriguez-Quintero CM, Redwan EM, Gupta MN, et al
    Do vaccines increase or decrease susceptibility to diseases other than those they protect against?
    Vaccine. 2023 Dec 28:S0264-410X(23)01506-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  210. BARZEN G, Rieber F, Stangl K, Hahn K, et al
    mRNA vaccines for COVID-19 are safe and clinically effective in patients with cardiac amyloidosis.
    Vaccine. 2023 Dec 28:S0264-410X(23)01487-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  211. GHARPURE R, Akumu AO, Dawa J, Gobin S, et al
    Costs of seasonal influenza vaccine delivery in a pediatric demonstration project for children aged 6-23 months - Nakuru and Mombasa Counties, Kenya, 2019-2021.
    Vaccine. 2023 Dec 27:S0264-410X(23)01475-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  212. FONSECA HAR, Zimerman A, Monfardini F, Guimaraes HP, et al
    In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: A prespecified analysis of the VIP-ACS trial.
    Vaccine. 2023 Dec 27:S0264-410X(23)01531-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  213. SHENTON P, Schrader S, Smith J, Alafaci A, et al
    Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study.
    Vaccine. 2023 Dec 27:S0264-410X(23)01516-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  214. NGUYEN KH, Coy KC, Black CL, Scanlon P, et al
    Comparison of adult hesitancy towards COVID-19 vaccines and vaccines in general in the USA.
    Vaccine. 2023 Dec 23:S0264-410X(23)01488-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  215. SEPPALA E, Dahl J, Veneti L, Rydland KM, et al
    Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023.
    Vaccine. 2023 Dec 22:S0264-410X(23)01496-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  216. KACHKO A, Selvaraj P, Liu S, Kim J, et al
    Vaccine-associated respiratory pathology correlates with viral clearance and protective immunity after immunization with self-amplifying RNA expressing the spike (S) protein of SARS-CoV-2 in mouse models.
    Vaccine. 2023 Dec 22:S0264-410X(23)01498-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  217. LO E, Brousseau N, Defay F, Fortin E, et al
    Neighborhood-level vaccine impact on COVID-19 infection and hospital admission in Quebec, Canada, during the Delta and early Omicron periods.
    Vaccine. 2023 Dec 22:S0264-410X(23)01489-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  218. KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
    Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
    Vaccine. 2023 Dec 20:S0264-410X(23)01482-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  219. WOLFF M, Charpentier P, Canals A, Vial C, et al
    Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
    Vaccine. 2023 Dec 19:S0264-410X(23)01481-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  220. MIRIERI H, Nasimiyu C, Dawa J, Mburu C, et al
    Resilience of routine childhood immunization services in two counties in Kenya in the face of the COVID-19 pandemic.
    Vaccine. 2023;41:7695-7704.
    PubMed     Abstract available


  221. STUMPF J, Anders L, Siepmann T, Schwobel J, et al
    9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients.
    Vaccine. 2023 Dec 18:S0264-410X(23)01479-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  222. ARASHIRO T, Miwa M, Nakagawa H, Takamatsu J, et al
    COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study).
    Vaccine. 2023 Dec 18:S0264-410X(23)01480-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  223. DAWA J, Jalang'o R, Mirieri H, Kalani R, et al
    Comparing performance of year-round and campaign-mode influenza vaccination strategies among children aged 6-23 months in Kenya: 2019-2021.
    Vaccine. 2023 Dec 16:S0264-410X(23)01380-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  224. JACKSON LA, Stapleton JT, Walter EB, Chen WH, et al
    Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults.
    Vaccine. 2023 Dec 16:S0264-410X(23)01434-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  225. JIANG W, Lu C, Yan X, Tucker JD, et al
    Vaccine confidence mediates the association between a pro-social pay-it-forward intervention and improved influenza vaccine uptake in China: A mediation analysis.
    Vaccine. 2023 Dec 15:S0264-410X(23)01392-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  226. ZHAN XY, Chen Y, Zhang X, Shi Q, et al
    Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination.
    Vaccine. 2023 Dec 15:S0264-410X(23)01465-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  227. BAJRACHARYA D, Jansen RJ
    Observations of COVID-19 vaccine coverage and vaccine hesitancy on COVID-19 outbreak: An American ecological study.
    Vaccine. 2023 Dec 15:S0264-410X(23)01441-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  228. BURNS KE, Dube E, Godinho Nascimento H, Meyer SB, et al
    Examining vaccine hesitancy among a diverse sample of Canadian adults.
    Vaccine. 2023 Dec 15:S0264-410X(23)01476-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  229. DONG C, Ma Y, Zhu W, Wang Y, et al
    Influenza immune imprinting synergizes PEI-HA/CpG nanoparticle vaccine protection against heterosubtypic infection in mice.
    Vaccine. 2023 Dec 14:S0264-410X(23)01485-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  230. FERRONI E, Gennaro N, Maifredi G, Leoni O, et al
    Access to SARS-CoV-2 vaccination in immigrants in Italy, by geographical area of origin.
    Vaccine. 2023 Dec 13:S0264-410X(23)01387-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  231. CAO Z, Yu R, Yuan Q, Ji W, et al
    Impact of the COVID-19 pandemic on routine vaccination coverage under varying prevalence Conditions: A cohort study in Beijing, China.
    Vaccine. 2023 Dec 13:S0264-410X(23)01447-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  232. O'NEIL SS, Pendl-Robinson EL, Carosella EA, Sullivan BD, et al
    The importance of community-specific survey data in understanding behavioral and social drivers of COVID-19 vaccination: Lessons learned from urban neighborhoods in four United States cities.
    Vaccine. 2023 Dec 12:S0264-410X(23)01450-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  233. OPRIESSNIG T, Gauger PC, Filippsen Favaro P, Rawal G, et al
    An experimental universal swine influenza a virus (IAV) vaccine candidate based on the M2 ectodomain (M2e) peptide does not provide protection against H1N1 IAV challenge in pigs.
    Vaccine. 2023 Dec 11:S0264-410X(23)01445-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  234. LYTRAS T, Di Gregorio AAA, Apostolopoulos D, Naziris D, et al
    Effectiveness of COVID-19 vaccine mandates in raising vaccination rates among the elderly and general population in Europe: Controlled interrupted time series analysis.
    Vaccine. 2023 Dec 11:S0264-410X(23)01472-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  235. AKMATOVA R, Dzhangaziev B, Ebama MS, Otorbaeva D, et al
    Knowledge, attitudes, and practices (KAP) towards seasonal influenza and influenza vaccine among pregnant women in Kyrgyzstan: A cross-sectional study.
    Vaccine. 2023 Dec 9:S0264-410X(23)01453-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  236. MESIDOR M, Liu Y, Talbot D, Skowronski DM, et al
    Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review.
    Vaccine. 2023 Dec 9:S0264-410X(23)01446-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  237. SUI Y, Andersen H, Li J, Hoang T, et al
    SARS-CoV-2 mucosal vaccine protects against clinical disease with sex bias in efficacy.
    Vaccine. 2023 Dec 8:S0264-410X(23)01426-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  238. DI CHIARA C, Cantarutti A, Raffaella Petrara M, Bonfante F, et al
    Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5-11 years old children with prior COVID-19.
    Vaccine. 2023 Dec 8:S0264-410X(23)01439-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  239. CHENG DR, Reimer H, Le D, Crawford NW, et al
    Analyzing an immunization resource website: User browsing trends.
    Vaccine. 2023;41:7498-7502.
    PubMed     Abstract available


  240. YU Y, Zhang X, Lau MMC, Lau JTF, et al
    The intention to get COVID-19 booster vaccination and its association with cognitive and emotional factors: A survey of Chinese COVID-19 infected people in Hong Kong.
    Vaccine. 2023 Dec 7:S0264-410X(23)01448-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  241. GRAMACHO W, Turgeon M, Santos Mundim P, Pereira I, et al
    Why did Brazil fail to vaccinate children against COVID-19 during the pandemic? An assessment of attitudinal and behavioral determinants.
    Vaccine. 2023 Dec 6:S0264-410X(23)01432-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  242. CANEVARI JT, Cheng AC, Wu L, Rowe SL, et al
    The relative effectiveness of three and four doses of COVID-19 vaccine in Victoria, Australia: A data linkage study.
    Vaccine. 2023 Dec 5:S0264-410X(23)01393-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  243. MADNI SA, Sharma AJ, Zauche LH, Waters AV, et al
    CDC COVID-19 Vaccine Pregnancy Registry: Design, data collection, response rates, and cohort description.
    Vaccine. 2023 Dec 5:S0264-410X(23)01423-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  244. PRASERT K, Praphasiri P, Lerdsamran H, Nakphook S, et al
    Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial.
    Vaccine. 2023 Dec 1:S0264-410X(23)01396-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  245. GASHTI AB, Agbayani G, Hrapovic S, Nassoury N, et al
    Production, purification and immunogenicity of Gag virus-like particles carrying SARS-CoV-2 components.
    Vaccine. 2023 Dec 1:S0264-410X(23)01394-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    November 2023
  246. WANG Y, Hu Y, Ma Y, Li P, et al
    RBD class 1 and 2 antibody epitopes elicit around 70% neutralizing capacity against SARS-CoV-2 virus following boosting with inactivated virus vaccine.
    Vaccine. 2023 Nov 27:S0264-410X(23)01381-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  247. NISHIYAMA T, Miyamatsu Y, Park H, Nakamura N, et al
    Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history.
    Vaccine. 2023 Nov 25:S0264-410X(23)01384-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  248. DUCASA N, Benencio P, Mauro E, Anders M, et al
    Evaluation of the humoral response to the third dose of SARS-COV-2 vaccines in liver transplant recipients.
    Vaccine. 2023 Nov 24:S0264-410X(23)01383-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  249. PAYNE AB, Ciesla AA, Rowley EAK, Weber ZA, et al
    Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design.
    Vaccine. 2023 Nov 23:S0264-410X(23)01337-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  250. FITZPATRICK MC, Laufer RS, Baral R, Driscoll AJ, et al
    Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022.
    Vaccine. 2023;41:7047-7059.
    PubMed     Abstract available


  251. WANG B, McDonough J, Chen G, Ong JJ, et al
    Sociodemographic factors and attitudes associated with Australian parental acceptance of paediatric COVID-19 vaccination.
    Vaccine. 2023 Nov 22:S0264-410X(23)01336-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  252. NEELY SR, Hao F
    Breakthrough COVID-19 infections and perceived vaccine effectiveness.
    Vaccine. 2023 Nov 22:S0264-410X(23)01365-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  253. ZURCHER SJ, Signorell A, Lechot-Huser A, Aebi C, et al
    Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
    Vaccine. 2023;41:7226-7233.
    PubMed     Abstract available


  254. ECONOMIDOU EC, Soteriades ES
    Excess mortality in Cyprus during the COVID-19 vaccination campaign.
    Vaccine. 2023 Nov 22:S0264-410X(23)01361-0. doi: 10.1016/j.vaccine.2023.
    PubMed    


  255. LAW AW, Judy J, Atwell JE, Willis S, et al
    Maternal Tdap and influenza vaccination uptake 2017-2021 in the United States: Implications for maternal RSV vaccine uptake in the future.
    Vaccine. 2023 Nov 21:S0264-410X(23)01307-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  256. NAUGLE D, Tibbels N, Dosso A, Benie W, et al
    "I'd do it for my baby": Lessons learned from qualitative research on COVID-19 vaccination among pregnant women in Cote d'Ivoire.
    Vaccine. 2023 Nov 19:S0264-410X(23)01333-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  257. HAEDER SF
    Assessing parental intention to vaccinate against COVID-19, influenza, and RSV in the United States in late 2023.
    Vaccine. 2023 Nov 15:S0264-410X(23)01303-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  258. AMITAI N, Wertheimer R, Prais D, Wertheimer KO, et al
    Influenza vaccination in children with pulmonary disease during the COVID-19 pandemic.
    Vaccine. 2023 Nov 15:S0264-410X(23)01338-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  259. CHOI Y, Park S, Lee J, Kim Y, et al
    Who gets COVID-19 booster vaccination? Trust in public health institutions and promotion strategies post-pandemic in the Republic of Korea.
    Vaccine. 2023 Nov 15:S0264-410X(23)01294-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  260. SARAFIAN JT, Eucker SA, Gillman M, DeLaroche AM, et al
    Impact of a hypothetical COVID-19 vaccine mandate on parental likelihood to vaccinate children: Exploring school-related concerns and vaccination decision-making.
    Vaccine. 2023 Nov 14:S0264-410X(23)01334-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  261. PLUMB ID, Briggs Hagen M, Wiegand R, Dumyati G, et al
    Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.
    Vaccine. 2023 Nov 14:S0264-410X(23)01287-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  262. GUBERNOT D, Menis M, Whitaker B
    Background rates for severe cutaneous reactions in the US: Contextual support for safety assessment of COVID-19 vaccines and novel biologics.
    Vaccine. 2023;41:6922-6929.
    PubMed     Abstract available


  263. LASRADO N, Collier AY, Hachmann NP, Miller J, et al
    Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
    Vaccine. 2023;41:6904-6909.
    PubMed     Abstract available


  264. GOTO T, Chong Y, Tani N, Susai N, et al
    Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.
    Vaccine. 2023;41:7019-7025.
    PubMed     Abstract available


  265. CUBIZOLLES C, Barjat T, Chauleur C, Bruel S, et al
    Evaluation of intentions to get vaccinated against influenza, COVID 19, pertussis and to get a future vaccine against respiratory syncytial virus in pregnant women.
    Vaccine. 2023 Nov 12:S0264-410X(23)01280-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  266. JIANG X, Wang J, Li C, Yeoh EK, et al
    Impact of the surge of COVID-19 Omicron outbreak on the intention of seasonal influenza vaccination in Hong Kong: A cross-sectional study.
    Vaccine. 2023 Nov 11:S0264-410X(23)01304-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  267. GRABENSTEIN JD, Ferrara P, Mantovani LG, McGovern I, et al
    Evaluating risk of bias using ROBINS-I tool in nonrandomized studies of adjuvanted influenza vaccine.
    Vaccine. 2023 Nov 10:S0264-410X(23)01302-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  268. HERZIG VAN WEES S, Stalgren M, Viberg N, Puranen B, et al
    "Who is Anders Tegnell?" Unanswered questions hamper COVID-19 vaccine uptake: A qualitative study among ethnic minorities in Sweden.
    Vaccine. 2023 Nov 10:S0264-410X(23)01328-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  269. BRUXVOORT KJ, Sy LS, Hong V, Lewin B, et al
    Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US health care system.
    Vaccine. 2023 Nov 10:S0264-410X(23)01324-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  270. DUDLEY MZ, Schwartz B, Brewer J, Kan L, et al
    COVID-19 vaccination attitudes, values, intentions: US parents for their children, September 2021.
    Vaccine. 2023 Nov 9:S0264-410X(23)01295-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  271. ANDERSON EC, Blair PS, Finn A, Ingram J, et al
    Maternal vaccination provision in NHS maternity trusts across England.
    Vaccine. 2023 Nov 9:S0264-410X(23)01284-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  272. YANG C, Zheng Z, Zheng P, Chen J, et al
    Inactivated COVID-19 vaccines in peri-pregnancy period: Evaluation of safety for both pregnant women and neonates.
    Vaccine. 2023 Nov 8:S0264-410X(23)01322-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  273. INOUE Y, Li Y, Yamamoto S, Fukunaga A, et al
    The association between antipyretic analgesics use and SARS-CoV-2 antibody titers following the second dose of the BNT162b2 mRNA vaccine: An observational study.
    Vaccine. 2023 Nov 7:S0264-410X(23)01220-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  274. SPACKMAN E, Suarez DL, Lee CW, Pantin-Jackwood MJ, et al
    Efficacy of inactivated and RNA particle vaccines against a North American Clade 2.3.4.4b H5 highly pathogenic avian influenza virus in chickens.
    Vaccine. 2023 Nov 4:S0264-410X(23)01285-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  275. HANSEN LG, Larsen LE, Rasmussen TB, Miar Y, et al
    Investigation of the SARS-CoV-2 post-vaccination antibody response in Canadian farmed mink.
    Vaccine. 2023 Nov 4:S0264-410X(23)01288-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  276. JONES G, Perry M, Bailey R, Arumugam S, et al
    Dimensions of equality in uptake of COVID-19 vaccination in Wales, UK: A multivariable linked data population analysis.
    Vaccine. 2023 Nov 4:S0264-410X(23)01279-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  277. AKHTAR Z, Gotberg M, Erlinge D, Christiansen EH, et al
    Optimal timing of influenza vaccination among patients with acute myocardial infarction - Findings from the IAMI trial.
    Vaccine. 2023 Nov 2:S0264-410X(23)01211-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  278. CHEN GL, Yu XY, Luo LP, Zhang F, et al
    Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.
    Vaccine. 2023 Nov 2:S0264-410X(23)01278-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  279. BOLOTIN S, Osman S, Halperin S, Severini A, et al
    Immunity of Canadians and risk of epidemics workshop - Conference report.
    Vaccine. 2023;41:6775-6781.
    PubMed     Abstract available


  280. DO LAH, Le NTN, Mahmud S, Mulholland K, et al
    Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
    Vaccine. 2023;41:6782-6790.
    PubMed     Abstract available


  281. ALIZADEH M, Raj S, Shojadoost B, Matsuyama-Kato A, et al
    In ovo administration of retinoic acid enhances cell-mediated immune responses against an inactivated H9N2 avian influenza virus vaccine.
    Vaccine. 2023 Nov 1:S0264-410X(23)01261-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  282. JAMES WG, Stanberry LR, LaRussa PS, Grodman MD, et al
    Vaccines and global health: COVID-19 vaccine development, strategy, and implementation symposium - Summary of the meeting at Vagelos College of Physicians and Surgeons (February 22-26, 2021, New York).
    Vaccine. 2023 Nov 1:S0264-410X(23)01254-9. doi: 10.1016/j.vaccine.2023.
    PubMed    


    October 2023
  283. RAMSAY JA, Jones M, Vande More AM, Hunt SL, et al
    A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study).
    Vaccine. 2023 Oct 28:S0264-410X(23)01250-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  284. SALLOUM M, Paviotti A, Bastiaens H, Van Geertruyden JP, et al
    The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023.
    Vaccine. 2023 Oct 28:S0264-410X(23)01259-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  285. LIU Y, Sanchez-Ovando S, Carolan L, Dowson L, et al
    Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines.
    Vaccine. 2023 Oct 28:S0264-410X(23)01217-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  286. NYAMBAYO PPM, Gold MS, Mehta UC, Clarke S, et al
    Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial.
    Vaccine. 2023;41:6700-6709.
    PubMed     Abstract available


  287. TANI N, Ikematsu H, Goto T, Kondo S, et al
    Correlation between specific antibody response to wild-type BNT162b2 booster and the risk of breakthrough infection with omicron variants: Impact of household exposure in hospital healthcare workers.
    Vaccine. 2023;41:6672-6678.
    PubMed     Abstract available


  288. WALLIAR T, Khan B, Newstead S, Al-Assadi G, et al
    "Fighting the pandemic!" Western Australian pharmacists' perspectives on COVID-19 vaccines: A qualitative study.
    Vaccine. 2023 Oct 25:S0264-410X(23)01243-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  289. ANASTASSOPOULOU C, Boufidou F, Hatziantoniou S, Vasileiou K, et al
    Adverse events of acute nephrotoxicity reported to EudraVigilance and VAERS after COVID-19 vaccination.
    Vaccine. 2023 Oct 25:S0264-410X(23)01214-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  290. CENAT JM, Moshirian Farahi SMM, Broussard C, Dalexis RD, et al
    The state of COVID-19 vaccine confidence and need in Black individuals in Canada: Understanding the role of sociodemographic factors, health literacy, conspiracy theories, traumatic stressors and racial discrimination.
    Vaccine. 2023 Oct 25:S0264-410X(23)01246-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  291. KITIKOON P, Knetter SM, Mogler MA, Morgan CL, et al
    Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection.
    Vaccine. 2023 Oct 24:S0264-410X(23)01175-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  292. FLOR N, Garcia MI, Molineri A, Bottasso O, et al
    Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection.
    Vaccine. 2023 Oct 24:S0264-410X(23)01221-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  293. BRESEE J, Koh M, Chadwick C, Jit M, et al
    The need and ongoing efforts to understand the full value of improved influenza vaccines.
    Vaccine. 2023 Oct 21:S0264-410X(23)01245-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  294. WANGCHUK S, Prabhakaran AO, Dhakal GP, Zangmo C, et al
    Introducing seasonal influenza vaccine in Bhutan: Country experience and achievements.
    Vaccine. 2023 Oct 20:S0264-410X(23)01255-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  295. IRVING SA, Groom HC, Belongia EA, Crane B, et al
    Influenza vaccination coverage among persons ages six months and older in the Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons.
    Vaccine. 2023 Oct 20:S0264-410X(23)01206-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  296. TUNIS M, Deeks S, Harrison R, Quach C, et al
    Canada's National Advisory Committee on immunization: Adaptations and challenges during the COVID-19 pandemic.
    Vaccine. 2023;41:6538-6547.
    PubMed     Abstract available


  297. MORI Y, Uchida N, Wake A, Miyawaki K, et al
    Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
    Vaccine. 2023 Oct 20:S0264-410X(23)01022-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  298. HART R, Feygin Y, Kluthe T, Quinn KG, et al
    Emergency departments: An underutilized resource to address pediatric influenza vaccine coverage.
    Vaccine. 2023 Oct 19:S0264-410X(23)01222-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  299. MCCLYMONT E, Atkinson A, Albert A, Av-Gay G, et al
    Reactogenicity, pregnancy outcomes, and SARS-CoV-2 infection following COVID-19 vaccination during pregnancy in Canada: A national prospective cohort study.
    Vaccine. 2023 Oct 19:S0264-410X(23)01215-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  300. HONDA-OKUBO Y, Bowen R, Barker M, Bielefeldt-Ohmann H, et al
    Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants.
    Vaccine. 2023 Oct 18:S0264-410X(23)01190-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  301. RIEFOLO F, Castillo-Cano B, Martin-Perez M, Messina D, et al
    Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries.
    Vaccine. 2023 Oct 17:S0264-410X(23)01181-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  302. HAEDER SF
    U.S. public support and opposition to vaccination mandates in K-12 education in light of the COVID-19 pandemic.
    Vaccine. 2023 Oct 17:S0264-410X(23)01188-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  303. YANG H, Wang Z, Zhang Y, Xu M, et al
    Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 Omicron subvariant BF.7 among outpatients in Beijing, China.
    Vaccine. 2023 Oct 17:S0264-410X(23)01219-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  304. PLATENBURG PPLI, Deschamps F, Jung J, Leonard C, et al
    Carbohydrate fatty acid monosulphate ester is a potent adjuvant for low-dose seasonal influenza vaccines.
    Vaccine. 2023 Oct 16:S0264-410X(23)01189-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  305. LOPEZ-GOMEZ A, Pelaez-Prestel HF, Juarez I
    Approaches to evaluate the specific immune responses to SARS-CoV-2.
    Vaccine. 2023;41:6434-6443.
    PubMed     Abstract available


  306. MOSCA S, Lin Q, Stokes R, Bharucha T, et al
    Innovative method for rapid detection of falsified COVID-19 vaccines through unopened vials using handheld Spatially Offset Raman Spectroscopy (SORS).
    Vaccine. 2023 Oct 13:S0264-410X(23)01182-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  307. ARASHIRO T, Arima Y, Kuramochi J, Muraoka H, et al
    Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan.
    Vaccine. 2023 Oct 13:S0264-410X(23)01194-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  308. PARK H, Jang MS, Choi JA, Kim W, et al
    Nonclinical safety assessment and immunogenicity of rVSVInd(GML)-mspSGtc vaccine for SARS-CoV-2 in rabbits.
    Vaccine. 2023 Oct 9:S0264-410X(23)01178-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  309. MO C, Li X, Wu Q, Fan Y, et al
    SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses.
    Vaccine. 2023 Oct 9:S0264-410X(23)01156-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  310. SATHE N, Shaikh S, Bhavsar M, Parte L, et al
    Safety, immunogenicity and efficacy of Relcovax(R), a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
    Vaccine. 2023 Oct 8:S0264-410X(23)01176-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  311. LOPEZ-ZAMBRANO MA, Pita CC, Escribano MF, Galan Melendez IM, et al
    Factors associated to influenza vaccination among hospital's healthcare workers in the Autonomous Community of Madrid, Spain 2021-2022.
    Vaccine. 2023 Oct 6:S0264-410X(23)01117-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  312. PROCTER TD, Ogasawara H, Spruin S, Wijayasri S, et al
    Thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector COVID-19 vaccination in Canada.
    Vaccine. 2023 Oct 6:S0264-410X(23)01159-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  313. OZAWA S, Schuh HB, Nakamura T, Yemeke TT, et al
    How to increase and maintain high immunization coverage: Vaccination Demand Resilience (VDR) framework.
    Vaccine. 2023 Oct 3:S0264-410X(23)01097-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  314. ZACHRESON C, Tobin R, Szanyi J, Walker C, et al
    Individual variation in vaccine immune response can produce bimodal distributions of protection.
    Vaccine. 2023 Oct 2:S0264-410X(23)01095-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    September 2023
  315. OKOLI GN, Righolt CH, Zhang G, Alessi-Severini S, et al
    Impact of the universal seasonal influenza vaccination policy in the province of Manitoba, Canada: A population-based, province-wide record-linkage study.
    Vaccine. 2023 Sep 29:S0264-410X(23)01133-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  316. DIONNE M, Sauvageau C, Kiely M, Rathwell M, et al
    "The problem is not lack of information": A qualitative study of parents and school nurses' perceptions of barriers and potential solutions for HPV vaccination in schools.
    Vaccine. 2023 Sep 28:S0264-410X(23)01140-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  317. HARBOE ZB, Hald A, Ekenberg C, Ete Wareham N, et al
    Implementation of a vaccination clinic for adult solid organ transplant candidates: A single-center experience.
    Vaccine. 2023 Sep 27:S0264-410X(23)01106-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  318. LAVELL AHA, Schramade AE, Sikkens JJ, van der Straten K, et al
    25-Hydroxyvitamin D concentrations do not affect the humoral or cellular immune response following SARS-CoV-2 mRNA vaccinations.
    Vaccine. 2023 Sep 27:S0264-410X(23)00957-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  319. SHEN X, Hao Y, Wang S, Li D, et al
    Sequential heterologous immunization with COVID-19 vaccines induces broader neutralizing responses against SARS-CoV-2 variants in comparison with homologous boosters.
    Vaccine. 2023 Sep 26:S0264-410X(23)01100-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  320. CASSARINO N, Ahnger-Pier KK, Wurcel A
    Trends in COVID-19 and influenza vaccine ordering and distribution in Massachusetts jails.
    Vaccine. 2023 Sep 25:S0264-410X(23)01115-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  321. SANA S, Merkelbach I, Magnee T, Kollmann J, et al
    Identifying barriers to vaccination intention at walk-in vaccination facilities in deprived neighbourhoods: A cross-sectional survey.
    Vaccine. 2023 Sep 25:S0264-410X(23)01038-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  322. GOLOVKINA MI, Ertz SC, Lechnir SS, Hayney MS, et al
    Providing influenza vaccines at endoscopy visits increases influenza vaccine uptake.
    Vaccine. 2023 Sep 23:S0264-410X(23)01108-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  323. RAISER F, Davis M, Adelglass J, Cai MR, et al
    Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
    Vaccine. 2023;41:5965-5973.
    PubMed     Abstract available


  324. HAO F, Shao W
    Social network, political climate, income inequality, and Americans uptake of monovalent COVID-19 booster.
    Vaccine. 2023;41:6077-6082.
    PubMed     Abstract available


  325. NGAMCHALIEW P, Kaewkuea N, Nonthasorn N, Vonnasrichan T, et al
    Acceptance of COVID-19 vaccination and vaccine confidence levels in Thailand: A cross-sectional study.
    Vaccine. 2023 Sep 22:S0264-410X(23)01088-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  326. HOMAIRA N, He WQ, McRae J, Macartney K, et al
    Coverage and predictors of influenza and pertussis vaccination during pregnancy: a whole of population-based study.
    Vaccine. 2023 Sep 21:S0264-410X(23)01062-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  327. FU Y, Wu K, Wang Z, Yang H, et al
    Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods - United States, 11 December 2020 to 30 June 2022.
    Vaccine. 2023 Sep 21:S0264-410X(23)01025-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  328. WILKINSON B, Patel KS, Smith K, Walker R, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 vir
    Vaccine. 2023 Sep 20:S0264-410X(23)00871-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  329. ALHARBI HS
    Review: Factors influencing parents' decisions to vaccinate children against COVID-19.
    Vaccine. 2023 Sep 19:S0264-410X(23)01090-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  330. HAN C, Zhao ZZ, Chan P, Li F, et al
    A large survey on COVID-19 vaccination in patients with Parkinson's disease and healthy population.
    Vaccine. 2023 Sep 17:S0264-410X(23)01056-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  331. NELSON CB, Brady BL, Richards M, Lew CR, et al
    Optimal site of care for administration of extended half-life respiratory syncytial virus (RSV) antibodies to infants in the United States (US).
    Vaccine. 2023;41:5820-5824.
    PubMed     Abstract available


  332. SHAVER N, Katz M, Darko Asamoah G, Linkins LA, et al
    Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness.
    Vaccine. 2023 Sep 15:S0264-410X(23)01065-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  333. SURYAWANSHI YR
    An overview of protein-based SARS-CoV-2 vaccines.
    Vaccine. 2023 Sep 10:S0264-410X(23)01067-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  334. POTT H, Andrew MK, Shaffelburg Z, Nichols MK, et al
    Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canad
    Vaccine. 2023 Sep 9:S0264-410X(23)01026-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  335. YU J, Sreenivasan C, Sheng Z, Zhai SL, et al
    A recombinant chimeric influenza virus vaccine expressing the consensus H3 hemagglutinin elicits broad hemagglutination inhibition antibodies against divergent swine H3N2 influenza viruses.
    Vaccine. 2023 Sep 7:S0264-410X(23)01060-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  336. MONTEIRO HS, Lima Neto AS, Kahn R, Sousa GS, et al
    Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study.
    Vaccine. 2023;41:5742-5751.
    PubMed     Abstract available


  337. PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al
    Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and hospitalized Mu, Delta, and Omicron: A test-negative case-control study.
    Vaccine. 2023 Sep 5:S0264-410X(23)01028-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  338. YUE PHR, Lau HPB, Ng SM, Chan LWC, et al
    When to be vaccinated? What to consider? Modelling decision-making and time preference for COVID-19 vaccine through a conjoint experiment.
    Vaccine. 2023 Sep 5:S0264-410X(23)01024-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  339. PHILLIPS A, Jiang Y, Walsh D, Andrews N, et al
    Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis.
    Vaccine. 2023 Sep 5:S0264-410X(23)01045-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  340. ALSAIF F, Twigg M, Scott S, Blyth A, et al
    A systematic review of barriers and enablers associated with uptake of influenza vaccine among care home staff.
    Vaccine. 2023 Sep 4:S0264-410X(23)01048-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  341. CLAESSENS T, Krouwer S, Vandebosch H, Poels K, et al
    Pathways to informed choices: The impact of freedom of choice and two-sided messages on psychological reactance and vaccination intentions among individuals who express concerns.
    Vaccine. 2023 Sep 3:S0264-410X(23)00948-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  342. WILLIS DE, Moore R, Andersen JA, Li J, et al
    Correlates of COVID-19 vaccine coverage in Arkansas: Results from a weighted random sample survey.
    Vaccine. 2023 Sep 1:S0264-410X(23)01039-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  343. PORRAS-RAMIREZ A, Sanchez-Paris R, Lopez-Devia W, Moreno-Perilla Z, et al
    Confirmed cases of COVID-19 after vaccination against COVID in health personnel in Bogota, Colombia.
    Vaccine. 2023 Sep 1:S0264-410X(23)00924-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    August 2023
  344. SAKALA IG, Honda-Okubo Y, Petrovsky N
    Developmental and reproductive safety of Advax-CpG55.2 adjuvanted COVID-19 and influenza vaccines in mice.
    Vaccine. 2023 Aug 31:S0264-410X(23)01007-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  345. GRILLS LA, Wagner AL
    The impact of the COVID-19 pandemic on parental vaccine hesitancy: A cross-sectional survey.
    Vaccine. 2023 Aug 31:S0264-410X(23)00977-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  346. DUDLEY HM, O'Mara M, Auma A, Gong J, et al
    Rheumatoid arthritis and older age are associated with lower humoral and cellular immune response to primary series COVID-19 mRNA vaccine.
    Vaccine. 2023 Aug 31:S0264-410X(23)00965-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  347. REGAN AK, Fell DB, Wise LA, Vazquez-Benitez G, et al
    Challenges & opportunities for the epidemiological evaluation of the effects of COVID-19 vaccination on reproduction and pregnancy.
    Vaccine. 2023 Aug 31:S0264-410X(23)00964-7. doi: 10.1016/j.vaccine.2023.
    PubMed    


  348. PHIRIYASART F, Aimyong N, Jirapongsuwan A, Roseh N, et al
    COVID-19 vaccine hesitancy among older adult Thai Muslim people: A case-control study.
    Vaccine. 2023 Aug 27:S0264-410X(23)00994-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  349. YANG J, Li B, Yang D, Wu J, et al
    The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice.
    Vaccine. 2023 Aug 26:S0264-410X(23)01017-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  350. JANSSEN ERC, van Montfoort AZ, Hollman F, Lambers Heerspink FO, et al
    The prevalence and clinical course of shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccines in Dutch hospital workers.
    Vaccine. 2023 Aug 25:S0264-410X(23)00975-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  351. CHIBA S, Halfmann PJ, Iida S, Hirata Y, et al
    Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2.
    Vaccine. 2023 Aug 25:S0264-410X(23)01008-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  352. CHEN IR, Wang GJ, Hsueh PR, Chou CH, et al
    Immune responses and safety of COVID-19 vaccination in atypical hemolytic uremic syndrome patients in Taiwan.
    Vaccine. 2023 Aug 25:S0264-410X(23)00952-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  353. WATERLOW NR, Procter SR, van Leeuwen E, Radhakrishnan S, et al
    The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis.
    Vaccine. 2023 Aug 24:S0264-410X(23)00963-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  354. MOHAMMED IS, Widome R, Searle KM
    COVID-19 vaccine decision-making among Black women: A qualitative study.
    Vaccine. 2023 Aug 24:S0264-410X(23)00920-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  355. DENG L, Tapper K, Thosar D, Goeman E, et al
    Use of adrenaline to manage suspected anaphylaxis following COVID-19 vaccination: An Australian retrospective cohort study.
    Vaccine. 2023 Aug 24:S0264-410X(23)00956-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  356. GOULD S, Wrzesinski C, Stebbings R, Segal L, et al
    Report from an ICT 2022 workshop on toxicology for Covid19 vaccines: Industry, regulatory and CRO perspectives.
    Vaccine. 2023 Aug 24:S0264-410X(23)00972-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  357. STRUYF F, Hardt K, Van Rampelbergh R, Shukarev G, et al
    Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S.
    Vaccine. 2023;41:5351-5359.
    PubMed     Abstract available


  358. KUMRU OS, Sanyal M, Friedland N, Hickey JM, et al
    Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines.
    Vaccine. 2023 Aug 22:S0264-410X(23)00969-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  359. SU Y, Guo Z, Gu X, Sun S, et al
    Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China.
    Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  360. YAO T, Guo Y, Xu X, Zhang X, et al
    Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population.
    Vaccine. 2023 Aug 19:S0264-410X(23)00974-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  361. KENIGSBERG TA, Goddard K, Hanson KE, Lewis N, et al
    Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines.
    Vaccine. 2023 Aug 18:S0264-410X(23)00955-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  362. CHAIWONG W, Takheaw N, Pata S, Laopajon W, et al
    Neutralizing antibody and T-cell responses against SARS-CoV-2 variants by heterologous CoronaVac/ChAdOx-1 vaccination in elderly subjects with chronic obstructive pulmonary disease.
    Vaccine. 2023 Aug 18:S0264-410X(23)00966-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  363. PALACHE A, Billingsley JK, MacLaren K, Morgan L, et al
    Lessons learned from the COVID-19 pandemic for improved influenza control.
    Vaccine. 2023 Aug 17:S0264-410X(23)00960-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  364. MORRISON K, Cullen L, James AB, Chua V, et al
    Predictors of incomplete COVID-19 vaccine schedule among adults in Scotland: Two retrospective cohort analyses of the primary schedule and third dose.
    Vaccine. 2023 Aug 17:S0264-410X(23)00916-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  365. ZUR M, Shelef L, Glassberg E, Fink N, et al
    Are intelligent people more likely to get vaccinated? The association between COVID-19 vaccine adherence and cognitive profiles.
    Vaccine. 2023 Aug 15:S0264-410X(23)00951-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  366. SARNA M, Gebremedhin A, Richmond P, Levy A, et al
    Determining the true incidence of seasonal respiratory syncytial virus-confirmed hospitalizations in preterm and term infants in Western Australia.
    Vaccine. 2023;41:5216-5220.
    PubMed     Abstract available


  367. TOYAMA K, Eto T, Takazawa K, Shimizu S, et al
    DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.
    Vaccine. 2023 Aug 14:S0264-410X(23)00824-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  368. WITTAWATMONGKOL O, Bunjoungmanee P, Kosalaraksa P, Laoprasopwattana K, et al
    Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
    Vaccine. 2023 Aug 14:S0264-410X(23)00953-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  369. BERTHELEMY C, Bouche P, Lamiral Z, Boivin JM, et al
    Parental acceptability of vaccinating young children against influenza and COVID-19.
    Vaccine. 2023 Aug 12:S0264-410X(23)00929-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  370. HONDA-OKUBO Y, Bart Tarbet E, Hurst BL, Petrovsky N, et al
    An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection.
    Vaccine. 2023 Aug 9:S0264-410X(23)00941-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  371. BAGLIVO F, Magri M, De Angelis L, Aprile V, et al
    Performance comparison between heterologous and homologous COVID19 vaccine schedules on Omicron variant incidence: A real-world retrospective cohort study in Southern Italy.
    Vaccine. 2023 Aug 9:S0264-410X(23)00886-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  372. MAC S, Shi S, Millson B, Tehrani A, et al
    Burden of illness associated with Respiratory Syncytial Virus (RSV)-related hospitalizations among adults in Ontario, Canada: A retrospective population-based study.
    Vaccine. 2023;41:5141-5149.
    PubMed     Abstract available


  373. CHICOYE A, Crepey P, Nguyen VH, Marquez-Pelaez S, et al
    Contributions of cost-effectiveness analyses (CEA) to influenza vaccination policy for older adults in Europe.
    Vaccine. 2023 Aug 5:S0264-410X(23)00919-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  374. SIMMS AJ, King KD, Tsui N, Edwards SA, et al
    COVID-19 vaccine behaviour among citizens of the Metis Nation of Ontario: A qualitative study.
    Vaccine. 2023 Aug 5:S0264-410X(23)00891-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  375. VERJOVSKY M, Barreto MP, Carmo I, Coutinho B, et al
    Political quarrel overshadows vaccination advocacy: How the vaccine debate on Brazilian Twitter was framed by anti-vaxxers during Bolsonaro administration.
    Vaccine. 2023 Aug 5:S0264-410X(23)00921-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  376. CAMPBELL J, Kaur A, Gamino D, Benoit E, et al
    Individual and structural determinants of COVID-19 vaccine uptake in a marginalized community in the United States.
    Vaccine. 2023 Aug 5:S0264-410X(23)00923-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  377. MOSCARA L, Venerito V, Martinelli A, Di Lorenzo A, et al
    Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.
    Vaccine. 2023 Aug 4:S0264-410X(23)00874-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  378. XU S, Yu H, Cheng X, Wu J, et al
    Inactivated SARS-CoV-2 vaccination does not disturb the clinical course of Graves' disease: An observational cohort study.
    Vaccine. 2023 Aug 4:S0264-410X(23)00884-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  379. AUVIGNE V, Tamandjou Tchuem CR, Schaeffer J, Vaux S, et al
    Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original monovalent vaccines - A matched cohort study in France.
    Vaccine. 2023 Aug 2:S0264-410X(23)00917-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  380. MO J, Spackman E, Swayne DE
    Prediction of highly pathogenic avian influenza vaccine efficacy in chickens by comparison of in vitro and in vivo data: A meta-analysis and systematic review.
    Vaccine. 2023 Aug 1:S0264-410X(23)00922-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    July 2023
  381. HONDA-OKUBO Y, Sakala IG, Andre G, Tarbet EB, et al
    An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice.
    Vaccine. 2023 Jul 31:S0264-410X(23)00892-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  382. WALLACE M, Rosenblum HG, Moulia DL, Broder KR, et al
    A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States.
    Vaccine. 2023 Jul 30:S0264-410X(23)00868-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  383. LIU B, Stepien S, Qian J, Gidding H, et al
    Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection.
    Vaccine. 2023 Jul 29:S0264-410X(23)00881-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  384. AMANI A, Njoh AA, Atuhebwe P, Ndoula S, et al
    Beyond the numbers: An in-depth look at Cameroon's fifth national COVID-19 vaccination campaign through geographical and gender lenses.
    Vaccine. 2023 Jul 29:S0264-410X(23)00905-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  385. GREEN-MCKENZIE J, Shofer FS, Kruse G, Momplaisir F, et al
    COVID-19 vaccine uptake before and after a vaccine mandate at a major academic hospital: Trends by race/ethnicity and level of patient contact.
    Vaccine. 2023 Jul 28:S0264-410X(23)00853-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  386. LAVENDER B, Hooker C, Frampton C, Williams M, et al
    Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naive New Zealand cohort.
    Vaccine. 2023 Jul 27:S0264-410X(23)00882-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  387. ROSA RG, Falavigna M, Manfio JL, de Araujo CLP, et al
    BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study.
    Vaccine. 2023 Jul 26:S0264-410X(23)00869-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  388. KIM DH, Lee J, Youk S, Jeong JH, et al
    Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection.
    Vaccine. 2023;41:4787-4797.
    PubMed     Abstract available


  389. TAMADA Y, Takeuchi K, Kusama T, Maeda M, et al
    Effectiveness of COVID-19 vaccines against infection in Japan: A test-negative study from the VENUS study.
    Vaccine. 2023 Jul 22:S0264-410X(23)00856-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  390. GHAZY RM, Ibrahim SA, Taha SHN, Elshabrawy A, et al
    Attitudes of parents towards influenza vaccine in the Eastern Mediterranean Region: A multilevel analysis.
    Vaccine. 2023 Jul 20:S0264-410X(23)00808-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  391. ARAUJO-CHAVERON L, Sicsic J, Moffroid H, Diaz Luevano C, et al
    Impact of a COVID-19 certificate requirement on vaccine uptake pattern and intention for future vaccination. A cross-sectional study among French adults.
    Vaccine. 2023 Jul 20:S0264-410X(23)00805-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  392. KIM YA, Mousavi K, Yazdi A, Zwierzyna M, et al
    Computational design of mRNA vaccines.
    Vaccine. 2023 Jul 20:S0264-410X(23)00836-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  393. KATHERINE YIH W, Daley MF, Duffy J, Fireman B, et al
    Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink.
    Vaccine. 2023 Jul 19:S0264-410X(23)00823-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  394. PISL V, Vevera J
    COVID-19 vaccine uptake in mental healthcare users: Czech nationwide register study.
    Vaccine. 2023 Jul 19:S0264-410X(23)00840-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  395. ZIMMERMAN RK, Patricia Nowalk M, Dauer K, Clarke L, et al
    Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design.
    Vaccine. 2023 Jul 18:S0264-410X(23)00741-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  396. SABAT I, Neumann-Bohme S, Barros PP, Torbica A, et al
    Vaccine hesitancy comes in waves: Longitudinal evidence on willingness to vaccinate against COVID-19 from seven European countries.
    Vaccine. 2023 Jul 15:S0264-410X(23)00829-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  397. MOROS A, Prenafeta A, Barreiro A, Perozo E, et al
    Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate.
    Vaccine. 2023 Jul 15:S0264-410X(23)00820-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  398. CLOUSTON SAP, Hanes DW, Link BG
    Social inequalities and the early provision and dispersal of COVID-19 vaccinations in the United States: A population trends study.
    Vaccine. 2023 Jul 15:S0264-410X(23)00833-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  399. TALOTTA R
    COVID-19 mRNA vaccines as hypothetical epigenetic players: Results from an in silico analysis, considerations and perspectives.
    Vaccine. 2023 Jul 13:S0264-410X(23)00819-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  400. ALABANZA C, Gavrilov V, Scott T, Yang RS, et al
    Quantitation of strain-specific hemagglutinin trimers in mosaic quadrivalent influenza nanoparticle vaccine by ELISA.
    Vaccine. 2023 Jul 12:S0264-410X(23)00821-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  401. BEYERS KCL, Rbeihat MNM, S Vasconcelos D, Pasmans D, et al
    Preclinical evaluation of performance, safety and usability of VAX-ID(R), a novel intradermal injection device.
    Vaccine. 2023;41:4609-4615.
    PubMed     Abstract available


  402. AGRAWAL P, Damania D, Cseh A, Grab J, et al
    Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
    Vaccine. 2023 Jul 12:S0264-410X(23)00822-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  403. MINCHIN J, Harris GH, Baumann S, Smith ER, et al
    Exclusion of pregnant people from emergency vaccine clinical trials: A systematic review of clinical trial protocols and reporting from 2009 to 2019.
    Vaccine. 2023 Jul 11:S0264-410X(23)00776-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  404. WILLIS DE, Reece S, Gurel-Headley M, Selig JP, et al
    Social processes, practical issues, and COVID-19 vaccination among hesitant adults.
    Vaccine. 2023 Jul 7:S0264-410X(23)00809-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  405. FLEMING JA, Baral R, Higgins D, Khan S, et al
    Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
    Vaccine. 2023 Jul 6:S0264-410X(22)01212-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  406. ZHANG X, Shen P, Liu J, Ji X, et al
    Evaluating the effectiveness and cost-effectiveness of free influenza vaccination policy for older adults in Yinzhou, China: Study protocol of a real-world analyses.
    Vaccine. 2023 Jul 5:S0264-410X(23)00790-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  407. WAGNER A, Juvalta S, Speranza C, Suggs LS, et al
    Let's talk about COVID-19 vaccination: Relevance of conversations about COVID-19 vaccination and information sources on vaccination intention in Switzerland.
    Vaccine. 2023 Jul 5:S0264-410X(23)00807-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  408. LE H, de Klerk N, Blyth CC, Gidding H, et al
    Non-specific benefit of seasonal influenza vaccine on respiratory syncytial virus-hospitalisations in children: An instrumental variable approach using population-based data.
    Vaccine. 2023 Jul 3:S0264-410X(23)00788-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  409. PATEL UC, Schultz T, Schmidt J
    Veteran influenza vaccination acceptance rates after completion of the COVID-19 vaccination series among historical influenza vaccine refusers.
    Vaccine. 2023 Jul 3:S0264-410X(23)00803-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  410. ROSHCHINA Y, Rozhkova K, Roshchin S
    Between nudges and mandates: The drivers of COVID-19 vaccination intentions and subsequent uptake in Russia.
    Vaccine. 2023 Jul 3:S0264-410X(23)00756-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  411. TUCKERMAN J, Kaufman J, Overmars I, Holland P, et al
    Barriers to COVID-19 vaccination of migrant populations: A qualitative interview study of immunisation providers in Victoria, Australia.
    Vaccine. 2023 Jul 3:S0264-410X(23)00804-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  412. TROGSTAD L, Laake I, Robertson AH, Mjaaland S, et al
    Heavy bleeding and other menstrual disturbances in young women after COVID-19 vaccination.
    Vaccine. 2023 Jul 3:S0264-410X(23)00801-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    June 2023
  413. LIU Z, Pang C, Deng Y, Guo C, et al
    Humoral immune response following the inactivated quadrivalent influenza vaccination among HIV-infected and HIV-uninfected adults.
    Vaccine. 2023 Jun 30:S0264-410X(23)00616-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  414. SHINJOH M, Furuichi M, Tsuzuki S, Iqbal A, et al
    Effectiveness of inactivated influenza and COVID-19 vaccines in hospitalized children in 2022/23 season in Japan - The first season of co-circulation of influenza and COVID-19.
    Vaccine. 2023 Jun 30:S0264-410X(23)00785-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  415. LIU Y, Zhang A, Wang Y, Yang J, et al
    Immunogenicity and protective effects of recombinant bivalent COVID-19 vaccine in mice and rhesus macaques.
    Vaccine. 2023 Jun 30:S0264-410X(23)00789-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  416. KU JH, Sy LS, Qian L, Ackerson BK, et al
    Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study.
    Vaccine. 2023;41:4212-4219.
    PubMed     Abstract available


  417. VAN DER BOOR SC, Schmitz-de Vries ETJ, Smits D, Scholl JHG, et al
    Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands.
    Vaccine. 2023;41:4319-4326.
    PubMed     Abstract available


  418. ALVES K, Plested JS, Galbiati S, Chau G, et al
    Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
    Vaccine. 2023;41:4280-4286.
    PubMed     Abstract available


  419. ISHIKAWA K, Nascimento MC, Asano M, Hirata H, et al
    One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan.
    Vaccine. 2023;41:4199-4205.
    PubMed     Abstract available


  420. LEE KS, Rader NA, Miller-Stump OA, Cooper M, et al
    Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Vaccine. 2023 Jun 28:S0264-410X(23)00783-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  421. SHENG Y, Li Z, Lin X, Ma Y, et al
    The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine.
    Vaccine. 2023 Jun 28:S0264-410X(23)00759-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  422. DOMNICH A, Orsi A, Ogliastro M, Trombetta CS, et al
    Influenza vaccine effectiveness in preventing hospital encounters for laboratory-confirmed infection among Italian adults, 2022/23 season.
    Vaccine. 2023 Jun 27:S0264-410X(23)00775-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  423. KIM S, Ko M, Heo Y, Lee YK, et al
    Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.
    Vaccine. 2023 Jun 27:S0264-410X(23)00780-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  424. BARRIENTOS M, Vasquez-Lavin F, Rosales C, Bratti L, et al
    Understanding the role of personal experiences and contextual variables in shaping risk reduction preferences.
    Vaccine. 2023;41:4092-4105.
    PubMed     Abstract available


  425. TORP HANSEN K, Kusk Povlsen F, Hammer Bech B, Nygaard Hansen S, et al
    Immediate adverse reactions following COVID-19 vaccination among 16-65-year-old Danish citizens.
    Vaccine. 2023 Jun 23:S0264-410X(23)00758-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  426. TURLEY CB, Tables L, Fuller T, Sanders LJ, et al
    Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.
    Vaccine. 2023 Jun 23:S0264-410X(23)00755-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  427. SALEH SN, McDonald SA, Basit MA, Kumar S, et al
    Public perception of COVID-19 vaccines through analysis of Twitter content and users.
    Vaccine. 2023 Jun 23:S0264-410X(23)00743-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  428. HOWARD MC
    Integrating the person-centered approach with the study of vaccine hesitancy: Applying latent profile analysis to identify vaccine hesitancy subpopulations and assess their relations with correlates and vaccination outcomes.
    Vaccine. 2023 Jun 23:S0264-410X(23)00742-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  429. CHAUDHARY A, Madhavan R, Babji S, Raju R, et al
    Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India.
    Vaccine. 2023 Jun 23:S0264-410X(23)00744-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  430. AUGUSTYNIAK A, Szymanski T, Porzucek F, Mieloch AA, et al
    A cohort study reveals different dynamics of SARS-CoV-2-specific antibody formation after Comirnaty and Vaxzevria vaccination.
    Vaccine. 2023 Jun 21:S0264-410X(23)00665-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  431. LUANGASANATIP N, Painter C, Pan-Ngum W, Saralamba S, et al
    How to model the impact of vaccines for policymaking when the characteristics are uncertain: A case study in Thailand prior to the vaccine rollout during the COVID-19 pandemic.
    Vaccine. 2023 Jun 20:S0264-410X(23)00740-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  432. CHEN X, Lin Y, Yue S, Yang Y, et al
    PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness.
    Vaccine. 2023 Jun 20:S0264-410X(23)00737-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  433. EKIMOV A, Arunachalam AB, Blake T, Bodle J, et al
    Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine.
    Vaccine. 2023 Jun 19:S0264-410X(23)00726-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  434. HONDA-OKUBO Y, Li L, Andre G, Leong KH, et al
    An Advax-CpG55.2 adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge.
    Vaccine. 2023 Jun 19:S0264-410X(23)00748-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  435. UDA K, Okubo Y, Tsuge M, Tsukahara H, et al
    Impacts of routine varicella vaccination program and COVID-19 pandemic on varicella and herpes zoster incidence and health resource use among children in Japan.
    Vaccine. 2023 Jun 19:S0264-410X(23)00739-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  436. TZENG R, Huang FY, Lee J
    Compliance, procrastination and refusal: American COVID-19 vaccination trust and value orientation.
    Vaccine. 2023 Jun 19:S0264-410X(23)00745-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  437. MASOUD D, Pierz A, Rauh L, Cruz AK, et al
    Vaccine Trust Gauge: Mixed methods research to measure and understand vaccine trust.
    Vaccine. 2023 Jun 17:S0264-410X(23)00690-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  438. DOYON-PLOURDE P, Przepiorkowski J, Young K, Zhao L, et al
    Intraseasonal waning immunity of seasonal influenza vaccine - A systematic review and meta-analysis.
    Vaccine. 2023 Jun 16:S0264-410X(23)00713-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  439. DUNN DT, Gilson R, McCormack S, McCoy LE, et al
    Licenced doses of approved COVID-19 vaccines may not be optimal: A review of the early-phase, dose-finding trials.
    Vaccine. 2023 Jun 16:S0264-410X(23)00712-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  440. BISWAS RK, Afiaz A, Huq S, Farzana M, et al
    Public opinion on COVID-19 vaccine prioritization in Bangladesh: Who gets the vaccine and whom do you leave out?
    Vaccine. 2023 Jun 16:S0264-410X(23)00725-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  441. NISHIYAMA A, Adachi Y, Tonouchi K, Moriyama S, et al
    Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses.
    Vaccine. 2023 Jun 15:S0264-410X(23)00685-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  442. PIGNATTI P, Ramirez GA, Russo M, Marraccini P, et al
    Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to excipients.
    Vaccine. 2023 Jun 15:S0264-410X(23)00714-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  443. MUANGNOICHAROEN S, Wiangcharoen R, Nanthapisal S, Kamolratakul S, et al
    Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
    Vaccine. 2023 Jun 15:S0264-410X(23)00718-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  444. KENIGSBERG TA, Hanson KE, Klein NP, Zerbo O, et al
    Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink.
    Vaccine. 2023 Jun 15:S0264-410X(23)00717-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  445. PUTHANAKIT T, Chokephaibulkit K, Chaithongwongwatthana S, Bhat N, et al
    A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women.
    Vaccine. 2023 Jun 15:S0264-410X(23)00657-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  446. SHOAIBI A, Lloyd PC, Wong HL, Clarke TC, et al
    Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.
    Vaccine. 2023 Jun 14:S0264-410X(23)00682-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  447. CIEMINS EL, Gillen A, Tallam M
    RSV: A vaccine is coming, time to educate providers.
    Vaccine. 2023 Jun 14:S0264-410X(23)00695-3. doi: 10.1016/j.vaccine.2023.
    PubMed    


  448. SAADATIAN-ELAHI M, Henaff L, Elias C, Nunes MC, et al
    Patient influenza vaccination reduces the risk of hospital-acquired influenza: An incident test negative-case control study in Lyon university hospital, France (2004-2020).
    Vaccine. 2023 Jun 13:S0264-410X(23)00621-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  449. SALMANTON-GARCIA J, Wipfler P, Valle-Simon P, Merakou C, et al
    VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe.
    Vaccine. 2023;41:3915-3922.
    PubMed     Abstract available


  450. WOO EJ, Gee J, Marquez P, Baggs J, et al
    Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
    Vaccine. 2023 Jun 13:S0264-410X(23)00687-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  451. MUNOZ FM, Posavad CM, Richardson BA, Badell ML, et al
    COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.
    Vaccine. 2023 Jun 13:S0264-410X(23)00698-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  452. WATESKA AR, Nowalk MP, Lin CJ, Harrison LH, et al
    Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
    Vaccine. 2023 Jun 12:S0264-410X(23)00669-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  453. MA D, Tian S, Qin Q, Yu Y, et al
    Construction of an inhalable recombinant M2e-FP-expressing Bacillus subtilis spores-based vaccine and evaluation of its protection efficacy against influenza in a mouse model.
    Vaccine. 2023 Jun 10:S0264-410X(23)00655-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  454. MADRAN B, Kayi I, Beser A, Ergonul O, et al
    Uptake of COVID-19 vaccines among healthcare workers and the effect of nudging interventions: A mixed methods study.
    Vaccine. 2023 Jun 9:S0264-410X(23)00688-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  455. UI M, Hirama T, Akiba M, Honda M, et al
    Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan.
    Vaccine. 2023 Jun 9:S0264-410X(23)00663-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  456. MARTINEZ MR, Gao J, Wan H, Kang H, et al
    Inactivated influenza virions are a flexible vaccine platform for eliciting protective antibody responses against neuraminidase.
    Vaccine. 2023 Jun 8:S0264-410X(23)00629-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  457. NOGAREDA F, Gharpure R, Contreras M, Velandia M, et al
    Seasonal influenza vaccination in the Americas: Progress and challenges during the COVID-19 pandemic.
    Vaccine. 2023 Jun 8:S0264-410X(23)00689-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  458. DE GIER B, van Asten L, Boere TM, van Roon A, et al
    Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021-January 2022.
    Vaccine. 2023 Jun 8:S0264-410X(23)00660-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  459. ROY A, Polazzi S, Ploin D, Gillet Y, et al
    The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs.
    Vaccine. 2023;41:3796-3800.
    PubMed     Abstract available


  460. SHAW RJ, Doyle AJ, Millen EA, Stowe J, et al
    Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria.
    Vaccine. 2023 Jun 7:S0264-410X(23)00662-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  461. KATO H, Hozawa T, Fukushima W, Nobusawa E, et al
    Influenza vaccine viruses and the development of seasonal vaccines: A Japanese perspective.
    Vaccine. 2023 Jun 6:S0264-410X(23)00640-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  462. KIM DELUCA E, Gebremariam A, Rose A, Biggerstaff M, et al
    Cost-effectiveness of routine annual influenza vaccination by age and risk status.
    Vaccine. 2023 Jun 6:S0264-410X(23)00495-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  463. KIM WJ, Roberts CC, Song JY, Yoon JG, et al
    Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.
    Vaccine. 2023 Jun 6:S0264-410X(23)00683-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  464. PELLETIER C, Labbe F, Bettinger JA, Curran J, et al
    From high hopes to disenchantment: A qualitative analysis of editorial cartoons on COVID-19 vaccines in Canadian newspapers.
    Vaccine. 2023 Jun 6:S0264-410X(23)00658-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  465. ELDER E, Bangalore Revanna C, Johansson C, Wallin RPA, et al
    Protective immunity induced by an inhaled SARS-CoV-2 subunit vaccine.
    Vaccine. 2023 Jun 6:S0264-410X(23)00684-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  466. MAKANUT S, Wangteeraprasert A, Jitpewngam W, Ngoenkam J, et al
    Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
    Vaccine. 2023 Jun 5:S0264-410X(23)00666-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  467. WESSELINK AK, Lovett SM, Weinberg J, Geller RJ, et al
    COVID-19 vaccination and menstrual cycle characteristics: A prospective cohort study.
    Vaccine. 2023 Jun 5:S0264-410X(23)00681-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  468. KOZMA GT, Meszaros T, Berenyi P, Facsko R, et al
    Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG.
    Vaccine. 2023 Jun 5:S0264-410X(23)00667-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  469. ERGUN T, Hosgoren Tekin S, Apti Sengun O, Akin Cakici O, et al
    Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.
    Vaccine. 2023 Jun 3:S0264-410X(23)00615-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  470. FEDDEMA JJ, Fernald KDS, Schikan HGCP, van de Burgwal LHM, et al
    Upscaling vaccine manufacturing capacity - Kkey bottlenecks and lessons learned.
    Vaccine. 2023 Jun 3:S0264-410X(23)00554-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    May 2023
  471. WANG LJ, Tsai CS, Chou WJ, Li CJ, et al
    Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study.
    Vaccine. 2023 May 29:S0264-410X(23)00628-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  472. ARROSPIDE A, Sagardui MG, Larizgoitia I, Iturralde A, et al
    Effectiveness of the booster dose of COVID-19 vaccine in the Basque Country during the sixth wave: A nationwide cohort study.
    Vaccine. 2023 May 29:S0264-410X(23)00622-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  473. HU S, Xiong C, Zhao Y, Yuan X, et al
    Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARS-Cov-2 B.1.1.529 (Omicron) variant.
    Vaccine. 2023 May 29:S0264-410X(23)00617-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  474. MILLER ER, Moro PL, Shimabukuro TT, Carlock G, et al
    COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office.
    Vaccine. 2023 May 24:S0264-410X(23)00613-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  475. HORI D, Keneda Y, Ozaki A, Tabuchi T, et al
    Sexual orientation was associated with intention to be vaccinated with a smallpox vaccine against mpox: A cross-sectional preliminary survey in Japan.
    Vaccine. 2023 May 24:S0264-410X(23)00611-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  476. NUGENT C, Abul Y, White EM, Shehadeh F, et al
    Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers.
    Vaccine. 2023;41:3403-3409.
    PubMed     Abstract available


  477. JOUDEH AI, Lutf AQ, Mahdi S, Tran G, et al
    Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review.
    Vaccine. 2023 May 22:S0264-410X(23)00609-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  478. ALICANDRO G, Orena BS, Rosazza C, Cariani L, et al
    Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis.
    Vaccine. 2023 May 22:S0264-410X(23)00590-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  479. GHAZNAVI C, Eguchi A, Suu Lwin K, Yoneoka D, et al
    Estimating global changes in routine childhood vaccination coverage during the COVID-19 pandemic, 2020-2021.
    Vaccine. 2023 May 22:S0264-410X(23)00583-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  480. GUO BQ, Li HB, Yang LQ
    Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12-17 years.
    Vaccine. 2023 May 22:S0264-410X(23)00610-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  481. BOLSEWICZ KT, Steffens MS, King C, Abdi I, et al
    A qualitative study on COVID-19 pandemic impacts on parental attitudes and intentions for routine adolescent vaccinations: The role of trust.
    Vaccine. 2023 May 22:S0264-410X(23)00586-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  482. EGER J, Kaplan LC, Sternberg H
    How to reduce vaccination hesitancy? The relevance of evidence and its communicator.
    Vaccine. 2023 May 22:S0264-410X(23)00298-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  483. EMBI PJ, Levy ME, Patel P, DeSilva MB, et al
    Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021.
    Vaccine. 2023 May 22:S0264-410X(23)00588-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  484. BOING AF, Boing AC, Barberia L, Borges ME, et al
    Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: A multilevel study of 2021-2022 data.
    Vaccine. 2023 May 17:S0264-410X(23)00569-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  485. ZHOU ZH, Cortese MM, Fang JL, Wood R, et al
    Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination.
    Vaccine. 2023 May 16:S0264-410X(23)00568-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  486. BLACK SB, Chandler RE, Edwards KM, Sturkenboom MCJM, et al
    Assessing vaccine safety during a pandemic: Recent experience and lessons learned for the future.
    Vaccine. 2023 May 15:S0264-410X(23)00468-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  487. LIMAYE RJ, Singh P, Paul A, Fesshaye B, et al
    COVID-19 vaccine decision-making among pregnant and lactating women in Bangladesh.
    Vaccine. 2023 May 15:S0264-410X(23)00551-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  488. SURIE D, Bonnell LN, DeCuir J, Gaglani M, et al
    Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022.
    Vaccine. 2023 May 15:S0264-410X(23)00567-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  489. GEORGE TK, Nair NP, Singh AK, Dilesh Kumar A, et al
    Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach.
    Vaccine. 2023 May 12:S0264-410X(23)00486-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  490. KEHAGIA E, Papakyriakopoulou P, Valsami G
    Advances in intranasal vaccine delivery: A promising non-invasive route of immunization.
    Vaccine. 2023 May 11:S0264-410X(23)00529-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  491. ROBERTS-MCCARTHY E, Buck PO, Smith-Ray RL, Van de Velde N, et al
    Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic.
    Vaccine. 2023 May 11:S0264-410X(23)00383-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  492. LANGLETE P, Tesli M, Veneti L, Starrfelt J, et al
    Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 - January 2022.
    Vaccine. 2023 May 10:S0264-410X(23)00549-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  493. SMITH K, Hegazy K, Cai MR, McKnight I, et al
    Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials.
    Vaccine. 2023 May 10:S0264-410X(23)00543-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  494. VAN IERSEL SCJL, McDonald SA, de Gier B, Knol MJ, et al
    Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022.
    Vaccine. 2023 May 10:S0264-410X(23)00545-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  495. RUBIN THOMPSON LJ, Grubo M, Veller M, Badenhorst RH, et al
    Building global vaccine manufacturing capacity: Spotlight on Africa.
    Vaccine. 2023 May 10:S0264-410X(23)00527-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  496. CHIAVENNA C, Leone LP, Melegaro A, Rotesi T, et al
    Personal risk or societal benefit? Investigating adults' support for COVID-19 childhood vaccination.
    Vaccine. 2023 May 9:S0264-410X(23)00544-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  497. KURIYAMA K, Murakami K, Masuda T, Sugiura K, et al
    Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
    Vaccine. 2023 May 8:S0264-410X(23)00519-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  498. SUTTON WJH, Branham PJ, Williamson YM, Cooper HC, et al
    Quantification of SARS-CoV-2 spike protein expression from mRNA vaccines using isotope dilution mass spectrometry.
    Vaccine. 2023 May 8:S0264-410X(23)00458-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  499. BORDALO FERREIRA F, Rafael MA, Coimbra L, Boavida N, et al
    Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.
    Vaccine. 2023 May 8:S0264-410X(23)00530-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  500. FITZ-PATRICK D, Young M, Yacisin K, McElwee K, et al
    Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults >/=65 years old.
    Vaccine. 2023 May 8:S0264-410X(23)00520-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  501. KPOZEHOUEN EB, Heywood AE, Menzies R, Seale H, et al
    Informing the design of a whole of life immunisation register for Australia.
    Vaccine. 2023;41:3011-3018.
    PubMed     Abstract available


  502. RODRIGUEZ DM, Major CG, Sanchez-Gonzalez L, Jones E, et al
    Dengue vaccine acceptability before and after the availability of COVID-19 vaccines in Puerto Rico.
    Vaccine. 2023 May 5:S0264-410X(23)00516-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  503. KU JH, Sy LS, Qian L, Ackerson BK, et al
    Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study.
    Vaccine. 2023 May 3:S0264-410X(23)00498-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  504. FUKUNAGA R, Kaplan ZE, Rodriguez T, Hagan L, et al
    Attitudes towards COVID-19 vaccination among incarcerated persons in the Federal Bureau of Prisons, June-July 2021.
    Vaccine. 2023 May 2:S0264-410X(23)00512-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  505. LEFFERTS B, Bruden D, Plumb ID, Hodges E, et al
    Effectiveness of the COVID-19 vaccines on preventing symptomatic SARS-CoV-2 infections and hospitalizations in Southwestern Alaska, January-December 2021.
    Vaccine. 2023 May 1:S0264-410X(23)00496-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  506. MESINA FZ, Sapinoso FAD, De Castro JAV, Vaswani PPM, et al
    Hematologic adverse events reported after COVID-19 vaccination in the Philippines: A national database study.
    Vaccine. 2023 May 1:S0264-410X(23)00490-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  507. HUSSAINI L, Labberton AS, Winje BA, Kraft KB, et al
    COVID-19 vaccination rates among adolescents (12-17 years) by immigrant background and sociodemographic factors: A nationwide registry study in Norway.
    Vaccine. 2023 May 1:S0264-410X(23)00514-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  508. KUHLBRANDT C, McGowan CR, Stuart R, Grenfell P, et al
    COVID-19 vaccination decisions among Gypsy, Roma, and Traveller communities: A qualitative study moving beyond "vaccine hesitancy".
    Vaccine. 2023 May 1:S0264-410X(23)00515-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    April 2023
  509. MARCHESE AM, Zhou X, Kinol J, Underwood E, et al
    NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.
    Vaccine. 2023 Apr 29:S0264-410X(23)00467-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  510. VANNI T, da Graca Salomao M, Viscondi JYK, Braga PE, et al
    A randomized, double-blind, non-inferiority trial comparing the immunogenicity and safety of two seasonal inactivated influenza vaccines in adults.
    Vaccine. 2023 Apr 28:S0264-410X(23)00464-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  511. KOEN AL, Izu A, Baillie V, Kwatra G, et al
    Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
    Vaccine. 2023 Apr 27:S0264-410X(23)00483-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  512. KIM C, Aminawung JA, Brinkley-Rubinstein L, Wang EA, et al
    COVID-19 vaccine deliberation in individuals directly impacted by incarceration.
    Vaccine. 2023 Apr 26:S0264-410X(23)00492-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  513. ALSUHEBANY N, Alowais SA, Aldairem A, Almohareb SN, et al
    Identifying gaps in vaccination perception after mandating the COVID-19 vaccine in Saudi Arabia.
    Vaccine. 2023 Apr 26:S0264-410X(23)00481-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  514. LU X, Masuda S, Horlad H, Katoh T, et al
    Safety and adverse effects of the coronavirus disease 2019 vaccine among the general Japanese adult population.
    Vaccine. 2023 Apr 26:S0264-410X(23)00469-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  515. KIM SJ, Kwon SL, Lee JY, Oh J, et al
    Why school is crucial to increase vaccination coverage for children: Evaluation of school vaccination check program in South Korea 2021-2022.
    Vaccine. 2023 Apr 25:S0264-410X(23)00430-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  516. JIANG M, Vaisanen E, Kolehmainen P, Huttunen M, et al
    COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs.
    Vaccine. 2023 Apr 25:S0264-410X(23)00463-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  517. WALTER D, Ophir Y, Ye H
    Conspiracies, misinformation and resistance to public health measures during COVID-19 in white nationalist online communication.
    Vaccine. 2023;41:2868-2877.
    PubMed     Abstract available


  518. TAMANDJOU C, Auvigne V, Schaeffer J, Vaux S, et al
    Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France.
    Vaccine. 2023;41:2754-2760.
    PubMed     Abstract available


  519. MA L, Brecher M, Soufal A, Gaiotto T, et al
    Structural interrogation of a trimeric prefusion RSV fusion protein vaccine candidate by a camelid nanobody.
    Vaccine. 2023 Apr 19:S0264-410X(23)00413-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  520. BAO Y, He L, Miao B, Zhong Z, et al
    BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai.
    Vaccine. 2023 Apr 19:S0264-410X(23)00377-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  521. PILLSBURY A, Phillips A, Deng L, Quinn H, et al
    Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines.
    Vaccine. 2023 Apr 18:S0264-410X(23)00441-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  522. MAO Z, Li X, Dacosta-Urbieta A, Billard MN, et al
    Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe.
    Vaccine. 2023;41:2707-2715.
    PubMed     Abstract available


  523. HOUTSMA C, Raines AM, Reggio A, Rushing LK, et al
    COVID-19 vaccine distribution: A high reliability organization approach.
    Vaccine. 2023 Apr 17:S0264-410X(23)00423-1. doi: 10.1016/j.vaccine.2023.
    PubMed    


  524. GORDON SF, Lam J, Vasquez JT, Cercone R, et al
    A tailored COVID-19 vaccination pathway for children 5-11 years in Victoria, Australia.
    Vaccine. 2023 Apr 17:S0264-410X(23)00424-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  525. LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Biela M, et al
    COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS).
    Vaccine. 2023 Apr 14:S0264-410X(23)00427-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  526. FREITAG TL, Fagerlund R, Karam NL, Leppanen VM, et al
    Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
    Vaccine. 2023 Apr 14:S0264-410X(23)00403-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  527. ANDRAUD M, Herve S, Gorin S, Barbier N, et al
    Evaluation of early single dose vaccination on swine influenza A virus transmission in piglets: From experimental data to mechanistic modelling.
    Vaccine. 2023 Apr 13:S0264-410X(23)00401-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  528. ESTEPHAN L, Lin YC, Lin YT, Chen YH, et al
    Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.
    Vaccine. 2023 Apr 12:S0264-410X(23)00421-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  529. UEMURA K, Ono S, Michihata N, Yamana H, et al
    Duration of influenza vaccine effectiveness in the elderly in Japan: A retrospective cohort study using large-scale population-based registry data.
    Vaccine. 2023 Apr 10:S0264-410X(23)00373-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  530. RATHORE APS, St John AL
    Promises and challenges of mucosal COVID-19 vaccines.
    Vaccine. 2023 Apr 10:S0264-410X(23)00396-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  531. HARRIS C, Cottrell S, Perry M, Meaden R, et al
    A pilot intervention to improve uptake and equality of childhood influenza vaccination in an area of Wales, through the introduction of a mixed delivery model including nursery school immunisation sessions.
    Vaccine. 2023 Apr 8:S0264-410X(23)00382-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  532. LEIGH HOBBS J, Paul LA, Buchan SA, Harris T, et al
    Methodological changes implemented over time to support accurate and timely COVID-19 vaccine coverage estimates: Ontario, Canada.
    Vaccine. 2023 Apr 7:S0264-410X(23)00389-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  533. HARRIS JN, Mauro CM, Morgan TL, de Roche A, et al
    Factors impacting parental uptake of COVID-19 vaccination for U.S. Children ages 5-17.
    Vaccine. 2023 Apr 7:S0264-410X(23)00384-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  534. ALMAHASIS SO, Fox B, Ha D, Qian J, et al
    Pharmacy-based immunization in rural USA during the COVID-19 pandemic: A survey of community pharmacists from five southeastern states.
    Vaccine. 2023;41:2503-2513.
    PubMed     Abstract available


  535. SMITS PD, Gratzl S, Simonov M, Nachimuthu SK, et al
    Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities.
    Vaccine. 2023;41:2447-2455.
    PubMed     Abstract available


  536. GOLD MS, Amarasinghe A, Greenhawt M, Kelso JM, et al
    Anaphylaxis: Revision of the Brighton collaboration case definition.
    Vaccine. 2023;41:2605-2614.
    PubMed     Abstract available


  537. BURKHOLDER B, Wadood Z, Kassem AM, Ehrhardt D, et al
    The immediate impact of the COVID-19 pandemic on polio immunization and surveillance activities.
    Vaccine. 2023;41 Suppl 1:A2-A11.
    PubMed     Abstract available


  538. KALKOWSKA DA, Pallansch MA, Wassilak SGF, Cochi SL, et al
    Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
    Vaccine. 2023;41 Suppl 1:A136-A141.
    PubMed     Abstract available


  539. KALKOWSKA DA, Voorman A, Pallansch MA, Wassilak SGF, et al
    The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
    Vaccine. 2023;41 Suppl 1:A12-A18.
    PubMed     Abstract available


  540. PAYNE JR, Bose S, Kubiak RW, Nolen LD, et al
    Evaluation of mortality risk after COVID-19 vaccination, Utah 2021.
    Vaccine. 2023 Apr 5:S0264-410X(23)00380-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  541. BRAEYE T, Catteau L, Brondeel R, van Loenhout JAF, et al
    Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021-2022.
    Vaccine. 2023 Apr 5:S0264-410X(23)00376-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  542. KIM H, Cho HK, Kang YM, Sagong M, et al
    Protective efficacy of a bivalent H5 influenza vaccine candidate against both clades 2.3.2.1 and 2.3.4.4 high pathogenic avian influenza viruses in SPF chickens.
    Vaccine. 2023 Apr 4:S0264-410X(23)00311-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  543. PRADA E, Langbecker A, Catalan-Matamoros D
    Public discourse and debate about vaccines in the midst of the covid-19 pandemic: A qualitative content analysis of Twitter.
    Vaccine. 2023 Apr 4:S0264-410X(23)00375-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  544. FRODLUND M, Nived P, Chatzidionysiou A, Sodergren A, et al
    The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA).
    Vaccine. 2023 Apr 4:S0264-410X(23)00372-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  545. TOSHKOV D
    What accounts for the variation in COVID-19 vaccine hesitancy in Eastern, Southern and Western Europe?
    Vaccine. 2023 Apr 4:S0264-410X(23)00314-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  546. ALI Y, Piche-Renaud PP, Karimi-Shahrbabak E, Farrar DS, et al
    Pediatricians' perceptions, practices, and barriers regarding COVID-19 vaccine for children: A cross-sectional survey in Ontario, Canada.
    Vaccine. 2023 Apr 3:S0264-410X(23)00335-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  547. URQUIDI C, Santelices E, Lagomarcino AJ, Teresa Valenzuela M, et al
    The added effect of non-pharmaceutical interventions and lifestyle behaviors on vaccine effectiveness against severe COVID-19 in Chile: A matched case-double control study.
    Vaccine. 2023 Apr 3:S0264-410X(23)00354-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  548. MAQUILING A, Jeevakanthan A, Ho Mi Fane B
    The effect of vaccine mandate announcements on vaccine uptake in Canada: An interrupted time series analysis.
    Vaccine. 2023 Apr 3:S0264-410X(23)00334-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  549. CRIADO MF, Kassa A, Bertran K, Kwon JH, et al
    Efficacy of multivalent recombinant herpesvirus of turkey vaccines against high pathogenicity avian influenza, infectious bursal disease, and Newcastle disease viruses.
    Vaccine. 2023 Apr 1:S0264-410X(23)00349-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  550. LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al
    Lack of association between vaccination rates and excess mortality in Cyprus during the COVID-19 pandemic.
    Vaccine. 2023 Apr 1:S0264-410X(23)00316-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    March 2023
  551. XU S, Zhang B, Yao J, Ruan W, et al
    A new H9 influenza virus mRNA vaccine elicits robust protective immunity against infection.
    Vaccine. 2023 Mar 31:S0264-410X(23)00343-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  552. DATAR RS, Fette LM, Hinkelman AN, Hammershaimb EA, et al
    Factors associated with COVID-19 vaccination during June-October 2021: A multi-site prospective study.
    Vaccine. 2023 Mar 31:S0264-410X(23)00352-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  553. HU Y, Wang Y, Shao T, Tang W, et al
    Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.
    Vaccine. 2023 Mar 30:S0264-410X(23)00350-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  554. FUKUDA H, Maeda M, Murata F
    Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study.
    Vaccine. 2023 Mar 29:S0264-410X(23)00353-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  555. SU WJ, Arnold Chan K, Chuang JH, Wang TA, et al
    Acute reactions after a homologous primary COVID-19 vaccination series: Analysis of Taiwan V-Watch data.
    Vaccine. 2023 Mar 28:S0264-410X(23)00336-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  556. SANTI LAURINI G, Montanaro N, Broccoli M, Bonaldo G, et al
    Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.
    Vaccine. 2023 Mar 28:S0264-410X(23)00348-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  557. GIDENGIL CA, Parker AM, Markowitz LE, Gedlinske AM, et al
    Health care provider knowledge around shared clinical decision-making regarding HPV vaccination of adults aged 27-45 years in the United States.
    Vaccine. 2023 Mar 27:S0264-410X(23)00186-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  558. HU B, Yang W, Bouanchaud P, Chongo Y, et al
    Determinants of COVID-19 vaccine acceptance in Mozambique: The role of institutional trust.
    Vaccine. 2023 Mar 27:S0264-410X(23)00347-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  559. KANG SW, Park H, Yeun Kim J, Bae JY, et al
    Comparison of culture-competent virus shedding duration of SARS-CoV-2 Omicron variant in regard to vaccination status: A prospective cohort study.
    Vaccine. 2023 Mar 27:S0264-410X(23)00339-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  560. CESUR F, Atasever Z, Ozoran Y
    Impact of vitamin D3 supplementation on COVID-19 vaccine response and immunoglobulin G antibodies in deficient women: A randomized controlled trial.
    Vaccine. 2023 Mar 27:S0264-410X(23)00341-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  561. DUGOVICH AM, Cox TH, Weeda ER, Garner SS, et al
    First hepatitis B vaccine uptake in neonates prior to and during the COVID-19 pandemic.
    Vaccine. 2023 Mar 27:S0264-410X(23)00333-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  562. PANNUS P, Depickere S, Kemlin D, Georges D, et al
    Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naive nursing home residents and healthy adults.
    Vaccine. 2023 Mar 27:S0264-410X(23)00340-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  563. CIAPPONI A, Berrueta M, P K Parker E, Bardach A, et al
    Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis.
    Vaccine. 2023 Mar 27:S0264-410X(23)00332-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  564. VAN KESSEL R, Forman R, Milstein R, Mastylak A, et al
    Divergent COVID-19 vaccine policies: Policy mapping of ten European countries.
    Vaccine. 2023 Mar 22:S0264-410X(23)00320-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  565. YANG J, Huo X, Jiang Q, Liao Y, et al
    Preclinical safety evaluation of intradermal SARS-CoV-2 inactivated vaccine (Vero cells) administration in macaques.
    Vaccine. 2023 Mar 21:S0264-410X(23)00317-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  566. PHOOLCHAROEN W, Shanmugaraj B, Khorattanakulchai N, Sunyakumthorn P, et al
    Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
    Vaccine. 2023 Mar 21:S0264-410X(23)00312-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  567. SATO R
    Vaccine hesitancy against COVID-19 vaccine over time in Nigeria.
    Vaccine. 2023 Mar 21:S0264-410X(23)00313-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  568. ATMAR RL, Bernstein DI, Winokur P, Frey SE, et al
    Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial.
    Vaccine. 2023 Mar 18:S0264-410X(23)00285-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  569. SHEN AK, Browne S, Srivastava T, Kornides ML, et al
    Trusted messengers and trusted messages: The role for community-based organizations in promoting COVID-19 and routine immunizations.
    Vaccine. 2023;41:1994-2002.
    PubMed     Abstract available


  570. PEREZ MA, Hsiao HM, Chen X, Kunkel A, et al
    Serologic responses to COVID-19 vaccination in children with history of multisystem inflammatory syndrome (MIS-C).
    Vaccine. 2023 Mar 15:S0264-410X(23)00283-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  571. LIN JH, Huang YT, Yu JC, Chan KA, et al
    Mediation and instrumental variable analyses for vaccine-induced antibody titer against influenza B.
    Vaccine. 2023 Mar 14:S0264-410X(23)00261-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  572. LAMUDA PA, Azar A, Taylor BG, Balawajder EF, et al
    Latent class analysis of medical mistrust and COVID-19 vaccine hesitancy among adults in the United States just prior to FDA emergency use authorization.
    Vaccine. 2023 Mar 13:S0264-410X(23)00263-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  573. KELLY D, O'Donnell K, Marron L, Dwyer R, et al
    Immunocompromise among vaccinated versus unvaccinated COVID-19 cases admitted to critical care in Ireland, July to October 2021.
    Vaccine. 2023 Mar 13:S0264-410X(23)00258-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  574. KWAK HW, Park HJ, Jung SY, Oh EY, et al
    Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants.
    Vaccine. 2023;41:1892-1901.
    PubMed     Abstract available


  575. LIU YC, Munoz FM, Izurieta HS, Tamborska AA, et al
    Anosmia: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2023;41:1902-1910.
    PubMed     Abstract available


  576. SRIVASTAV A, Lu PJ, Amaya A, Dever JA, et al
    Prevalence of influenza-specific vaccination hesitancy among adults in the United States, 2018.
    Vaccine. 2023 Mar 10:S0264-410X(23)00255-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  577. SANCHEZ L, Nakama T, Nagai H, Matsuoka O, et al
    Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults >/= 60 years of age: Results from a phase III, randomized clinical trial.
    Vaccine. 2023 Mar 9:S0264-410X(23)00225-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  578. PLUMB ID, Fette LM, Tjaden AH, Feldstein L, et al
    Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.
    Vaccine. 2023 Mar 9:S0264-410X(23)00253-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  579. IKEWAKI N, Kurosawa G, Levy GA, Preethy S, et al
    Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta glucans as a safer strategy in management.
    Vaccine. 2023 Mar 8:S0264-410X(23)00252-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  580. HART RJ, Baumer-Mouradian S, Bone JN, Olson P, et al
    Factors associated with US caregivers' uptake of pediatric COVID-19 vaccine by race and ethnicity.
    Vaccine. 2023 Mar 6:S0264-410X(23)00242-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  581. BAEK YJ, Kim WJ, Ko JH, Lee YJ, et al
    A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen.
    Vaccine. 2023;41:1694-1702.
    PubMed     Abstract available


  582. GRIGNOLIO CORSINI A, Zagarella RM, Adamo M, Caporale C, et al
    From COVID-19 vaccine candidates to compulsory vaccination: The attitudes of Italian citizens in the key 7-month of vaccination campaign.
    Vaccine. 2023 Mar 3:S0264-410X(23)00243-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  583. ESTEPHAN L, Liu LT, Lien CE, Smith ER, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.
    Vaccine. 2023 Mar 3:S0264-410X(23)00245-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  584. XIE S, Monteiro K, Gjelsvik A
    The association between maternal influenza vaccination during pregnancy and adverse birth outcomes in the United States: Pregnancy risk Assessment Monitoring System (PRAMS).
    Vaccine. 2023 Mar 2:S0264-410X(23)00228-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  585. LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Olbromski MJ, et al
    COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) - preliminary study.
    Vaccine. 2023 Mar 2:S0264-410X(23)00227-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  586. HURSTAK EE, Paasche-Orlow MK, Hahn EA, Henault LE, et al
    The mediating effect of health literacy on COVID-19 vaccine confidence among a diverse sample of urban adults in Boston and Chicago.
    Vaccine. 2023 Mar 2:S0264-410X(23)00202-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  587. GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al
    Willingness to vaccinate children against COVID-19 declined during the pandemic.
    Vaccine. 2023 Mar 2:S0264-410X(23)00223-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  588. NA L, Banks S, Wang PP
    Racial and ethnic disparities in COVID-19 vaccine uptake: A mediation framework.
    Vaccine. 2023 Mar 1:S0264-410X(23)00241-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    February 2023
  589. MALTEZOU HC, Hatziantoniou S, Theodoridou K, Vasileiou K, et al
    Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.
    Vaccine. 2023 Feb 27:S0264-410X(23)00221-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  590. TAMANDJOU TCHUEM CR, Auvigne V, Vaux S, Montagnat C, et al
    Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Vaccine. 2023 Feb 27:S0264-410X(23)00216-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  591. O'KENNEDY MM, Abolnik C, Smith T, Motlou T, et al
    Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits.
    Vaccine. 2023 Feb 27:S0264-410X(23)00185-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  592. ITAMOCHI M, Yazawa S, Inasaki N, Saga Y, et al
    Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Vaccine. 2023 Feb 27:S0264-410X(23)00222-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  593. GETANEH AM, Li X, Mao Z, Johannesen CK, et al
    Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries.
    Vaccine. 2023;41:1623-1631.
    PubMed     Abstract available


  594. FEITSMA EA, Janssen YF, Boersma HH, van Sleen Y, et al
    A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
    Vaccine. 2023 Feb 23:S0264-410X(23)00200-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  595. KABIR SULAIMAN S, Sale Musa M, Isma'il Tsiga-Ahmed F, Muhammad Dayyab F, et al
    COVID-19 vaccine hesitancy among people living with HIV in a low-resource setting: A multi-center study of prevalence, correlates and reasons.
    Vaccine. 2023 Feb 23:S0264-410X(23)00199-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  596. CANNON K, Cardona JF, Yacisin K, Thompson A, et al
    Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.
    Vaccine. 2023 Feb 22:S0264-410X(22)01459-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  597. MOORE KA, Leighton T, Ostrowsky JT, Anderson CJ, et al
    A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy.
    Vaccine. 2023 Feb 21:S0264-410X(23)00167-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  598. ZHANG H, Chen L, Huang Z, Li D, et al
    The effects of parent's health literacy and health beliefs on vaccine hesitancy.
    Vaccine. 2023 Feb 21:S0264-410X(23)00161-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  599. HAMBURG M, Poland GA
    The time is now for committed and comprehensive action to attain more broadly protective coronavirus vaccines: The coronavirus vaccines R&D roadmap.
    Vaccine. 2023 Feb 21:S0264-410X(23)00196-2. doi: 10.1016/j.vaccine.2023.
    PubMed    


  600. MOTTA M, Callaghan T, Lunz-Trujillo K, Lockman A, et al
    Erroneous Consonance. How inaccurate beliefs about physician opinion influence COVID-19 vaccine hesitancy.
    Vaccine. 2023 Feb 20:S0264-410X(23)00195-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  601. USTYUGOVA IV, Pougatcheva S, Farrell T, Strugnell T, et al
    AF03 adjuvant improves anti-hemagglutinin and anti-neuraminidase immune responses induced by licensed seasonal quadrivalent influenza vaccines in mice.
    Vaccine. 2023 Feb 18:S0264-410X(23)00169-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  602. GEOGHEGAN S, Acosta F, Stephens LC, Gillan H, et al
    Maternity care provider acceptance of a future Group B Streptococcus vaccine - A qualitative study in three countries.
    Vaccine. 2023 Feb 18:S0264-410X(23)00172-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  603. FORD A, Hwang A, Mo AX, Baqar S, et al
    Meeting Summary: Global Vaccine and Immunization Research Forum, 2021.
    Vaccine. 2023 Feb 18:S0264-410X(23)00163-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  604. DUDLEY MZ, Gerber JE, Budigan Ni H, Blunt M, et al
    Vaccinomics: A scoping review.
    Vaccine. 2023 Feb 18:S0264-410X(23)00135-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  605. RANADE D, Jena R, Patil K, Dogar V, et al
    A novel high throughput plate-based method for 2-PE quantification in novel multidose vaccines (R21 malaria, Covishield and Covovax) and combination vaccines (Hexavalent).
    Vaccine. 2023 Feb 17:S0264-410X(23)00174-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  606. PARODI A, Martini M
    History of vaccine and immunization: Vaccine-hesitancy discussion in Germany in XIX century.
    Vaccine. 2023 Feb 17:S0264-410X(23)00164-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  607. MEYER C, Goffe L, Antonopoulou V, Graham F, et al
    Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England.
    Vaccine. 2023 Feb 17:S0264-410X(23)00182-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  608. MORAIS A, Morais J, Felix M, Neto Z, et al
    Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019-2020.
    Vaccine. 2023 Feb 17:S0264-410X(23)00170-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  609. ZIMMERMANN BM, Paul KT, Araujo ER, Buyx A, et al
    The social and socio-political embeddedness of COVID-19 vaccination decision-making: A five-country qualitative interview study from Europe.
    Vaccine. 2023 Feb 16:S0264-410X(23)00139-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  610. BENEDICT KPOZEHOUEN E, Arrudsivah B, Raina Macintyre C
    Knowledge, attitudes and practices of health care workers in a cardiology department on influenza vaccination.
    Vaccine. 2023 Feb 15:S0264-410X(23)00112-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  611. CAMPMAN SL, van Rossem G, Boyd A, Coyer L, et al
    Intent to vaccinate against SARS-CoV-2 and its determinants across six ethnic groups living in Amsterdam, the Netherlands: A cross-sectional analysis of the HELIUS study.
    Vaccine. 2023 Feb 13:S0264-410X(23)00165-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  612. BARNES K, Faasse K, Colagiuri B
    The impact of side effect framing on COVID-19 booster vaccine intentions in an Australian sample.
    Vaccine. 2023 Feb 13:S0264-410X(23)00158-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  613. SAELEE R, Chandra Murthy N, Patel Murthy B, Zell E, et al
    Minority Health Social Vulnerability Index and COVID-19 vaccination coverage - The United States, December 14, 2020-January 31, 2022.
    Vaccine. 2023 Feb 13:S0264-410X(23)00157-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  614. WANKHEDE D, Grover S, Hofman P
    Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis.
    Vaccine. 2023 Feb 13:S0264-410X(23)00115-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  615. AFREH OK, Angwaawie P, Attivor E, Boateng LA, et al
    Examining confidence and hesitancy towards COVID-19 vaccines: A cross-sectional survey using in-person data collection in rural Ghana.
    Vaccine. 2023 Feb 13:S0264-410X(23)00159-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  616. FACCHIN G, Bella A, Del Manso M, Rota MC, et al
    Decline in reported measles cases in Italy in the COVID-19 era, January 2020 - July 2022: The need to prevent a resurgence upon lifting non-pharmaceutical pandemic measures.
    Vaccine. 2023;41:1286-1289.
    PubMed     Abstract available


  617. SELL H, Raj Paudel Y, Voaklander D, MacDonald SE, et al
    School immunization coverage in adolescents during the COVID-19 pandemic: A retrospective cohort study.
    Vaccine. 2023;41:1333-1341.
    PubMed     Abstract available


  618. DE VRIES M, Claassen L, Lambooij MS, Timen A, et al
    Did the temporary suspension of Vaxzveria vaccinations influence COVID-19 vaccination intentions, vaccination perceptions and trust in the vaccination campaign? A repeated survey study in the Netherlands.
    Vaccine. 2023 Feb 10:S0264-410X(23)00138-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  619. HOSAIN R, Aquino P, Baccarini C, Smolenov I, et al
    Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study.
    Vaccine. 2023 Feb 10:S0264-410X(23)00144-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  620. SHEN AK, Browne S, Srivastava T, Kornides ML, et al
    Persuading the "Movable Middle": Characteristics of effective messages to promote routine and COVID-19 vaccinations for adults and children - The impact of COVID-19 on beliefs and attitudes.
    Vaccine. 2023 Feb 9:S0264-410X(23)00141-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  621. SILVA VASCONCELOS G, da Conceicao Rodrigues Fernandes M, Cardoso Matsui T, Claudia Dos Santos Luciano M, et al
    Persistent SARS-COV-2 infection in vaccinated individual with three doses of COVID-19 vaccine.
    Vaccine. 2023 Feb 9:S0264-410X(23)00145-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  622. BUNTINX E, Brochado L, Borja-Tabora C, Yu CY, et al
    Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naive and exposed individuals in a phase 2/3, double-blind, randomized study.
    Vaccine. 2023 Feb 9:S0264-410X(23)00143-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  623. FEIKIN DR, Higdon MM, Andrews N, Collie S, et al
    Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization.
    Vaccine. 2023 Feb 9:S0264-410X(23)00146-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  624. BUGHIN J, Cincera M, Peters K, Reykowska D, et al
    Make it or break it: On-time vaccination intent at the time of Covid-19.
    Vaccine. 2023 Feb 8:S0264-410X(23)00140-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  625. WATANABE A, Iwagami M, Yasuhara J, Takagi H, et al
    Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis.
    Vaccine. 2023 Feb 8:S0264-410X(23)00134-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  626. FELL DB, Torok E, Sprague AE, Regan AK, et al
    Temporal trends and determinants of COVID-19 vaccine coverage and series initiation during pregnancy in Ontario, Canada, December 2020 to December 2021: A population-based retrospective cohort study.
    Vaccine. 2023 Feb 3:S0264-410X(23)00114-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  627. HASSAN RAZA S, Yousaf M, Zaman U, Waheed Khan S, et al
    Unlocking infodemics and mysteries in COVID-19 vaccine hesitancy: Nexus of conspiracy beliefs, digital informational support, psychological Well-being, and religious fatalism.
    Vaccine. 2023 Feb 3:S0264-410X(23)00079-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  628. LI R, Liu H, Fairley CK, Ong JJ, et al
    mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia.
    Vaccine. 2023 Feb 3:S0264-410X(23)00126-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  629. MALTEZOU HC, Basoulis D, Bonelis K, Gamaletsou MN, et al
    Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece.
    Vaccine. 2023 Feb 2:S0264-410X(23)00109-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  630. HAMADA H, Futamura M, Ito H, Yamamoto R, et al
    Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study.
    Vaccine. 2023 Feb 1:S0264-410X(23)00082-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  631. JOHNSON R, Djaafara B, Haw D, Doohan P, et al
    The societal value of SARS-CoV-2 booster vaccination in Indonesia.
    Vaccine. 2023 Feb 1:S0264-410X(23)00110-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  632. ANDREJKO KL, Myers JF, Fukui N, Nelson L, et al
    Real-world uptake of COVID-19 vaccination among individuals expressing vaccine hesitancy: A registry-linkage study.
    Vaccine. 2023 Feb 1:S0264-410X(23)00108-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    January 2023
  633. UWAMINO Y, Yokoyama T, Sato Y, Shibata A, et al
    Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine.
    Vaccine. 2023 Jan 31:S0264-410X(23)00081-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  634. GRESSENS SB, Wiedemann A, Dechenaud M, Dupuis J, et al
    Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies.
    Vaccine. 2023 Jan 30:S0264-410X(23)00095-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  635. MATTA MG, Pulido L, Herrera-Paz JJ, Picco JM, et al
    Influenza and pneumococcal vaccine prescription for adults during COVID-19 first wave in three regions of Argentina.
    Vaccine. 2023 Jan 27:S0264-410X(23)00088-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  636. RODRIGUEZ-APONTE SA, Dalvie NC, Wong TY, Johnston RS, et al
    Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants.
    Vaccine. 2023;41:1108-1118.
    PubMed     Abstract available


  637. PARODI JB, Indavere A, Bobadilla Jacob P, Toledo GC, et al
    Impact of COVID-19 vaccination in post-COVID cardiac complications.
    Vaccine. 2023 Jan 27:S0264-410X(23)00084-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  638. HARBIN A, Laventhal N, Navin M
    Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of COVID-19.
    Vaccine. 2023 Jan 27:S0264-410X(23)00087-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  639. KRAUSE NM, Beets B, Howell EL, Tosteson H, et al
    Collateral damage from debunking mRNA vaccine misinformation.
    Vaccine. 2023;41:922-929.
    PubMed     Abstract available


  640. RENNERT W, Hindiyeh M, Allahham M, Mercer LD, et al
    Introducing ROTAVAC(R) to the occupied Palestinian Territories: Impact on diarrhea incidence, rotavirus prevalence and genotype composition.
    Vaccine. 2023;41:945-954.
    PubMed     Abstract available


  641. KUZEL TG, Fu J, Anderson M, Stec M, et al
    Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naive and previously-infected individuals.
    Vaccine. 2023;41:879-882.
    PubMed     Abstract available


  642. FAIZULOEV E, Gracheva A, Korchevaya E, Smirnova D, et al
    Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity.
    Vaccine. 2023;41:892-902.
    PubMed     Abstract available


  643. MYERS TR, Marquez PL, Gee JM, Hause AM, et al
    The v-safe after vaccination health checker: Active vaccine safety monitoring during CDC's COVID-19 pandemic response.
    Vaccine. 2023 Jan 23:S0264-410X(22)01545-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  644. VATCHARAVONGVAN P, Boonyanitchayakul N, Khampachuea P, Sinturong I, et al
    Health Belief Model and parents' acceptance of the Pfizer-BioNTech and Sinopharm COVID-19 vaccine for children aged 5-18 years Old: A national survey.
    Vaccine. 2023 Jan 23:S0264-410X(23)00050-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  645. TENG Y, Hanibuchi T, Machida M, Nakaya T, et al
    Psychological determinants of COVID-19 vaccine acceptance: A comparison between immigrants and the host population in Japan.
    Vaccine. 2023 Jan 23:S0264-410X(23)00056-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  646. ZOLOTAROVA T, Dussault C, Park H, Varsaneux O, et al
    Education increases COVID-19 vaccine uptake among people in Canadian federal prisons in a prospective randomized controlled trial: The EDUCATE study.
    Vaccine. 2023 Jan 23:S0264-410X(23)00061-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  647. GROSSMAN-GIRON A, Tzur Bitan D, Shemesh S, Mayer Y, et al
    COVID-19 vaccine hesitancy scale and its association with actual COVID-19 vaccine uptake in Israel.
    Vaccine. 2023 Jan 23:S0264-410X(23)00065-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  648. MALLAH SI, Alawadhi A, Jawad J, Wasif P, et al
    Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
    Vaccine. 2023 Jan 23:S0264-410X(23)00053-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  649. STRATHDEE SA, Abramovitz D, Vera CF, Artamonova I, et al
    Predictors of COVID-19 vaccine uptake among people who inject drugs.
    Vaccine. 2023 Jan 23:S0264-410X(23)00063-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  650. KRAMER C, Song M, Sufrin CB, Eber GB, et al
    COVID-19 vaccination hesitancy and uptake: Perspectives from people released from the Federal Bureau of Prisons.
    Vaccine. 2023 Jan 21:S0264-410X(23)00060-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  651. DARBY B, Alexander V, Murphy J
    SARS-CoV-2 vaccine breakthrough infections in Virginia, January 17, 2021 - June 30, 2021.
    Vaccine. 2023 Jan 20:S0264-410X(23)00062-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  652. BIANCHI FP, Stefanizzi P, Martinelli A, Brescia N, et al
    COVID-19 vaccination hesitancy in people affected by diabetes and strategies to increase vaccine compliance: A systematic narrative review and meta-analysis.
    Vaccine. 2023 Jan 20:S0264-410X(23)00058-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  653. DUDLEY MZ, Schuh HB, Shaw J, Rimal RN, et al
    COVID-19 vaccination among different types of US Healthcare Personnel.
    Vaccine. 2023 Jan 20:S0264-410X(23)00051-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  654. GHORBANI A, Ngunjiri JM, Edward C Abundo M, Pantin-Jackwood M, et al
    Development of in Ovo-Compatible NS1-truncated live attenuated influenza vaccines by modulation of hemagglutinin cleavage and polymerase Acidic X Frameshifting sites.
    Vaccine. 2023 Jan 18:S0264-410X(23)00029-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  655. MOINI A, Rabiei M, Pirjani R, Abiri A, et al
    COVID‑19 vaccine hesitancy among pregnant women and their reported reasons for vaccine refusal - A prospective study in Tehran, Iran.
    Vaccine. 2023 Jan 16:S0264-410X(23)00032-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  656. BEDSTON S, Lowthian E, Jarvis CI, Akbari A, et al
    COVID-19 booster vaccination uptake and infection breakthrough amongst health care workers in Wales: A national prospective cohort study.
    Vaccine. 2023 Jan 13:S0264-410X(23)00034-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  657. YANG H, Li Z, Zhang R, Guo S, et al
    Safety of primary immunization using inactivated SARS-CoV-2 vaccine (CoronaVac(R)) among population aged 3 years and older in a large-scale use: A multi-center open-label study in China.
    Vaccine. 2023 Jan 13:S0264-410X(23)00031-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  658. KALRA S, Kalra D, Grafova I, Rubin JS, et al
    Association of death or illness from COVID-19 among family and friends on vaccine uptake within four months of the Emergency Use Authorization. Findings from a national survey in the United States.
    Vaccine. 2023 Jan 13:S0264-410X(23)00035-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  659. KLUWER B, Margrethe Rydland K, Nybru Gleditsch R, Mamelund SE, et al
    Social and demographic patterns of influenza vaccination coverage in Norway, influenza seasons 2014/15 to 2020/21.
    Vaccine. 2023 Jan 11:S0264-410X(23)00013-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  660. ELLISON TJ, Talbott GC, Henderson DR
    Intradermal delivery of a quadrivalent cell-based seasonal influenza vaccine using an adjuvanted skin patch vaccination platform.
    Vaccine. 2023;41:304-314.
    PubMed     Abstract available


  661. ASLAM J, Khan FS, Talha Haris M, Hewadmal H, et al
    Prior immunization status of COVID-19 patients and disease severity: A multicenter retrospective cohort study assessing the different types of immunity.
    Vaccine. 2023;41:598-605.
    PubMed    


  662. MOELLER-ARENDT M, van de Witte S, Nauta J, de Voogd H, et al
    Enhanced passive safety surveillance of Influvac(R) and Influvac(R) Tetra: Results from seven consecutive seasons.
    Vaccine. 2023;41:606-613.
    PubMed     Abstract available


  663. KEVIN YIN J, Harris RC, Loiacono MM, Chit A, et al
    Letter to editor regarding a review of MF59-adjuvanted influenza vaccine by Gartner et al.
    Vaccine. 2023 Jan 9:S0264-410X(22)01559-6. doi: 10.1016/j.vaccine.2022.
    PubMed    


  664. MORO PL, Zhang B, Ennulat C, Harris M, et al
    Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
    Vaccine. 2023 Jan 9:S0264-410X(23)00016-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  665. WHITEHEAD HS, French CE, Caldwell DM, Letley L, et al
    A systematic review of communication interventions for countering vaccine misinformation.
    Vaccine. 2023 Jan 9:S0264-410X(22)01593-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  666. WAGNER AL, Moniz MH, Stout MJ, Townsel C, et al
    Experiences, risk perceptions, and COVID-19 vaccination outcomes among hospital workers.
    Vaccine. 2023 Jan 9:S0264-410X(23)00012-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  667. MENON I, Kang SM, Braz Gomes K, Uddin MN, et al
    Laser-assisted intradermal delivery of a microparticle vaccine for respiratory syncytial virus induces a robust immune response.
    Vaccine. 2023 Jan 9:S0264-410X(23)00002-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  668. CHAWANPAIBOON S, Anuwutnawin S, Kanjanapongporn A, Pooliam J, et al
    Breastfeeding women's attitudes towards and acceptance and rejection of COVID-19 vaccination: Implementation research.
    Vaccine. 2023 Jan 9:S0264-410X(23)00015-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  669. TULLOCH JSP, Lawrenson K, Gordon AL, Ghebrehewet S, et al
    COVID-19 vaccine hesitancy in care home staff: A survey of Liverpool care homes.
    Vaccine. 2023 Jan 9:S0264-410X(23)00009-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  670. LONG Z, He J, Shuai Q, Zhang K, et al
    Influenza vaccination-induced H3 stalk-reactive memory B-cell clone expansion.
    Vaccine. 2023 Jan 6:S0264-410X(22)01603-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  671. EBRAHIMI N, Mazdak M, Shaygannejad V, Mirmosayyeb O, et al
    CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series.
    Vaccine. 2023 Jan 6:S0264-410X(23)00004-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  672. JANG Y, Cho H, Chun J, Park K, et al
    Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice.
    Vaccine. 2023 Jan 6:S0264-410X(22)01602-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  673. TSUCHIYA Y, Tamura H, Fujii K, Numaguchi H, et al
    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan.
    Vaccine. 2023 Jan 5:S0264-410X(23)00006-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  674. TORALES J, Cuenca-Torres O, Barrios L, Armoa-Garcia L, et al
    An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
    Vaccine. 2023;41:109-118.
    PubMed     Abstract available


  675. MAERTZDORF KM, Rietman ML, Lambooij MS, Verschuren WMM, et al
    Willingness to get vaccinated against influenza, pneumococcal disease, pertussis, and herpes zoster - A pre-COVID-19 exploration among the older adult population.
    Vaccine. 2023 Jan 4:S0264-410X(23)00001-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  676. BAGGA S, Krishnan A, Dar L
    Revisiting live attenuated influenza vaccine efficacy among children in developing countries.
    Vaccine. 2023 Jan 3:S0264-410X(22)01594-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  677. REGO RT, Kenney B, Ngugi AK, Espira L, et al
    COVID-19 vaccination refusal trends in Kenya over 2021.
    Vaccine. 2023 Jan 3:S0264-410X(22)01601-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  678. SHOOK NJ, Oosterhoff B, Sevi B
    A longitudinal assessment of variability in COVID-19 vaccine hesitancy and psychosocial correlates in a national United States sample.
    Vaccine. 2023 Jan 2:S0264-410X(22)01600-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  679. FORD JS, Rouleau SG, Wagner JL, Adams CB, et al
    Assessment of a COVID-19 vaccination protocol for unhoused patients in the emergency department.
    Vaccine. 2023 Jan 2:S0264-410X(22)01598-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


    December 2022
  680. GAMBLE A, Hastings TJ, Westrick SC, Smith M, et al
    COVID-19 booster vaccination in rural community pharmacies.
    Vaccine. 2022 Dec 26:S0264-410X(22)01576-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  681. XIE Z, Hamadi HY, Mainous AG, Hong YR, et al
    Association of dual COVID-19 and seasonal influenza vaccination with COVID-19 infection and disease severity.
    Vaccine. 2022 Dec 23:S0264-410X(22)01568-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  682. ANDREJKO KL, Myers JF, Openshaw J, Fukui N, et al
    Receipt of COVID-19 and seasonal influenza vaccines in California (USA) during the 2021-2022 influenza season.
    Vaccine. 2022 Dec 23:S0264-410X(22)01578-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  683. SAIAG E, Alcalay Y, Marudi O, Orr-Urtreger A, et al
    Cellular and humoral immune response to the fourth Pfizer-BioNTech COVID-19 vaccine dose in individuals aged 60 years and older.
    Vaccine. 2022 Dec 21:S0264-410X(22)01560-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  684. WAND O, Breslavsky A, Bar-Shai A, Levy C, et al
    One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine.
    Vaccine. 2022 Dec 21:S0264-410X(22)01567-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  685. XU S, Huang R, Sy LS, Hong V, et al
    A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination.
    Vaccine. 2022 Dec 20:S0264-410X(22)01561-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  686. RANE MS, Robertson MM, Kulkarni SG, Frogel D, et al
    Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting.
    Vaccine. 2022 Dec 20:S0264-410X(22)01564-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  687. WILLIAMS KV, Moehling Geffel K, Alcorn JF, Patricia Nowalk M, et al
    Factors associated with humoral immune response in older adults who received egg-free influenza vaccine.
    Vaccine. 2022 Dec 19:S0264-410X(22)01566-3. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  688. DUDLEY MZ, Barnett EE, Paulenich A, Omer SB, et al
    Characterization of parental intention to vaccinate elementary school aged children in the state of California.
    Vaccine. 2022 Dec 19:S0264-410X(22)01544-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  689. BOISSON A, Morgan CE, Stover A, Ngimbi P, et al
    Changes in hepatitis B vaccine perception in response to the COVID-19 pandemic: Development of the Shift in vaccine confidence (SVC) survey tool.
    Vaccine. 2022 Dec 16:S0264-410X(22)01542-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  690. YIH WK, Daley MF, Duffy J, Fireman B, et al
    A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink.
    Vaccine. 2022 Dec 16:S0264-410X(22)01541-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  691. SONOYAMA T, Iwata S, Shinkai M, Iwata-Yoshikawa N, et al
    Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
    Vaccine. 2022 Dec 16:S0264-410X(22)01540-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  692. PAPAZACHARIOU A, Tsioutis C, Lytras T, Malikides O, et al
    The impact of seasonal influenza vaccination uptake on COVID-19 vaccination attitudes in a rural area in Greece.
    Vaccine. 2022 Dec 15:S0264-410X(22)01539-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  693. VAUX S, Fonteneau L, Pefau M, Venier AG, et al
    Vaccination against influenza, measles, pertussis and varicella in workers in healthcare facilities in France: A national cross-sectional study in 2019.
    Vaccine. 2022 Dec 15:S0264-410X(22)01537-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  694. OLAYINKA F, Sauer M, Menning L, Summers D, et al
    Building and sustaining public and political commitment to the value of vaccination: Recommendations for the Immunization Agenda 2030 (Strategic Priority Area 2).
    Vaccine. 2022 Dec 15:S0264-410X(22)01451-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  695. CHEN L, Levine MZ, Zhou S, Bai T, et al
    Mild and asymptomatic influenza B virus infection among unvaccinated pregnant persons: Implication for effectiveness of non-pharmaceutical intervention and vaccination to prevent influenza.
    Vaccine. 2022 Dec 14:S0264-410X(22)01468-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  696. OHNO M, Sagata M, Sekiya T, Nomura N, et al
    Assessing the pyrogenicity of whole influenza virus particle vaccine in cynomolgus macaques.
    Vaccine. 2022 Dec 14:S0264-410X(22)01534-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  697. IBROCI E, Liu X, Lieb W, Jessel R, et al
    Impact of prenatal COVID-19 vaccination on delivery and neonatal outcomes: Results from a New York City cohort.
    Vaccine. 2022 Dec 14:S0264-410X(22)01226-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  698. SAINI SJ, Carle AC, Forsyth AR, Chi DL, et al
    Association between caregiver opposition to topical fluoride and COVID-19 vaccines.
    Vaccine. 2022 Dec 14:S0264-410X(22)01532-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  699. SALVATORE PP, Lee CC, Sleweon S, McCormick DW, et al
    Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July-August 2021.
    Vaccine. 2022 Dec 13:S0264-410X(22)01458-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  700. CHIBA S, Hatta M, Pattinson D, Yasuhara A, et al
    Ferret model to mimic the sequential exposure of humans to historical H3N2 influenza viruses.
    Vaccine. 2022 Dec 12:S0264-410X(22)01518-3. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  701. CHO BH, Athar HM, Bates LG, Yarnoff BO, et al
    Patient flow time data of COVID-19 vaccination clinics in 23 sites, United States, April and May 2021.
    Vaccine. 2022 Dec 12:S0264-410X(22)01527-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  702. TADDIO A, Ilersich ANT, Bucci L, McMurtry CM, et al
    Letting kids play their CARDs (Comfort, Ask, Relax, Distract) to help cope with needle-related fear and pain: Results from user testing.
    Vaccine. 2022;40:7667-7675.
    PubMed     Abstract available


  703. HALL PA, Meng G, Boudreau C, Hudson A, et al
    Social cognitive predictors of vaccination status, uptake and mitigation behaviors in the Canadian COVID-19 Experiences survey.
    Vaccine. 2022 Dec 12:S0264-410X(22)01526-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  704. CUDDIHY MT, Berger WL, Cummings PL, Keith R, et al
    An organizational assessment of 101 Community-Based Adult Services centers to identify and address gaps in influenza vaccination among Medicare-Medicaid beneficiaries.
    Vaccine. 2022 Dec 10:S0264-410X(22)01490-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  705. PEPIN S, Samson SI, Alvarez FP, Dupuy M, et al
    Corrigendum to "Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III trial in the northern and southern Hemispheres" [Vaccin
    Vaccine. 2022 Dec 9:S0264-410X(22)01483-9. doi: 10.1016/j.vaccine.2022.
    PubMed    


  706. FERNANDES NEHAB M, Goncalves Camacho K, Teixeira Reis A, Junqueira-Marinho MF, et al
    Willingness of Brazilian caregivers in having their children and adolescents vaccinated against Covid-19.
    Vaccine. 2022 Dec 9:S0264-410X(22)01520-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  707. WALLACE AS, Ryman TK, Privor-Dumm L, Morgan C, et al
    Leaving no one behind: Defining and implementing an integrated life course approach to vaccination across the next decade as part of the immunization Agenda 2030.
    Vaccine. 2022 Dec 8:S0264-410X(22)01452-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  708. ANDERSON-CHAVARRIA M, Turner J
    Searching for the 'Trigger': An ethnographic analysis of parental beliefs regarding autism causation and vaccination in Puerto Rico.
    Vaccine. 2022 Dec 7:S0264-410X(22)01488-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  709. LATKIN C, Dayton L, Miller J, Eschliman E, et al
    Trusted information sources in the early months of the COVID-19 pandemic predict vaccination uptake over one year later.
    Vaccine. 2022 Dec 6:S0264-410X(22)01510-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  710. SERISIER A, Beale S, Boukari Y, Hoskins S, et al
    A case-crossover study of the effect of vaccination on SARS-CoV-2 transmission relevant behaviours during a period of national lockdown in England and Wales.
    Vaccine. 2022 Dec 5:S0264-410X(22)01497-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  711. IWAI-SAITO K, Sato K, Kondo K
    Associations of influenza and pneumococcal vaccinations with burdens of older family caregivers: The Japan Gerontological Evaluation study (JAGES) cross-sectional study.
    Vaccine. 2022 Dec 2:S0264-410X(22)01460-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  712. CASPERSEN IH, Juvet LK, Feiring B, Laake I, et al
    Menstrual disturbances in 12- to 15-year-old girls after one dose of COVID-19 Comirnaty vaccine: Population-based cohort study in Norway.
    Vaccine. 2022 Dec 2:S0264-410X(22)01492-X. doi: 10.1016/j.vaccine.2022.
    PubMed    


  713. STOLIAROFF-PEPIN A, Peine C, Herath T, Lachmann J, et al
    Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022.
    Vaccine. 2022 Dec 2:S0264-410X(22)01489-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  714. AL-KASSAB-CORDOVA A, Silva-Perez C, Mendez-Guerra C, Sangster-Carrasco L, et al
    Inequalities in infant vaccination coverage during the COVID-19 pandemic: A population-based study in Peru.
    Vaccine. 2022 Dec 2:S0264-410X(22)01491-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  715. INGRAM C, Roe M, Downey V, Phipps L, et al
    Exploring key informants' perceptions of Covid-19 vaccine hesitancy in a disadvantaged urban community in Ireland: Emergence of a '4Cs' model.
    Vaccine. 2022 Dec 2:S0264-410X(22)01496-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  716. UTTEKAR S, MacDonald N, Orenstein WA, Danchin M, et al
    Empowering Health Workers to Build Public Trust in Vaccination: Experience from the International Pediatric Association's Online Vaccine Trust Course, 2020-2021.
    Vaccine. 2022 Dec 2:S0264-410X(22)01485-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  717. BENDER FL, Rief W, Wilhelm M
    Really just a little prick? A meta-analysis on adverse events in placebo control groups of seasonal influenza vaccination RCTs.
    Vaccine. 2022 Dec 1:S0264-410X(22)01431-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  718. WONG HL, Tworkoski E, Ke Zhou C, Hu M, et al
    Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older.
    Vaccine. 2022 Dec 1:S0264-410X(22)01493-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


    November 2022
  719. SUN Y, Huang SK, Arlikatti S, Lindell MK, et al
    What attributes influence rural household's willingness to get vaccinated for COVID-19? Perspectives from six Chinese townships.
    Vaccine. 2022 Nov 29:S0264-410X(22)01487-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  720. TANG S, Liu X, Jia Y, Chen H, et al
    Education level modifies parental hesitancy about COVID-19 vaccinations for their children.
    Vaccine. 2022 Nov 29:S0264-410X(22)01484-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  721. CHRISTOU-ERGOS M, Wiley KE, Leask J
    Willingness to receive a vaccine is influenced by adverse events following immunisation experienced by others.
    Vaccine. 2022 Nov 26:S0264-410X(22)01447-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  722. MICHELLE DRIEDGER S, Capurro G, Tustin J, Jardine CG, et al
    "I won't be a guinea pig": Rethinking public health communication and vaccine hesitancy in the context of COVID-19.
    Vaccine. 2022 Nov 25:S0264-410X(22)01469-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  723. STOCKER A, Hoffmann J, Mause L, Neufeind J, et al
    What impact does the attitude toward COVID-19 vaccination have on physicians as vaccine providers? A cross sectional study from the German outpatient sector.
    Vaccine. 2022 Nov 25:S0264-410X(22)01466-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  724. ZARZECZNA N, Bertlich T, Veckalov B, Rutjens BT, et al
    Spirituality is associated with Covid-19 vaccination scepticism.
    Vaccine. 2022 Nov 25:S0264-410X(22)01463-3. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  725. RADER B, Chiang ME, Kriner DL, Weintraub RL, et al
    Persistent drop in confidence following US recommended pause of Ad26.COV2.S vaccine administration.
    Vaccine. 2022 Nov 25:S0264-410X(22)01448-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  726. LIP A, Pateman M, Fullerton MM, Chen HM, et al
    Vaccine hesitancy educational tools for healthcare providers and trainees: A scoping review.
    Vaccine. 2022 Nov 24:S0264-410X(22)01225-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  727. KATHERINE YIH W, Daley MF, Duffy J, Fireman B, et al
    Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink.
    Vaccine. 2022 Nov 24:S0264-410X(22)01467-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  728. HUMBLE RM, Scott SD, Dube E, Olson J, et al
    The impact of the COVID-19 pandemic on parents' perceptions and acceptance of routine childhood vaccination in Canada: A national longitudinal study.
    Vaccine. 2022 Nov 24:S0264-410X(22)01465-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  729. TANAKA H, Mukai J, Kushibiki K, Mizushima S, et al
    Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers.
    Vaccine. 2022 Nov 24:S0264-410X(22)01462-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  730. CAETANO C, Morgado ML, Patricio P, Leite A, et al
    Measuring the impact of COVID-19 vaccination and immunity waning: A modelling study for Portugal.
    Vaccine. 2022;40:7115-7121.
    PubMed     Abstract available


  731. KAUFMANN J, DeVoe JE, Angier H, Moreno L, et al
    Association of parent influenza vaccination and early childhood vaccinations using linked electronic health record data.
    Vaccine. 2022;40:7097-7107.
    PubMed     Abstract available


  732. HASSAN YAM, Daud Ali M, Al-Eid RR, Al-Ghuraya FA, et al
    A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia.
    Vaccine. 2022;40:7087-7096.
    PubMed     Abstract available


  733. FRANCO C, Herazo-Padilla N, Castaneda JA
    A queueing Network approach for capacity planning and patient Scheduling: A case study for the COVID-19 vaccination process in Colombia.
    Vaccine. 2022;40:7073-7086.
    PubMed     Abstract available


  734. HODGSON D, Koltai M, Krauer F, Flasche S, et al
    Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales.
    Vaccine. 2022;40:7151-7157.
    PubMed     Abstract available


  735. ZHOU W, Tang B, Bai Y, Shao Y, et al
    The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study.
    Vaccine. 2022;40:7141-7150.
    PubMed     Abstract available


  736. WILLAME C, Dodd C, Duran CE, Elbers R, et al
    Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study.
    Vaccine. 2022 Nov 22:S0264-410X(22)01429-3. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  737. OZDARENDELI A, Sezer Z, Pavel STI, Inal A, et al
    Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials.
    Vaccine. 2022 Nov 22:S0264-410X(22)01380-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  738. ELICABE RJ, Distel MN, Jofre BL, Leporati M, et al
    Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina.
    Vaccine. 2022 Nov 21:S0264-410X(22)01416-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  739. NIQUEUX E, Flodrops M, Allee C, Lebras MO, et al
    Evaluation of three hemagglutinin-based vaccines for the experimental control of a panzootic clade 2.3.4.4b A(H5N8) high pathogenicity avian influenza virus in mule ducks.
    Vaccine. 2022 Nov 18:S0264-410X(22)01398-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  740. FEKETE M, Horvath A, Santa B, Tomisa G, et al
    COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease - A cross-sectional study in Hungary.
    Vaccine. 2022 Nov 18:S0264-410X(22)01415-3. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  741. MCCORMICK DW, Hagan LM, Salvatore PP, Magleby R, et al
    SARS-CoV-2 viral shedding in vaccinated and unvaccinated persons: A case series.
    Vaccine. 2022 Nov 18:S0264-410X(22)01428-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  742. KAHN AL, Steffen CA, Henaff L, MacDonald NE, et al
    COVID-19 vaccine policy development in a sample of 44 countries - Key findings from a December 2021 survey of National Immunization Technical Advisory Groups (NITAGs).
    Vaccine. 2022 Nov 17:S0264-410X(22)01427-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  743. PANICKAN S, Bhatia S, Bhat S, Bhandari N, et al
    Reverse genetics based H5N2 vaccine provides clinical protection against H5N1, H5N8 and H9N2 avian influenza infection in chickens.
    Vaccine. 2022;40:6998-7008.
    PubMed     Abstract available


  744. ALFANO V, Ercolano S
    Your vaccine attitude determines your altitude. What are the determinants of attitudes toward vaccination?
    Vaccine. 2022;40:6987-6997.
    PubMed     Abstract available


  745. TURBYFILL C, Adams K, Tenforde MW, Murray NL, et al
    Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States.
    Vaccine. 2022;40:6979-6986.
    PubMed     Abstract available


  746. KULKARNI AV, Jaggaiahgari S, Iyengar S, Simhadri V, et al
    Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients.
    Vaccine. 2022;40:6971-6978.
    PubMed     Abstract available


  747. HE H, Zhu Y, Jin M, Zhou Y, et al
    The decline in immunity and circulation of pertussis among Chinese population during the COVID-19 pandemic: A cross-sectional sero-epidemiological study.
    Vaccine. 2022;40:6956-6962.
    PubMed     Abstract available


  748. ATTWELL K, Rizzi M, Paul KT
    Consolidating a research agenda for vaccine mandates.
    Vaccine. 2022 Nov 14. pii: S0264-410X(22)01384.
    PubMed     Abstract available


  749. ZIMMERMAN T, Shiroma K, Fleischmann KR, Xie B, et al
    Misinformation and COVID-19 vaccine hesitancy.
    Vaccine. 2022 Nov 14:S0264-410X(22)01402-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  750. VANWORMER JJ, Alicea G, Weichelt BP, Berg RL, et al
    COVID-19 vaccine coverage disparities in rural and farm children.
    Vaccine. 2022 Nov 14:S0264-410X(22)01403-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  751. FABIANI M, Mateo-Urdiales A, Sacco C, Rota MC, et al
    Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study.
    Vaccine. 2022 Nov 14:S0264-410X(22)01399-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  752. MANANDHAR P, Wannemuehler K, Danovaro-Holliday MC, Nic Lochlainn L, et al
    Use of catch-up vaccinations in the second year of life (2YL) platform to close immunity gaps: A secondary DHS analysis in Pakistan, Philippines, and South Africa.
    Vaccine. 2022 Nov 14. pii: S0264-410X(22)01301.
    PubMed     Abstract available


  753. JACKSON ML, Phillips CH, Wellwood S, Kiniry E, et al
    Burden of medically attended influenza infection and cases averted by vaccination - United States, 2016/17 through 2018/19 influenza seasons.
    Vaccine. 2022 Nov 12. pii: S0264-410X(22)01397.
    PubMed     Abstract available


  754. KPOZEHOUEN EB, Tan T, Macintyre CR
    Uptake of influenza, pneumococcal and herpes zoster vaccines among people with heart failure and atrial fibrillation.
    Vaccine. 2022 Nov 12. pii: S0264-410X(22)01377.
    PubMed     Abstract available


  755. DE FIGUEIREDO A, Simas C, Larson HJ
    COVID-19 vaccine acceptance and its socio-demographic and emotional determinants: A multi-country cross-sectional study.
    Vaccine. 2022 Nov 10:S0264-410X(22)01310-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  756. DENG T, Li T, Chen G, Zhu Y, et al
    Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation.
    Vaccine. 2022;40:6839-6848.
    PubMed     Abstract available


  757. REN H, Li H, Cao L, Wang Z, et al
    Intranasal immunization with HRSV prefusion F protein and CpG adjuvant elicits robust protective effects in mice.
    Vaccine. 2022;40:6830-6838.
    PubMed     Abstract available


  758. HASHIMOTO M, Aoe S, Kawazu Y, Seki NM, et al
    Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques.
    Vaccine. 2022 Nov 8. pii: S0264-410X(22)01379.
    PubMed     Abstract available


  759. MOLL K, Lufkin B, Fingar KR, Ke Zhou C, et al
    Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
    Vaccine. 2022 Nov 8:S0264-410X(22)01373-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  760. TAKEUCHI Y, Iwagami M, Ono S, Michihata N, et al
    A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01370.
    PubMed     Abstract available


  761. HAO XB, Anand M, Wang TR, Rao AR, et al
    Reducing COVID vaccine hesitancy by inducing a comparative mindset.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01359.
    PubMed     Abstract available


  762. GUERIN RJ, Naeim A, Baxter-King R, Okun AH, et al
    Parental intentions to vaccinate children against COVID-19: Findings from a U.S. National Survey.
    Vaccine. 2022 Nov 7:S0264-410X(22)01371-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  763. BEALE S, Burns R, Braithwaite I, Byrne T, et al
    Occupation, Worker Vulnerability, and COVID-19 Vaccination Uptake: Analysis of the Virus Watch prospective cohort study.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01362.
    PubMed     Abstract available


  764. SKAWRAN S, Schiesser H, Maurer A, Sartoretti T, et al
    Frequency and temporal evolution of COVID-19 vaccination rate among oncological patients undergoing 18F-FDG-PET.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01376.
    PubMed     Abstract available


  765. WU YY, Zhang W
    Demographic disparities in COVID-19 vaccine hesitancy among U.S. adults: Analysis of household pulse survey data from Jul 21 to Oct 11 in 2021.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01381.
    PubMed     Abstract available


  766. LOPEZ-DORIGA RUIZ P, Gunnes N, Michael Gran J, Karlstad O, et al
    Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01367.
    PubMed     Abstract available


  767. OSOWICKI J, Morgan HJ, Harris A, Clothier HJ, et al
    Guillain-Barre syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01366.
    PubMed     Abstract available


  768. LEUNG J, Gray EB, Anderson TC, Sharkey SM, et al
    Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50-64 years in the United States.
    Vaccine. 2022 Nov 5. pii: S0264-410X(22)01328.
    PubMed     Abstract available


  769. MORSTEAD T, Zheng J, Sin NL, DeLongis A, et al
    Perceived threat and coping responses during the COVID-19 pandemic: Prospective associations with vaccine hesitancy.
    Vaccine. 2022 Nov 4. pii: S0264-410X(22)01363.
    PubMed     Abstract available


  770. MALDEN DE, Gee J, Glenn S, Li Z, et al
    Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system.
    Vaccine. 2022 Nov 3. pii: S0264-410X(22)01361.
    PubMed     Abstract available


  771. TOMPKINS LK, Baggs J, Myers TR, Gee JM, et al
    Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01342.
    PubMed     Abstract available


  772. CHANG CT, Lim XJ, Chew CC, Rajan P, et al
    Preferences and willingness of accepting COVID-19 vaccine booster: Results from a middle-income country.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01334.
    PubMed     Abstract available


  773. LUCINDE RK, Karia B, Ouma N, Amadi D, et al
    The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study.
    Vaccine. 2022 Nov 1:S0264-410X(22)01345-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


    October 2022
  774. KUNASEKARAN M, Moa A, Hooshmand E, Trent M, et al
    Effectiveness estimates for enhanced trivalent influenza vaccines in an aged care summer outbreak.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)00766.
    PubMed     Abstract available


  775. KUNASEKARAN M, Poulos CJ, Chughtai AA, Heslop DJ, et al
    Factors associated with repeated influenza vaccine uptake among aged care staff in an Australian sample from 2017 to 2019.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)00981.
    PubMed     Abstract available


  776. CRUZ MC, Nascimento-Carvalho CM
    The early evolution of COVID-19 incidence and mortality among people aged under 80 years or 80 years and above after COVID-19 vaccine implementation in the state of Bahia, Brazil.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01335.
    PubMed     Abstract available


  777. LIMAYE RJ, Paul A, Gur-Arie R, Zavala E, et al
    A socio-ecological exploration to identify factors influencing the COVID-19 vaccine decision-making process among pregnant and lactating women: Findings from Kenya.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01331.
    PubMed     Abstract available


  778. CAPURRO G, Maier R, Tustin J, Jardine CG, et al
    "They're trying to bribe you and taking away your freedoms": COVID-19 vaccine hesitancy in communities with traditionally low vaccination rates.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01338.
    PubMed     Abstract available


  779. SIANI A, Tranter A
    Is vaccine confidence an unexpected victim of the COVID-19 pandemic?
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01337.
    PubMed     Abstract available


  780. MARIE REINHART A, Tian Y, Lilly AE
    The role of trust in COVID-19 vaccine hesitancy and acceptance among Black and White Americans.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01330.
    PubMed     Abstract available


  781. THULUVA S, Paradkar V, Gunneri S, Yerroju V, et al
    Safety, tolerability and immunogenicity of Biological E's CORBEVAX vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01308.
    PubMed     Abstract available


  782. HEYERDAHL LW, Dielen S, Dodion H, Van Riet C, et al
    Strategic silences, eroded trust: The impact of divergent COVID-19 vaccine sentiments on healthcare workers' relations with peers and patients.
    Vaccine. 2022 Oct 27. pii: S0264-410X(22)01306.
    PubMed     Abstract available


  783. SCHIFF J, Schmidt AR, Pham PK, Perez JB, et al
    Parental attitudes in the pediatric emergency department about the COVID-19 vaccine.
    Vaccine. 2022 Oct 26. pii: S0264-410X(22)01309.
    PubMed     Abstract available


  784. MALTEZOU HC, Ledda C, Gagneux-Brunon A, Botelho-Nevers E, et al
    Mandatory COVID-19 vaccination for healthcare personnel in the era of new SARS-CoV-2 variants.
    Vaccine. 2022 Oct 26. pii: S0264-410X(22)01313.
    PubMed    


  785. MALTEZOU HC, Gamaletsou MN, Koukou DM, Giannouchos TV, et al
    Association between COVID-19 vaccination status, time elapsed since the last vaccine dose, morbidity, and absenteeism among healthcare personnel: A prospective, multicenter study.
    Vaccine. 2022 Oct 26. pii: S0264-410X(22)01304.
    PubMed     Abstract available


  786. PHOKSAWAT W, Nithichanon A, Lerdsamran H, Wongratanacheewin S, et al
    Phenotypic and functional changes of T cell subsets after CoronaVac vaccination.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01265.
    PubMed     Abstract available


  787. MADEWELL ZJ, Chacon-Fuentes R, Badilla-Vargas X, Ramirez C, et al
    Knowledge, attitudes, and practices regarding seasonal influenza vaccination during pregnancy in Costa Rica: A mixed-methods study.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01284.
    PubMed     Abstract available


  788. SUN R, Budhwani H
    Negative sentiments toward novel coronavirus (COVID-19) vaccines.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01297.
    PubMed     Abstract available


  789. ARRIETA A, Garcia-Prado A, Sarmiento JP, Paz Castro C, et al
    Identifying early adopters of COVID-19 vaccines in Latin America.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01294.
    PubMed     Abstract available


  790. LAI L, Rouphael N, Xu Y, Kabbani S, et al
    An Oil-in-Water adjuvant significantly increased influenza A/H7N9 split virus Vaccine-Induced circulating follicular helper T (cTFH) cells and antibody responses.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01146.
    PubMed     Abstract available


  791. BLANCO S, Spinsanti L, Javier Aguilar J, Diaz A, et al
    Neutralizing response elicited by homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variants.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01283.
    PubMed     Abstract available


  792. DUCLOS P, MacDonald NE, Dochez C, Thacker N, et al
    Report of the 2nd workshop of the International Collaboration on advanced vaccinology training.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01222.
    PubMed     Abstract available


  793. SANTIBANEZ TA, Black CL, Vogt TM, Chatham-Stephens K, et al
    Where are children ages 5-17 years receiving their COVID-19 vaccinations? Variations over time and by sociodemographic characteristics, United States.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01282.
    PubMed     Abstract available


  794. STONER MCD, Tweedy D, Comello MGL, Toval C, et al
    Using narratives to inform the development of a digital health intervention related to COVID-19 vaccination in Black young adults in Georgia, North Carolina and Alabama.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01286.
    PubMed     Abstract available


  795. ZHONG VW, Li X, Ran J, Hu G, et al
    Vaccination, symptomatic infection and negative conversion of viral RNA by body mass index, diabetes, and age: An observational study.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01262.
    PubMed     Abstract available


  796. HOSHI SL, Shono A, Seposo X, Okubo R, et al
    Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01259.
    PubMed     Abstract available


  797. HALL PA, Meng G, Sakib MN, Quah ACK, et al
    Do the vaccinated perform less distancing, mask wearing and hand hygiene? A test of the risk compensation hypothesis in a representative sample during the COVID-19 pandemic.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01289.
    PubMed     Abstract available


  798. GOLLAMUDI J, Sartain SE, Navaei AH, Aneja S, et al
    Thrombosis and thromboembolism: Brighton collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2022;40:6431-6444.
    PubMed     Abstract available


  799. LIAO SH, Chang WJ, Hsu CY, Ming-Fang Yen A, et al
    Evaluating correlates of protection for mix-match vaccine against COVID-19 VOCs with potential of evading immunity.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01258.
    PubMed     Abstract available


  800. TAKAHASHI Y, Ishitsuka K, Sampei M, Okawa S, et al
    COVID-19 vaccine literacy and vaccine hesitancy among pregnant women and mothers of young children in Japan.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01227.
    PubMed     Abstract available


  801. RHODES S, Smith N, Evans T, White R, et al
    Identifying COVID-19 optimal vaccine dose using mathematical immunostimulation/immunodynamic modelling.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01260.
    PubMed     Abstract available


  802. CREISHER PS, Campbell AD, Perry JL, Roznik K, et al
    Influenza subtype-specific maternal antibodies protect offspring against infection but inhibit vaccine-induced immunity and protection in mice.
    Vaccine. 2022 Oct 14. pii: S0264-410X(22)01241.
    PubMed     Abstract available


  803. SAADE EA, Abul Y, McConeghy K, Edward Davidson H, et al
    High-dose influenza vaccines for the prevention of hospitalization due to cardiovascular events in older adults in the nursing home: Post-hoc analysis of a cluster-randomized trial.
    Vaccine. 2022 Oct 13. pii: S0264-410X(22)01215.
    PubMed     Abstract available


  804. HUDSON A, Hall PA, Hitchman SC, Meng G, et al
    Cognitive predictors of COVID-19 mitigation behaviors in vaccinated and unvaccinated general population members.
    Vaccine. 2022 Oct 13. pii: S0264-410X(22)01242.
    PubMed     Abstract available


  805. LIU S, Yang G, Li M, Sun F, et al
    Transcutaneous immunization via dissolving microneedles protects mice from lethal influenza H7N9 virus challenge.
    Vaccine. 2022 Oct 12. pii: S0264-410X(22)01102.
    PubMed     Abstract available


  806. VOGELSANG EM, Polonijo AN
    Scarier than the flu shot? : The social determinants of shingles and influenza vaccinations among U.S. older adults.
    Vaccine. 2022 Oct 8. pii: S0264-410X(22)01183.
    PubMed     Abstract available


  807. CHEN JY, Hsieh SM, Hwang SJ, Liu CS, et al
    Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study.
    Vaccine. 2022 Oct 7. pii: S0264-410X(22)01200.
    PubMed     Abstract available


  808. ELHARAKE JA, Omer SB, Schwartz JL
    Country immunization policies for refugees across 20 low-middle income and 20 high-income countries.
    Vaccine. 2022;40:6017-6022.
    PubMed     Abstract available


  809. EKTARE V, Lang J, Choi Y, Finelli L, et al
    The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States.
    Vaccine. 2022;40:6064-6073.
    PubMed     Abstract available


  810. MARLOWE E, Pranikoff S, Borsheim B, Salafian K, et al
    Pilot study to determine effect of an altruism intervention focusing on herd immunity to enhance influenza vaccination rates.
    Vaccine. 2022 Oct 6. pii: S0264-410X(22)01194.
    PubMed     Abstract available


  811. PAGUIO JA, Ojikutu BO, Alfonso PG, Yao JS, et al
    Association of culturally competent care with influenza vaccination coverage in the United States.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01065.
    PubMed     Abstract available


  812. CHUGHTAI AA, Mohammed S, Al Ariqi L, McCarron M, et al
    Development of a road map to scale up the uptake and utilization of influenza vaccine in 22 countries of Eastern Mediterranean Region.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01159.
    PubMed     Abstract available


  813. BYRNE A, Thompson LA, Filipp SL, Ryan K, et al
    COVID-19 vaccine perceptions and hesitancy amongst parents of school-aged children during the pediatric vaccine rollout.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01221.
    PubMed     Abstract available


  814. VAN EWIJK CE, Hazelhorst EI, Hahne SJM, Knol MJ, et al
    COVID-19 outbreak in an elderly care home: Very low vaccine effectiveness and late impact of booster vaccination campaign.
    Vaccine. 2022 Oct 4. pii: S0264-410X(22)01213.
    PubMed     Abstract available


  815. CHAO CR, Xu L, Cannizzaro N, Bronstein D, et al
    Trends in HPV vaccine administration and HPV vaccine coverage in children by race/ethnicity and socioeconomic status during the COVID-19 pandemic in an integrated health care system in California.
    Vaccine. 2022 Oct 3. pii: S0264-410X(22)01195.
    PubMed     Abstract available


  816. AL-SHAIKH A, Mahmoud RI, Boukerdenna H, Muthu N, et al
    Counselling of non-communicable diseases' patients for COVID-19 vaccine uptake in Jordan: Evaluating the intervention.
    Vaccine. 2022 Oct 3. pii: S0264-410X(22)01214.
    PubMed     Abstract available


  817. FERREIRA LS, de Almeida GB, Borges ME, Simon LM, et al
    Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil.
    Vaccine. 2022 Oct 3. pii: S0264-410X(22)01216.
    PubMed     Abstract available


  818. ODIO CD, Katzelnick LC
    'Mix and Match' vaccination: Is dengue next?
    Vaccine. 2022 Oct 1. pii: S0264-410X(22)01101.
    PubMed     Abstract available


    September 2022
  819. WILLIAMS E, Colson J, Valiathan R, Carreno JM, et al
    Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2.
    Vaccine. 2022;40:5868-5872.
    PubMed     Abstract available


  820. SPETZ M, Lundberg L, Nwaru C, Li H, et al
    An intersectional analysis of sociodemographic disparities in Covid-19 vaccination: A nationwide register-based study in Sweden.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01186.
    PubMed     Abstract available


  821. HATHAWAY CA, Siegel EM, Gonzalez BD, Oswald LB, et al
    Individual-level factors associated with COVID-19 vaccine acceptance among U.S. patients with cancer.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01184.
    PubMed     Abstract available


  822. MARCHESE AM, Beyhaghi H, Orenstein WA
    With established safe and effective use, protein vaccines offer another choice against COVID-19.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01185.
    PubMed    


  823. SILVA-VALENCIA J, Soto-Becerra P, Escobar-Agreda S, Fernandez-Navarro M, et al
    Relative vaccine effectiveness of the booster dose of COVID-19 vaccine for preventing death in individuals with a primary regimen based on the BBIBP-CorV, ChAdOx1-S, or BNT162b2 vaccines during the Omicron wave in Peru: A nested case-control study usi
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01189.
    PubMed     Abstract available


  824. TRAKARNVANICH T, Ngamvichchukorn T, Phumisantiphong U, Pholtawornkulchai K, et al
    Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01187.
    PubMed     Abstract available


  825. CERVANTES-TORRES J, Rosales-Mendoza S, Cabello C, Montero L, et al
    Towards the development of an epitope-focused vaccine for SARS-CoV-2.
    Vaccine. 2022 Sep 27. pii: S0264-410X(22)01168.
    PubMed     Abstract available


  826. LLOYD PC, Hu M, Wong HL, Shoaibi A, et al
    Near real-time surveillance of safety outcomes in US COVID-19 vaccine recipients aged 12 to 64 years.
    Vaccine. 2022 Sep 27. pii: S0264-410X(22)01167.
    PubMed     Abstract available


  827. ZHU H, Li X, Ren X, Chen H, et al
    Improving cross-protection against influenza virus in mice using a nanoparticle vaccine of mini-HA.
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01165.
    PubMed     Abstract available


  828. OHTA M, Kambayashi Y, Mita H, Kuroda T, et al
    Protective efficacy of a reverse genetics-derived inactivated vaccine against equine influenza virus in horses.
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01155.
    PubMed     Abstract available


  829. TOLSTRUP WESTER C, Lybecker Scheel-Hincke L, Bovil T, Andersen-Ranberg K, et al
    Prayer frequency and COVID-19 vaccine hesitancy among older adults in Europe.
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01153.
    PubMed     Abstract available


  830. GATES DM, Cohen SA, Orr K, Caffrey AR, et al
    Pediatric influenza vaccination rates lower than previous estimates in the United States.
    Vaccine. 2022 Sep 24. pii: S0264-410X(22)01162.
    PubMed     Abstract available


  831. MOHAMMED AH, Hassan BAR, Wayyes AM, Gadhban AQ, et al
    Parental health beliefs, intention, and strategies about covid-19 vaccine for their children: A cross-sectional analysis from five Arab countries in the Middle East.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01161.
    PubMed     Abstract available


  832. MUES KE, Kirk B, Patel DA, Gelman A, et al
    Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01120.
    PubMed     Abstract available


  833. RUCKSTUHL L, Czock A, Haile SR, Lang P, et al
    Influence of cantonal health policy frameworks & activities on the influenza vaccination rate in patients with non-communicable diseases in Switzerland.
    Vaccine. 2022 Sep 22. pii: S0264-410X(22)01148.
    PubMed     Abstract available


  834. ROMER D, Winneg KM, Jamieson PE, Brensinger C, et al
    Misinformation about vaccine safety and uptake of COVID-19 vaccines among adults and 5-11-year-olds in the United States.
    Vaccine. 2022 Sep 22. pii: S0264-410X(22)01154.
    PubMed     Abstract available


  835. LIU B, Gidding H, Stepien S, Cretikos M, et al
    Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection.
    Vaccine. 2022 Sep 21. pii: S0264-410X(22)01126.
    PubMed     Abstract available


  836. KIEFER MK, Mehl R, Rood KM, Germann K, et al
    Association between social vulnerability and COVID-19 vaccination hesitancy and vaccination in pregnant and postpartum individuals.
    Vaccine. 2022 Sep 21. pii: S0264-410X(22)01152.
    PubMed     Abstract available


  837. SHAPIRO JR, Privor-Dumm L, Rosser EN, Leng SX, et al
    The intersection of gender and race in older adults' decision to receive COVID-19 vaccines.
    Vaccine. 2022 Sep 20:S0264-410X(22)01151-3. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  838. GRAAF A, Petric PP, Sehl-Ewert J, Henritzi D, et al
    Cold-passaged isolates and bat-swine influenza a chimeric viruses as modified live-attenuated vaccines against influenza a viruses in pigs.
    Vaccine. 2022 Sep 19. pii: S0264-410X(22)01108.
    PubMed     Abstract available


  839. NTZIORA F, Georgia Kostaki E, Karapanou A, Mylona M, et al
    Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers.
    Vaccine. 2022 Sep 19. pii: S0264-410X(22)01150.
    PubMed     Abstract available


  840. CARRENO JM, Singh G, Tcheou J, Srivastava K, et al
    mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations.
    Vaccine. 2022 Sep 14. pii: S0264-410X(22)01003.
    PubMed     Abstract available


  841. FRANKENTHAL D, Zatlawi M, Karni-Efrati Z, Keinan-Boker L, et al
    COVID-19 vaccine hesitancy among Israeli adults before and after vaccines' availability: A cross-sectional national survey.
    Vaccine. 2022 Sep 14. pii: S0264-410X(22)01078.
    PubMed     Abstract available


  842. CREVECOEUR J, Hens N, Neyens T, Lariviere Y, et al
    Change in COVID19 outbreak pattern following vaccination in long-term care facilities in Flanders, Belgium.
    Vaccine. 2022 Sep 14. pii: S0264-410X(22)01124.
    PubMed     Abstract available


  843. OSEI I, Sarwar G, Hossain I, Sonko K, et al
    Attendance and vaccination at immunization clinics in rural Gambia before and during the COVID-19 pandemic.
    Vaccine. 2022 Sep 13. pii: S0264-410X(22)01125.
    PubMed     Abstract available


  844. DAY ME, Klein M, Sucharew H, Carol Burkhardt M, et al
    Declining influenza vaccination rates in an underserved pediatric primary care center during the COVID-19 pandemic.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01121.
    PubMed     Abstract available


  845. ZACE D, La Gatta E, Petrella L, Di Pietro ML, et al
    The impact of COVID-19 vaccines on fertility-A systematic review and meta-analysis.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01118.
    PubMed     Abstract available


  846. FRIEDMAN-KLABANOFF DJ, Tjaden AH, Santacatterina M, Munawar I, et al
    Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01116.
    PubMed     Abstract available


  847. MONFARED IG
    The connection between COVID-19 vaccine abundance, vaccination coverage, and public trust in government across the globe.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01107.
    PubMed     Abstract available


  848. NAEIM A, Guerin RJ, Baxter-King R, Okun AH, et al
    Strategies to increase the intention to get vaccinated against COVID-19: Findings from a nationally representative survey of US adults, October 2020 to October 2021.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01117.
    PubMed     Abstract available


  849. ISHIGURO C, Mimura W, Murata F, Fukuda H, et al
    Development and application of a Japanese vaccine database for comparative assessments in the post-authorization phase: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study.
    Vaccine. 2022 Sep 9. pii: S0264-410X(22)01077.
    PubMed     Abstract available


  850. TEPEROWSKI MONRAD J, Quaade S, Powell-Jackson T
    Supply, then demand? Health expenditure, political leanings, cost obstacles to care, and vaccine hesitancy predict state-level COVID-19 vaccination rates.
    Vaccine. 2022 Sep 8. pii: S0264-410X(22)01041.
    PubMed     Abstract available


  851. CEANNT R, Vallieres F, Burns H, Murphy J, et al
    Covid-19 vaccine hesitancy and resistance amongst parents of children under 18 years of age in Ireland.
    Vaccine. 2022 Sep 7. pii: S0264-410X(22)01082.
    PubMed     Abstract available


  852. MOK CC, Chan KL, Tse SM
    Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01067.
    PubMed     Abstract available


  853. LUBIS TA, Gunardi H, Herqutanto, Soedjatmiko S, et al
    Educational videos to address vaccine hesitancy in childhood immunization.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01035.
    PubMed     Abstract available


  854. HABERSAAT KB, Narayan S, Malue Nielsen S, Scherzer M, et al
    How health workers can make a difference in the public COVID-19 vaccination response.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01081.
    PubMed    


  855. PERRIER Q, Lupo J, Gerster T, Augier C, et al
    SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipients.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01064.
    PubMed     Abstract available


  856. BOLSEWICZ KT, Steffens MS, Karpish L, Bullivant B, et al
    "Every interaction you have ...should be an opportunity to discuss and offer influenza vaccination". Health service perspectives on influenza vaccination promotion and delivery to Aboriginal families living in New South Wales, Australia.
    Vaccine. 2022 Sep 1. pii: S0264-410X(22)01047.
    PubMed     Abstract available


    August 2022
  857. HRIN ML, Emmerich VK, Ip EH, Feldman SR, et al
    Development and validation of a COVID-19 vaccine hesitancy scale for adults in the United States.
    Vaccine. 2022 Aug 31. pii: S0264-410X(22)01052.
    PubMed     Abstract available


  858. FRAIMAN J, Erviti J, Jones M, Greenland S, et al
    Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults.
    Vaccine. 2022 Aug 30. pii: S0264-410X(22)01028.
    PubMed     Abstract available


  859. JACOBSON M, Chang TY, Shah M, Pramanik R, et al
    Can financial incentives and other nudges increase COVID-19 vaccinations among the vaccine hesitant? A randomized trial.
    Vaccine. 2022 Aug 30. pii: S0264-410X(22)01050.
    PubMed     Abstract available


  860. SARKAR P, Chandrasekaran V, Gunasekaran D, Chinnakali P, et al
    COVID-19 vaccine hesitancy among health care worker-parents (HCWP) in Puducherry, India and its implications on their children: A cross sectional descriptive study.
    Vaccine. 2022 Aug 29. pii: S0264-410X(22)01040.
    PubMed     Abstract available


  861. CAO X, Zai J, Zhao Q, Xie L, et al
    Intranasal immunization with recombinant Vaccinia virus encoding trimeric SARS-CoV-2 spike receptor-binding domain induces neutralizing antibody.
    Vaccine. 2022 Aug 29. pii: S0264-410X(22)01044.
    PubMed     Abstract available


  862. SANCHEZ-SAEZ F, Peiro S, Cuenca L, Vanaclocha H, et al
    Side effects during the week after first dose vaccination with four Covid-19 vaccines. Results of the ProVaVac Survey Study with 13,837 people in Spain.
    Vaccine. 2022 Aug 29. pii: S0264-410X(22)01007.
    PubMed     Abstract available


  863. DOYON-PLOURDE P, Fortin E, Quach C
    Evaluation of the 2018-2019 vaccine effectiveness against medically attended influenza-like illness using medical records and claims data.
    Vaccine. 2022 Aug 27. pii: S0264-410X(22)00976.
    PubMed     Abstract available


  864. CHUAN VOO T, Savulescu J, Schaefer O, Ho Zhi Ling A, et al
    COVID-19 differentiated measures for unvaccinated individuals: The need for clear goals and strong justifications.
    Vaccine. 2022;40:5333-5337.
    PubMed     Abstract available


  865. PIDIYAR V, Kumraj G, Ahmed K, Ahmed S, et al
    COVID-19 management landscape: A need for an affordable platform to manufacture safe and efficacious biotherapeutics and prophylactics for the developing countries.
    Vaccine. 2022;40:5302-5312.
    PubMed     Abstract available


  866. ROSHCHINA Y, Roshchin S, Rozhkova K
    Determinants of COVID-19 vaccine hesitancy and resistance in Russia.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01032.
    PubMed     Abstract available


  867. TERESA VIETRI M, D'Elia G, Caliendo G, Passariello L, et al
    Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01034.
    PubMed     Abstract available


  868. HEMMI T, Ainai A, Hashiguchi T, Tobiume M, et al
    Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01038.
    PubMed     Abstract available


  869. KIKUT A, Clark D, Jesch E, Hornik R, et al
    Strengthened belief in vaccine effectiveness predicted increased COVID-19 vaccination intention and behaviour: Results from a nationally representative longitudinal survey of U.S. adults from July 2020 to April/May 2021.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01036.
    PubMed     Abstract available


  870. OKUYAMA M, Morino S, Tanaka K, Nakamura-Miwa H, et al
    Vasovagal reactions after COVID-19 vaccination in Japan.
    Vaccine. 2022 Aug 25. pii: S0264-410X(22)01046.
    PubMed     Abstract available


  871. LIM AH, Ab Rahman N, Ong SM, Paraja J, et al
    Evaluation of BNT162b2 vaccine effectiveness in Malaysia: test negative case-control study.
    Vaccine. 2022 Aug 24. pii: S0264-410X(22)01005.
    PubMed     Abstract available


  872. WILLIS GA, Bloomfield L, Berry M, Bulsara C, et al
    The impact of a vaccine mandate and the COVID-19 pandemic on influenza vaccination uptake in Western Australian health care students.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01026.
    PubMed     Abstract available


  873. JAFFRY M, Mostafa F, Mandava K, Rosario S, et al
    No significant increase in Guillain-Barre syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01025.
    PubMed     Abstract available


  874. MARRON L, Ferenczi A, O'Brien KM, Cotter S, et al
    Views on COVID-19 vaccination of young children in Ireland, results from a cross-sectional survey of parents.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01013.
    PubMed     Abstract available


  875. STIVANELLO E, Beghelli C, Cardoni F, Giansante C, et al
    Short-term mortality following COVID-19 vaccination in Bologna, Italy: a one-year study.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01029.
    PubMed     Abstract available


  876. WANG X, Deng Y, Zhao L, Wang L, et al
    Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01030.
    PubMed     Abstract available


  877. KANOKUDOM S, Assawakosri S, Suntronwong N, Chansaenroj J, et al
    Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01011.
    PubMed     Abstract available


  878. DOCHEZ C, Duclos P, MacDonald N, Steffen C, et al
    Advanced vaccinology training globally: Update and impact of the COVID-19 crisis.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01006.
    PubMed     Abstract available


  879. KURASHIMA K, Numano T, Yoshino A, Osawa A, et al
    Antibody titers among healthcare workers for coronavirus disease 2019 at 6 months after BNT162b2 vaccination.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01027.
    PubMed     Abstract available


  880. TOAPANTA-YANCHAPAXI L, Chiquete E, Avila-Rojo E, Lopez-Yanez S, et al
    Humoral response to different SARS-CoV-2 vaccines in orthotopic liver transplant recipients.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01012.
    PubMed     Abstract available


  881. CLEMENS SAC, Fortaleza CMCB, Crowe M, Pollard A, et al
    Safety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01010.
    PubMed     Abstract available


  882. MIHIGO RM, Okeibunor JC, Karmal F, O'Malley H, et al
    The Addis Declaration on Immunization: A binding reminder of the political support needed to achieve universal immunization in Africa.
    Vaccine. 2022;40:5126-5130.
    PubMed     Abstract available


  883. PSARIDI L, Maltezou HC, Simonidou S, Lialliou I, et al
    Neutralizing antibody responses in healthcare personnel after three doses of mRNA BNT162b2 vaccine and association with baseline characteristics and past SARS-CoV-2 infection.
    Vaccine. 2022 Aug 19. pii: S0264-410X(22)01008.
    PubMed     Abstract available


  884. STOECKEL F, Stockli S, Phillips J, Lyons B, et al
    Stamping the vaccine passport? Public support for lifting COVID-19 related restrictions for vaccinated citizens in France, Germany, and Sweden.
    Vaccine. 2022 Aug 18. pii: S0264-410X(22)00965.
    PubMed     Abstract available


  885. LAFFAN MA, Rees S, Yadavalli M, Ferstenberg LB, et al
    Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations.
    Vaccine. 2022 Aug 18. pii: S0264-410X(22)00964.
    PubMed     Abstract available


  886. AMANI A, Ngo Bama S, Dia M, Nguefack Lekelem S, et al
    Challenges, best practices, and lessons learned from oral cholera mass vaccination campaign in urban Cameroon during the COVID-19 era.
    Vaccine. 2022 Aug 18. pii: S0264-410X(22)01004.
    PubMed     Abstract available


  887. WYMORE BRAND M, Anderson TK, Kitikoon P, Brian Kimble J, et al
    Bivalent hemagglutinin and neuraminidase influenza replicon particle vaccines protect pigs against influenza a virus without causing vaccine associated enhanced respiratory disease.
    Vaccine. 2022 Aug 17. pii: S0264-410X(22)00937.
    PubMed     Abstract available


  888. LINNANDER E, Ineza L, Mupeta Bobo P, Bechtold K, et al
    Improving management of vaccine supply chains: A multi-methods evaluation of vSTEP in Zambia.
    Vaccine. 2022 Aug 17. pii: S0264-410X(22)00914.
    PubMed     Abstract available


  889. MATSUURA T, Fukushima W, Nakagama Y, Kido Y, et al
    Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00984.
    PubMed     Abstract available


  890. ALKETBI LMB, Al Hosani F, Al Memari S, Al Mazrouei S, et al
    Parents' views on the acceptability of a COVID-19 vaccine for their children: A cross-sectional study in Abu Dhabi-United Arab Emirates.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00954.
    PubMed     Abstract available


  891. CASEROTTI M, Gavaruzzi T, Girardi P, Sellaro R, et al
    People's perspectives about COVID-19 vaccination certificate: Findings from a representative Italian sample.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00980.
    PubMed     Abstract available


  892. ELLIOTT CBP, Chambers CS
    A historical analysis of vaccine mandates in the United States military and its application to the COVID-19 vaccine mandate.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00982.
    PubMed     Abstract available


  893. VISKUPIC F, Wiltse DL, Badahdah A
    Reminders of existing vaccine mandates increase support for a COVID-19 vaccine mandate: Evidence from a survey experiment.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00978.
    PubMed     Abstract available


  894. OMER SB, O'Leary ST, Bednarczyk RA, Ellingson MK, et al
    Multi-tiered intervention to increase maternal immunization coverage: A randomized, controlled trial.
    Vaccine. 2022;40:4955-4963.
    PubMed     Abstract available


  895. SCHMIDTKE KA, Skrybant M, Kudrna L, Russell S, et al
    A workshop to co-design messages that may increase uptake of vaccines: A case study.
    Vaccine. 2022 Aug 12. pii: S0264-410X(22)00951.
    PubMed     Abstract available


  896. PROUT A, Rustandi RR, Tubbs C, Winters MA, et al
    Functional profiling of Covid 19 vaccine candidate by flow virometry.
    Vaccine. 2022 Aug 9. pii: S0264-410X(22)00963.
    PubMed     Abstract available


  897. PERROUD JM, Soldano S, Avancena ALV, Wagner A, et al
    Adult vaccination uptake strategies in low- and middle-income countries: A systematic review.
    Vaccine. 2022 Aug 8. pii: S0264-410X(22)00952.
    PubMed     Abstract available


  898. HU S, Xiong C, Li Q, Wang Z, et al
    COVID-19 vaccine hesitancy cannot fully explain disparities in vaccination coverage across the contiguous United States.
    Vaccine. 2022 Aug 8. pii: S0264-410X(22)00947.
    PubMed     Abstract available


  899. DE SWART RL, de Leeuw OS, Oreshkova N, Gerhards NM, et al
    Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters.
    Vaccine. 2022;40:4676-4681.
    PubMed     Abstract available


  900. ESTRELA M, Magalhaes Silva T, Roque V, Rebelo Gomes E, et al
    Unravelling the drivers behind COVID-19 vaccination hesitancy and refusal among teachers: A nationwide study.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00955.
    PubMed     Abstract available


  901. YEO J, Furr Gudmundsen C, Fazel S, Corrigan A, et al
    A behavior change model to address caregiver hesitancy around COVID-19 vaccination in pediatrics.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00949.
    PubMed     Abstract available


  902. ULRICH AK, Pankratz GK, Bohn B, Yendell S, et al
    COVID-19 vaccine confidence and reasons for vaccination among health care workers and household members.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00956.
    PubMed     Abstract available


  903. SQUIRE JD, Joshi AY
    Response to mRNA COVID-19 vaccination in three XLA patients.
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00941.
    PubMed     Abstract available


  904. SNYDER J, Goldenberg M, Crooks VA, Katz R, et al
    Crowdfunding narratives and the valuation of vaccines for COVID-19.
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00946.
    PubMed     Abstract available


  905. CIMA MJ, McCormick D, Porter A 3rd, Zohoori N, et al
    COVID-19 vaccine uptake among Arkansas public K-12 school teachers and staff.
    Vaccine. 2022 Aug 2. pii: S0264-410X(22)00942.
    PubMed     Abstract available


  906. BAUMER-MOURADIAN SH, Hart RJ, Bone JN, Seiler M, et al
    Should COVID-19 vaccines be mandated in schools? - an international caregiver perspective.
    Vaccine. 2022 Aug 1. pii: S0264-410X(22)00921.
    PubMed     Abstract available


  907. KORODI M, Horvath I, Rakosi K, Jenei Z, et al
    Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers.
    Vaccine. 2022 Aug 1. pii: S0264-410X(22)00936.
    PubMed     Abstract available


    July 2022
  908. SHINKAI M, Sonoyama T, Kamitani A, Shibata RY, et al
    Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.
    Vaccine. 2022;40:4328-4333.
    PubMed     Abstract available


  909. SADOFF J, Le Gars M, Brandenburg B, Cardenas V, et al
    Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
    Vaccine. 2022;40:4403-4411.
    PubMed     Abstract available


  910. NOWALK MP, D'Agostino H, Dauer K, Stiegler M, et al
    Estimating the burden of adult hospitalized RSV infection including special populations.
    Vaccine. 2022;40:4121-4127.
    PubMed     Abstract available


  911. SALMANTON-GARCIA J, Stewart FA, Heringer S, Koniordou M, et al
    VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment.
    Vaccine. 2022;40:4090-4097.
    PubMed     Abstract available


  912. CHEN H, Huang Z, Chang S, Hu M, et al
    Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiorit
    Vaccine. 2022 Jul 29. pii: S0264-410X(22)00919.
    PubMed     Abstract available


  913. ROSE O, Erzkamp S, Schobel W, Grajeda M, et al
    COVID-19 vaccinations in German pharmacies: A survey on patient and provider satisfaction.
    Vaccine. 2022 Jul 28. pii: S0264-410X(22)00925.
    PubMed     Abstract available


  914. RAMMAURO F, Carrion F, Olivero-Deibe N, Flo M, et al
    Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2.
    Vaccine. 2022 Jul 27. pii: S0264-410X(22)00911.
    PubMed     Abstract available


  915. SHENYU W, Xiaoqian D, Bo C, Xuan D, et al
    Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China.
    Vaccine. 2022 Jul 26. pii: S0264-410X(22)00908.
    PubMed     Abstract available


  916. KRAUSE PR, Arora N, Dowling W, Munoz-Fontela C, et al
    Making more COVID-19 vaccines available to address global needs: Considerations and a framework for their evaluation.
    Vaccine. 2022 Jul 26. pii: S0264-410X(22)00916.
    PubMed    


  917. MCMILLAN CLD, Amarilla AA, Modhiran N, Choo JJY, et al
    Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00888.
    PubMed     Abstract available


  918. DUGORD C, Franc C
    Trajectories and individual determinants of repeated seasonal flu vaccination use over the long term using data from the French E3N cohort.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00855.
    PubMed     Abstract available


  919. SETHY G, Chisema M, Sharma L, Joshi K, et al
    COVID-19 vaccine express strategy in Malawi: An effort to reach the un-reach.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00887.
    PubMed     Abstract available


  920. MIMURA W, Ishiguro C, Fukuda H
    Influenza vaccine effectiveness against hospitalization during the 2018/2019 season among older persons aged>/=75years in Japan: The LIFE-VENUS Study.
    Vaccine. 2022 Jul 15. pii: S0264-410X(22)00852.
    PubMed     Abstract available


  921. VASUDEVAN L, Bruening R, Hung A, Woolson S, et al
    COVID-19 vaccination intention and activation among health care system employees: A mixed methods study.
    Vaccine. 2022 Jul 13. pii: S0264-410X(22)00884.
    PubMed     Abstract available


  922. PRIDDY FH, Williams M, Carson S, Lavender B, et al
    Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00885.
    PubMed     Abstract available


  923. ORTQVIST AK, Dahlqwist E, Magnus MC, Ljung R, et al
    COVID-19 vaccination in pregnant women in Sweden and Norway.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00859.
    PubMed     Abstract available


  924. GODDARD K, Lewis N, Fireman B, Weintraub E, et al
    Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00860.
    PubMed     Abstract available


  925. CUFFEL A, Maylin S, Le Buanec H, Delaugerre C, et al
    Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00857.
    PubMed     Abstract available


  926. PADRON-REGALADO E, Medina-Rivero E
    Perspectives for licensing vaccines in Mexico.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00854.
    PubMed     Abstract available


  927. WYPLOSZ B, Fernandes J, Sultan A, Roche N, et al
    Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study.
    Vaccine. 2022 Jul 7. pii: S0264-410X(22)00841.
    PubMed     Abstract available


  928. ZHANG Y, Wang Y, Jia C, Li G, et al
    Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects >/=3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial.
    Vaccine. 2022 Jul 7. pii: S0264-410X(22)00846.
    PubMed     Abstract available


  929. CHADWICK C, Friede M, Moen A, Nannei C, et al
    Technology transfer programme for influenza vaccines - Lessons from the past to inform the future.
    Vaccine. 2022 Jul 6. pii: S0264-410X(22)00826.
    PubMed    


  930. XIRIDOU M, Adam P, Meiberg A, Visser M, et al
    The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study.
    Vaccine. 2022 Jul 4. pii: S0264-410X(22)00847.
    PubMed     Abstract available


  931. MCCORMICK DW, Konkle SL, Magleby R, Chakrabarti AK, et al
    SARS-CoV-2 infection risk among vaccinated and unvaccinated household members during the Alpha variant surge - Denver, Colorado, and San Diego, California, January-April 2021.
    Vaccine. 2022 Jul 4. pii: S0264-410X(22)00835.
    PubMed     Abstract available


  932. HOU Z, Guo J, Lai X, Zhang H, et al
    Influenza vaccination hesitancy and its determinants among elderly in China: A national cross-sectional study.
    Vaccine. 2022 Jul 1. pii: S0264-410X(22)00832.
    PubMed     Abstract available


  933. BARRALL AL, Hoff NA, Nkamba DM, Musene K, et al
    Hesitancy to receive the novel coronavirus vaccine and potential influences on vaccination among a cohort of healthcare workers in the Democratic Republic of the Congo.
    Vaccine. 2022 Jul 1. pii: S0264-410X(22)00842.
    PubMed     Abstract available


  934. SKIRROW H, Barnett S, Bell S, Mounier-Jack S, et al
    Women's views and experiences of accessing pertussis vaccination in pregnancy and infant vaccinations during the COVID-19 pandemic: A multi-methods study in the UK.
    Vaccine. 2022 Jul 1. pii: S0264-410X(22)00845.
    PubMed     Abstract available


    June 2022
  935. HILLS T, Paterson A, Woodward R, Middleton F, et al
    The effect of needle length and skin to deltoid muscle distance in adults receiving an mRNA COVID-19 vaccine.
    Vaccine. 2022 Jun 29. pii: S0264-410X(22)00839.
    PubMed     Abstract available


  936. WONG SC, Chan VW, Lam GKM, Yuen LL, et al
    The impact of personal coaching on influenza vaccination among healthcare workers before and during COVID-19 pandemic.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00836.
    PubMed     Abstract available


  937. MEDEIROS MZ, Soares PF, Fialho BC, Gauss L, et al
    Vaccine innovation model: A technology transfer perspective in pandemic contexts.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00823.
    PubMed     Abstract available


  938. LEE JT, Sean Hu S, Zhou T, Bonner KE, et al
    Employer requirements and COVID-19 vaccination and attitudes among healthcare personnel in the U.S.: Findings from National Immunization Survey Adult COVID Module, August - September 2021.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00838.
    PubMed     Abstract available


  939. MOGHNIEH R, Abdallah D, Sayegh MH, Rahman Bizri A, et al
    Response to letter to the editor: Immunophenotyping of SARS-CoV-2 and vaccine design.
    Vaccine. 2022;40:3987-3988.
    PubMed    


  940. CIMOLAI N
    Immunophenotyping of SARS-CoV-2 and vaccine design.
    Vaccine. 2022;40:3985-3986.
    PubMed    


  941. STRAUS W, Rubin H
    COVID-19 vaccine safety monitoring in low and middle income countries - Time for a bold new approach.
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00822.
    PubMed    


  942. SEYRAN M
    Artificial intelligence and clinical data suggest the T cell-mediated SARS-CoV-2 nonstructural protein intranasal vaccines for global COVID-19 immunity.
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00821.
    PubMed     Abstract available


  943. SHIVJI R, Conocchia R, Korakianiti E, Jekerle V, et al
    Considerations for the chemistry, manufacturing and Controls (CMC) - quality package for COVID-19 vaccines- interim lessons learnt by the European medicines Agency (EMA).
    Vaccine. 2022 Jun 24. pii: S0264-410X(22)00827.
    PubMed     Abstract available


  944. WILSON B, Mukundan Geetha K
    Nanomedicine to deliver biological macromolecules for treating COVID-19.
    Vaccine. 2022;40:3931-3941.
    PubMed     Abstract available


  945. CARTANYA-HUESO A, Martinez-Sanchez JM, Carlos Martin-Sanchez J, Lidon-Moyano C, et al
    Relationship between double COVID-19 vaccine uptake and trust in effectiveness and safety of vaccination in general in 23 Member states of the European Union: an ecological study.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00820.
    PubMed     Abstract available


  946. AL-MUSTAPHA AI, Okechukwu O, Olayinka A, Muhammed OR, et al
    A national survey of COVID-19 vaccine acceptance in Nigeria.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00818.
    PubMed     Abstract available


  947. LOHMANN S, Albarracin D
    Trust in the public health system as a source of information on vaccination matters most when environments are supportive.
    Vaccine. 2022 Jun 23. pii: S0264-410X(22)00759.
    PubMed     Abstract available


  948. RONZANI P, Panizza F, Martini C, Savadori L, et al
    Countering vaccine hesitancy through medical expert endorsement.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00780.
    PubMed     Abstract available


  949. KORVES C, Izurieta HS, Smith J, Zwain GM, et al
    Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00816.
    PubMed     Abstract available


  950. DIONATO FAV, Jalalizadeh M, Buosi K, Visacri MB, et al
    BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial.
    Vaccine. 2022 Jun 20. pii: S0264-410X(22)00803.
    PubMed     Abstract available


  951. ATWELL JE, Lutz CS, Sparrow EG, Feikin DR, et al
    Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Vaccine. 2022 Jun 17. pii: S0264-410X(22)00783.
    PubMed     Abstract available


  952. CANADAY LM, Resnick JD, Liu H, Powell H, et al
    HA and M2 sequences alter the replication of 2013-16 H1 live attenuated influenza vaccine infection in human nasal epithelial cell cultures.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00733.
    PubMed     Abstract available


  953. UWAMINO Y, Kurafuji T, Takato K, Sakai A, et al
    Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00763.
    PubMed     Abstract available


  954. MOUTA NUNES DE OLIVEIRA P, Mendes-de-Almeida DP, Bertollo Gomes Porto V, Crespo Cordeiro C, et al
    Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil.
    Vaccine. 2022 Jun 16. pii: S0264-410X(22)00761.
    PubMed     Abstract available


  955. REICHERZ F, Golding L, Lavoie PM, Abu-Raya B, et al
    Decay of anti-Bordetella pertussis antibodies in women of childbearing age following COVID-19 non-pharmaceutical measures.
    Vaccine. 2022;40:3746-3751.
    PubMed     Abstract available


  956. FREW PM, Gonzalez-Casanova I, Otieno NA, Malik FA, et al
    Development of effective messages to promote maternal immunization in Kenya.
    Vaccine. 2022;40:3761-3770.
    PubMed     Abstract available


  957. BRAUNFELD JB, Carson HN, Williams SR, Schwartz LM, et al
    Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00778.
    PubMed     Abstract available


  958. GAMBRELL A, Sundaram M, Bednarczyk RA
    Estimating the number of US children susceptible to measles resulting from COVID-19-related vaccination coverage declines.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00782.
    PubMed     Abstract available


  959. CHUNG JR, Kim SS, Flannery B, Smith ME, et al
    Vaccine-associated attenuation of subjective severity among outpatients with influenza.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00767.
    PubMed     Abstract available


  960. FOLEGATTI PM, Jenkin D, Morris S, Gilbert S, et al
    Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00755.
    PubMed     Abstract available


  961. HERNANDEZ LM, Sumathy K, Sahastrabuddhe S, Excler JL, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00753.
    PubMed     Abstract available


  962. RAZZAGHI H, Yankey D, Vashist K, Lu PJ, et al
    COVID-19 vaccination coverage and intent among women aged 18-49 years by pregnancy status, United States, April-November 2021.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00779.
    PubMed     Abstract available


  963. PHATARPHEKAR A, Vidyadhar Reddy GEC, Gokhale A, Karanam G, et al
    RelCoVax(R), a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice.
    Vaccine. 2022 Jun 13. pii: S0264-410X(22)00775.
    PubMed     Abstract available


  964. WIEMKEN TL, Salas J, Hoft DF, Jacobs C, et al
    In response to: JVAC-D-21-02863, detection of a potential error in the results of the manuscript, dementia risk following influenza vaccination in a large veteran cohort, that could call into question the main conclusion.
    Vaccine. 2022;40:3529.
    PubMed    


  965. VUICHARD-GYSIN D, Schoenenberger A
    Detection of a potential error in the results of the manuscript "Dementia risk following influenza vaccination in a large veteran cohort" that could eventually call into question the main conclusion.
    Vaccine. 2022;40:3528.
    PubMed    


  966. SCHENK J, Abrams S, Litzroth A, Cornelissen L, et al
    Identifying immunity gaps for measles using Belgian serial serology data.
    Vaccine. 2022;40:3676-3683.
    PubMed     Abstract available


  967. POLLET J, Strych U, Chen WH, Versteeg L, et al
    Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
    Vaccine. 2022;40:3655-3663.
    PubMed     Abstract available


  968. EVANS S, Holt D, Weil-Olivier C, Finnegan G, et al
    Building population and health system resilience: Using lessons learned during the COVID pandemic to implement life-course immunisation policy.
    Vaccine. 2022;40:3511-3513.
    PubMed    


  969. WILLIAMS E, Craig K, Chiu C, Davies H, et al
    Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop.
    Vaccine. 2022;40:3484-3489.
    PubMed     Abstract available


  970. SPARROW E, Adetifa I, Chaiyakunapruk N, Cherian T, et al
    WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
    Vaccine. 2022;40:3506-3510.
    PubMed     Abstract available


  971. EVANS B, Jombart T
    Worldwide routine immunisation coverage regressed during the first year of the COVID-19 pandemic.
    Vaccine. 2022;40:3531-3535.
    PubMed     Abstract available


  972. KUNASEKARAN MP, Chughtai AA, Heslop DJ, Poulos CJ, et al
    Influenza cases in nine aged care facilities in Sydney, Australia over a three-year surveillance period, 2018-2020.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00476.
    PubMed     Abstract available


  973. HALME J, Syrjanen RK, Baum U, Palmu AA, et al
    Effectiveness of trivalent influenza vaccines against hospitalizations due to laboratory-confirmed influenza a in the elderly: Comparison of test-negative design with register-based designs.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00716.
    PubMed     Abstract available


  974. ZHAO FJ, Liu LT, Wang Z, Wang NX, et al
    Development and immunogenicity evaluation of porcine deltacoronavirus inactivated vaccine with different adjuvants in mice.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00721.
    PubMed     Abstract available


  975. LEAV B, Straus W, White P, Leav A, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00752.
    PubMed     Abstract available


  976. KOBAYASHI T, Nishina Y, Tomoi H, Harada K, et al
    Corowa-kun: A messenger app chatbot delivers COVID-19 vaccine information, Japan 2021.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00754.
    PubMed     Abstract available


  977. LIN K, Liu M, Bao L, Lv Q, et al
    Safety and protective capability of an inactivated SARS-CoV-2 vaccine on pregnancy, lactation and the growth of offspring in hACE2 mice.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00765.
    PubMed     Abstract available


  978. ZHANG H, Li Y, Peng S, Jiang Y, et al
    The effect of health literacy on COVID-19 vaccine hesitancy among community population in China: The moderating role of stress.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00762.
    PubMed     Abstract available


  979. DIAZ-MENENDEZ M, de la Calle-Prieto F, Montejano R, Arsuaga M, et al
    Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failure.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00751.
    PubMed     Abstract available


  980. NIESSEN FA, Knol MJ, Hahne SJM, Bonten MJM, et al
    Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands: A test-negative case-control study.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00758.
    PubMed     Abstract available


  981. BASS JR, Poland GA
    Shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccination.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00750.
    PubMed     Abstract available


  982. WYNBERG E, Han AX, Boyd A, van Willigen HDG, et al
    The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00748.
    PubMed     Abstract available


  983. WALKER JL, Schultze A, Tazare J, Tamborska A, et al
    Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00757.
    PubMed     Abstract available


  984. FLYNN JA, Weber T, Cejas PJ, Cox KS, et al
    Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00382.
    PubMed     Abstract available


  985. HASHIMOTO M, Nagata N, Homma T, Maeda H, et al
    Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00718.
    PubMed     Abstract available


  986. EUGENIA-TOLEDO-ROMANI M, Verdecia-Sanchez L, Rodriguez-Gonzalez M, Rodriguez-Noda L, et al
    Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00717.
    PubMed     Abstract available


  987. DAYTON L, Miller J, Strickland J, Davey-Rothwell M, et al
    A socio-ecological perspective on parents' intentions to vaccinate their children against COVID-19.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00736.
    PubMed     Abstract available


  988. EL-SHESHENY R, El Taweel A, Gomaa MR, Roshdy WH, et al
    Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00734.
    PubMed     Abstract available


  989. SHANMUGARAJ B, Khorattanakulchai N, Panapitakkul C, Malla A, et al
    Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00735.
    PubMed     Abstract available


  990. WATANABE A, Nishida S, Burcu T, Shibahara T, et al
    Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-beta-cyclodextrin: A phase 1 clinical trial.
    Vaccine. 2022 Jun 4. pii: S0264-410X(22)00677.
    PubMed     Abstract available


  991. AB RAHMAN N, Lim MT, Lee FY, Lee SC, et al
    Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00700.
    PubMed     Abstract available


  992. STEAD M, Ford A, Eadie D, Biggs H, et al
    A "step too far" or "perfect sense"? A qualitative study of British adults' views on mandating COVID-19 vaccination and vaccine passports.
    Vaccine. 2022 Jun 3. pii: S0264-410X(22)00696.
    PubMed     Abstract available


    May 2022
  993. TOOR J, Li X, Jit M, Trotter CL, et al
    COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00698.
    PubMed     Abstract available


  994. WOO EJ, Dimova RB
    Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting system.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00704.
    PubMed     Abstract available


  995. MERRICK E, Weissman JP, Patel SJ
    Utilizing Google trends to monitor coronavirus vaccine interest and hesitancies.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00699.
    PubMed     Abstract available


  996. FISHMAN J, Salmon MK, Scheitrum D, Aleks Schaefer K, et al
    Comparative effectiveness of mandates and financial policies targeting COVID-19 vaccine hesitancy: A randomized, controlled survey experiment.
    Vaccine. 2022 May 30. pii: S0264-410X(22)00702.
    PubMed     Abstract available


  997. SHIOHARA M, Suzuki S, Shichinohe S, Ishigaki H, et al
    Inactivated whole influenza virus particle vaccines induce neutralizing antibodies with an increase in immunoglobulin gene subclones of B-lymphocytes in cynomolgus macaques.
    Vaccine. 2022 May 28. pii: S0264-410X(22)00640.
    PubMed     Abstract available


  998. SHAPIRO BEN DAVID S, Mizrahi B, Rahamim-Cohen D, Supino-Rosin L, et al
    Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study.
    Vaccine. 2022 May 28. pii: S0264-410X(22)00668.
    PubMed     Abstract available


  999. LAI X, Li M, Hou Z, Guo J, et al
    Factors associated with caregivers' hesitancy to vaccinate children against influenza: A cross-sectional survey in China.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00606.
    PubMed     Abstract available


  1000. PATEL KM, Shafiq M, Malik AA, Cobanoglu A, et al
    Relationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00680.
    PubMed     Abstract available


  1001. SOEGIARTO G, Wulandari L, Purnomosari D, Dhia Fahmita K, et al
    Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00676.
    PubMed     Abstract available


  1002. DUBE C, Paris-Robidas S, Andreani G, Gutzeit C, et al
    Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00641.
    PubMed     Abstract available


  1003. MOSS P, Berenbaum F, Curigliano G, Grupper A, et al
    Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00682.
    PubMed     Abstract available


  1004. HALSTEAD IN, McKay RT, Lewis GJ
    COVID-19 and seasonal flu vaccination hesitancy: Links to personality and general intelligence in a large, UK cohort.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00678.
    PubMed     Abstract available


  1005. DUBE E, Gagnon D, MacDonald N
    Between persuasion and compulsion: The case of COVID-19 vaccination in Canada.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00670.
    PubMed    


  1006. ABRAHAM N, Spruin S, Rossi T, Fireman B, et al
    Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
    Vaccine. 2022 May 25. pii: S0264-410X(22)00667.
    PubMed     Abstract available


  1007. BECK E, Biundo E, Devlin N, Doherty TM, et al
    Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework.
    Vaccine. 2022 May 23. pii: S0264-410X(22)00490.
    PubMed     Abstract available


  1008. FOO D, Sarna M, Pereira G, Moore HC, et al
    Maternal influenza vaccination and child mortality: Longitudinal, population-based linked cohort study.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00614.
    PubMed     Abstract available


  1009. KITCHEN M, Leierer G, Kistner O, Wodal W, et al
    High seroprotection rates and geometric mean titre increases after repeated annual influenza vaccinations in a cohort of HIV-infected adults in Austria.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00575.
    PubMed     Abstract available


  1010. MCELFISH PA, Selig JP, Scott AJ, Rowland B, et al
    Associations between 5-year influenza vaccination and sociodemographic factors and healthcare access among Arkansans.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00615.
    PubMed     Abstract available


  1011. SZANYI J, Wilson T, Scott N, Blakely T, et al
    A log-odds system for waning and boosting of COVID-19 vaccine effectiveness.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00634.
    PubMed     Abstract available


  1012. CARSON B, Isaacs J, Carilli T
    Jabbing together? The complementarity between social capital, formal public health rules, and COVID-19 vaccine rates in the United States.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00612.
    PubMed     Abstract available


  1013. STEELFISHER GK, Caporello H, McIntosh R, Muhammad Safdar R, et al
    Preventing erosion of oral polio vaccine acceptance: A role for vaccinator visits and social norms.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00567.
    PubMed     Abstract available


  1014. SIQUEIRA PG, Duarte HO, Moura MDC
    Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00633.
    PubMed     Abstract available


  1015. SALO-TUOMINEN K, Teros-Jaakkola T, Toivonen L, Ollila H, et al
    Parental socioeconomic and psychological determinants of the 2009 pandemic influenza A(H1N1) vaccine uptake in children.
    Vaccine. 2022 May 17. pii: S0264-410X(22)00582.
    PubMed     Abstract available


  1016. ROBERTSON DA, Mohr KS, Barjakova M, Lunn PD, et al
    Experimental pre-tests of public health communications on the COVID-19 vaccine: A null finding for medical endorsement, risk and altruism.
    Vaccine. 2022 May 16. pii: S0264-410X(22)00613.
    PubMed     Abstract available


  1017. TSAI SY, Yeh TY, Chiu NC, Huang CT, et al
    National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan during NH 20/21.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00588.
    PubMed     Abstract available


  1018. IWATA S, Sonoyama T, Kamitani A, Shibata R, et al
    Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00494.
    PubMed     Abstract available


  1019. ALYA WA, Maraqa B, Nazzal Z, Odeh M, et al
    COVID-19 vaccine uptake and its associated factors among Palestinian healthcare workers: Expectations beaten by reality.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00610.
    PubMed     Abstract available


  1020. KUMAR SURI R, Hayman B, Prasad SD, Makhoana M, et al
    Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00576.
    PubMed     Abstract available


  1021. DUC DANG A, Dinh Vu T, Hai Vu H, Thanh Ta V, et al
    Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00526.
    PubMed     Abstract available


  1022. RUSKIN AC, Rice S, O'Connor M, Ruskin KJ, et al
    Effects of vaccination status in the United States on willingness to undergo surgery during a pandemic: A prospective survey study.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00583.
    PubMed     Abstract available


  1023. MANCARELLA M, Natarelli F, Bertolini C, Zagari A, et al
    Catch-up vaccination campaign in children between 6 and 8 years old during COVID-19 pandemic: The experience in a COVID hub in Milan, Italy.
    Vaccine. 2022 May 12. pii: S0264-410X(22)00573.
    PubMed     Abstract available


  1024. CHONG-VALBUENA A, De-Jesus-Maria I, Agurto-Ramirez A, Puchades-Gimeno F, et al
    Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between naive and previously infected by SARS-CoV-2.
    Vaccine. 2022 May 12. pii: S0264-410X(22)00586.
    PubMed     Abstract available


  1025. TEASDALE CA, Ratzan S, Stuart Lathan H, Rauh L, et al
    Acceptability of COVID-19 vaccine mandates among New York City parents, November 2021.
    Vaccine. 2022 May 11. pii: S0264-410X(22)00580.
    PubMed     Abstract available


  1026. GUPTA C, Sachdeva A, Khamar J, Bu C, et al
    Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: A systematic review and meta-analysis.
    Vaccine. 2022 May 10. pii: S0264-410X(22)00468.
    PubMed     Abstract available


  1027. KITRO A, Sirikul W, Thongkum W, Soponpong S, et al
    Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
    Vaccine. 2022;40:2915-2924.
    PubMed     Abstract available


  1028. PERUMAL N, Steffen A, Ullrich A, Siedler A, et al
    Impact of COVID-19 immunisation on COVID-19 incidence, hospitalisations, and deaths by age group in Germany from December 2020 to October 2021.
    Vaccine. 2022;40:2910-2914.
    PubMed     Abstract available


  1029. YI S, Choe YJ, Lim DS, Lee HR, et al
    Impact of national Covid-19 vaccination Campaign, South Korea.
    Vaccine. 2022 May 8. pii: S0264-410X(22)00572.
    PubMed     Abstract available


  1030. BIFULCO M, Di Zazzo E, Pisanti S, Martini M, et al
    The nineteenth-century experience of the kingdom of the two Sicilies on mandatory vaccination: An Italian phenomenon?
    Vaccine. 2022 May 6. pii: S0264-410X(22)00492.
    PubMed     Abstract available


  1031. LUMBRERAS ARETA M, Valiton A, Diana A, Morales M, et al
    Flu and pertussis vaccination during pregnancy in Geneva during the COVID-19 pandemic: A multicentric, prospective, survey-based study.
    Vaccine. 2022 May 6. pii: S0264-410X(22)00533.
    PubMed     Abstract available


  1032. YU Y, Ma YL, Luo S, Wang S, et al
    Prevalence and factors of influenza vaccination during the COVID-19 pandemic among university students in China.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00532.
    PubMed     Abstract available


  1033. BELLIZZI S, Panu Napodano CM, Pinto S, Pichierri G, et al
    COVID-19 and seasonal influenza: The potential 2021-22 "Twindemic".
    Vaccine. 2022 May 5. pii: S0264-410X(22)00531.
    PubMed    


  1034. GASTEIGER N, Gasteiger C, Vedhara K, Broadbent E, et al
    Characteristics associated with the willingness to receive a COVID-19 vaccine and an exploration of the general public's perceptions: A mixed-methods approach.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00547.
    PubMed     Abstract available


  1035. NAULT L, Marchitto L, Goyette G, Tremblay-Sher D, et al
    Covid-19 vaccine immunogenicity in people living with HIV-1.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00543.
    PubMed     Abstract available


  1036. REES F, Geiger M, Lilleholt L, Zettler I, et al
    Measuring parents' readiness to vaccinate themselves and their children against COVID-19.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00549.
    PubMed     Abstract available


  1037. LEIGH JP, Moss SJ, White TM, Picchio CA, et al
    Factors affecting COVID-19 vaccine hesitancy among healthcare providers in 23 countries.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00545.
    PubMed     Abstract available


  1038. LIU W, Lien YH, Lee PI, Chan TC, et al
    Impact of prior infection and repeated vaccination on post-vaccination antibody titers of the influenza A(H1N1)pdm09 strain in Taiwan schoolchildren: Implications for public health.
    Vaccine. 2022 May 4. pii: S0264-410X(22)00358.
    PubMed     Abstract available


  1039. PERSSON U, Olofsson S, Althin R, Palmborg A, et al
    Acceptance and application of a broad population health perspective when evaluating vaccine.
    Vaccine. 2022 May 4. pii: S0264-410X(22)00425.
    PubMed     Abstract available


  1040. BOSE AS, Rai P, Gupta BP, Pradhan R, et al
    Nepal measles outbreak response immunization during COVID-19: A risk-based intervention strategy.
    Vaccine. 2022;40:2884-2893.
    PubMed     Abstract available


  1041. BOTHUN LS, Feeder SE, Poland GA
    Readability of COVID-19 vaccine information for the general public.
    Vaccine. 2022 May 3. pii: S0264-410X(22)00546.
    PubMed     Abstract available


  1042. NANTANEE R, Aikphaibul P, Jaru-Ampornpan P, Sodsai P, et al
    Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00521.
    PubMed     Abstract available


  1043. FEIKIN DR, Abu-Raddad LJ, Andrews N, Davies MA, et al
    Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00523.
    PubMed     Abstract available


    April 2022
  1044. MASUDA T, Murakami K, Sugiura K, Sakui S, et al
    Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
    Vaccine. 2022 Apr 29. pii: S0264-410X(22)00463.
    PubMed     Abstract available


  1045. HUSSAIN B, Latif A, Timmons S, Nkhoma K, et al
    Overcoming COVID-19 vaccine hesitancy among ethnic minorities: A systematic review of UK studies.
    Vaccine. 2022 Apr 28. pii: S0264-410X(22)00446.
    PubMed     Abstract available


  1046. NASREEN S, Calzavara A, Buchan SA, Thampi N, et al
    Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00520.
    PubMed     Abstract available


  1047. DEMIR E, Dheir H, Safak S, Serra Artan A, et al
    Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipients.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00519.
    PubMed     Abstract available


  1048. KULCZYCKI A, Shewchuk R
    Back to Basics: A general approach to improving Covid and adult immunization delivery focused on Pharmacy-Based immunization services.
    Vaccine. 2022;40:2647-2649.
    PubMed    


  1049. MARKOVITZ NH, Strome AL, Patel PK
    Commentary: "The vaccine Selfie" and its influence on COVID-19 vaccine acceptance.
    Vaccine. 2022 Apr 26. pii: S0264-410X(22)00503.
    PubMed    


  1050. KRUPP K, Galea J, Madhivanan P, Gerald L, et al
    Conversational artificial intelligence: A new approach for increasing influenza vaccination rates in children with asthma?
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00496.
    PubMed    


  1051. MCCOSKER LK, El-Heneidy A, Seale H, Ware RS, et al
    Strategies to improve vaccination rates in people who are homeless: A systematic review.
    Vaccine. 2022 Apr 25. pii: S0264-410X(22)00436.
    PubMed     Abstract available


  1052. BEYER WEP, Palache AM, Boulfich M, Osterhaus ADME, et al
    Clinical relevance of increased antibody titres in older adults upon vaccination with squalene-adjuvanted versus non-adjuvanted influenza vaccines.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00489.
    PubMed     Abstract available


  1053. STRECKENBACH B, Baldt J, Heidler F, Frahm N, et al
    General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis.
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00428.
    PubMed     Abstract available


  1054. SALO H, Lehtonen T, Auranen K, Baum U, et al
    Predictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: A population-based register study with implications to vaccinations.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00495.
    PubMed     Abstract available


  1055. TAMANG ST, Dorji T
    COVID-19 vaccinations in Bhutan - Mix-and-Match to Boosters: An experience.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00499.
    PubMed     Abstract available


  1056. ANTONOPOULOU T, Athanassakis I
    SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination?
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00501.
    PubMed    


  1057. SHEA LL, Becker A, Lee BK, Miller KK, et al
    Self-reported COVID-19 vaccination acceptance and hesitancy among autistic adults.
    Vaccine. 2022 Apr 22. pii: S0264-410X(22)00500.
    PubMed     Abstract available


  1058. ORTIZ JR, Spearman PW, Goepfert PA, Cross K, et al
    Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.
    Vaccine. 2022 Apr 21. pii: S0264-410X(22)00366.
    PubMed     Abstract available


  1059. CAN G, Acar HC, Aydin SN, Balkan II, et al
    Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers.
    Vaccine. 2022;40:2574-2579.
    PubMed     Abstract available


  1060. GARTNER BC, Weinke T, Wahle K, Kwetkat A, et al
    Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.
    Vaccine. 2022 Apr 19. pii: S0264-410X(22)00440.
    PubMed     Abstract available


  1061. SINGH BK, Walker J, Paul P, Reddy S, et al
    De-escalation of asymptomatic testing and potential of future COVID-19 outbreaks in US nursing homes amidst rising community vaccination coverage: A modeling study.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00467.
    PubMed     Abstract available


  1062. LI L, Honda-Okubo Y, Baldwin J, Bowen R, et al
    Covax-19/Spikogen(R) vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00469.
    PubMed     Abstract available


  1063. WANLAPAKORN N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, et al
    Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00471.
    PubMed     Abstract available


  1064. SAADE A, Cha L, Tadie E, Jurado B, et al
    Delay between COVID-19 complete vaccination and SARS-CoV-2 infection among healthcare workers.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00473.
    PubMed     Abstract available


  1065. CHRISSIAN AA, Oyoyo UE, Patel P, Lawrence Beeson W, et al
    Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00474.
    PubMed     Abstract available


  1066. XU S, Hong V, Sy LS, Glenn SC, et al
    Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic.
    Vaccine. 2022 Apr 18. pii: S0264-410X(22)00464.
    PubMed     Abstract available


  1067. MACINTYRE CR, Heslop DJ, Nguyen P, Adam D, et al
    Pacific Eclipse - A tabletop exercise on smallpox pandemic response.
    Vaccine. 2022;40:2478-2483.
    PubMed     Abstract available


  1068. BRAEYE T, Catteau L, Brondeel R, van Loenhout JAF, et al
    Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00441.
    PubMed     Abstract available


  1069. FENOLLAR F, Thomas L, Raoult D, Gautret P, et al
    Screening for SARS-CoV-2 antibodies to save vaccine doses.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00444.
    PubMed    


  1070. MORO PL, Olson CK, Clark E, Marquez P, et al
    Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00447.
    PubMed     Abstract available


  1071. YAN Y, Naito T, Tabe Y, Ito K, et al
    Increased delta variant SARS-CoV-2 infections in a highly vaccinated medical center in Japan.
    Vaccine. 2022 Apr 12. pii: S0264-410X(22)00445.
    PubMed     Abstract available


  1072. SHINJOH M, Furuichi M, Kobayashi H, Yamaguchi Y, et al
    Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00449.
    PubMed     Abstract available


  1073. CEYLAN ME, Onen Unsalver B, Donmez A, Kaya Yertutanol FD, et al
    A case of myocarditis and isolated hypopotassemia after Biontech-Pfizer vaccine for Covid-19.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00432.
    PubMed    


  1074. LJUNG R, Feychting M, Burstrom B, Moller J, et al
    Differences by region of birth in SARS-CoV-2 vaccine coverage and positive SARS-CoV-2 test among 400 000 healthcare workers and the general population in Sweden.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00431.
    PubMed     Abstract available


  1075. BENINGER P
    Need for a contingency dimension when planning vaccine development in a pandemic environment.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00401.
    PubMed    


  1076. ZHU XM, Yan W, Sun J, Liu L, et al
    Patterns and influencing factors of COVID-19 vaccination willingness among college students in China.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00433.
    PubMed     Abstract available


  1077. SPRINGER S, Kaatz M, Zieger M
    Evaluation of weekly COVID-19 vaccination and case data supports negative correlation between incidence and vaccination in German federal states and cities during 4th wave.
    Vaccine. 2022 Apr 11. pii: S0264-410X(22)00430.
    PubMed     Abstract available


  1078. PARK SJ, Kang YM, Cho HK, Kim DY, et al
    Corrigendum to 'Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice' [Vaccine 39 (2021) 6213-6220].
    Vaccine. 2022 Apr 9. pii: S0264-410X(22)00221.
    PubMed    


  1079. AINSLIE KEC, Riley S
    Is annual vaccination best? A modelling study of influenza vaccination strategies in children.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00384.
    PubMed     Abstract available


  1080. MAYFIELD HJ, Lau CL, Sinclair JE, Brown SJ, et al
    Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00418.
    PubMed     Abstract available


  1081. BELDA F, Mora O, Lopez Martinez M, Torres N, et al
    Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00419.
    PubMed     Abstract available


  1082. ERFANI P, Sandoval RS, Rich KM, Ojo A, et al
    Ask Me Anything": Lessons learned in implementing a COVID-19 vaccine information initiative in Massachusetts jails.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00439.
    PubMed     Abstract available


  1083. KENIGSBERG TA, Hause AM, McNeil MM, Nelson JC, et al
    Dashboard development for near real-time visualization of COVID-19 vaccine safety surveillance data in the vaccine safety datalink.
    Vaccine. 2022 Apr 8. pii: S0264-410X(22)00426.
    PubMed     Abstract available


  1084. LINKINS LA, Iorio A, Little J, Lavis J, et al
    Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19.
    Vaccine. 2022 Apr 7. pii: S0264-410X(22)00422.
    PubMed    


  1085. DE-LOS-RIOS-PINTO A, Fernandez-Guzman D, Soriano-Moreno DR, Sangster-Carrasco L, et al
    Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru.
    Vaccine. 2022 Apr 7. pii: S0264-410X(22)00421.
    PubMed     Abstract available


  1086. SHAH S, Gui H, Chua PEY, Tan JB, et al
    Factors associated with COVID-19 vaccination intent in Singapore, Australia and Hong Kong.
    Vaccine. 2022 Apr 5. pii: S0264-410X(22)00381.
    PubMed     Abstract available


  1087. WALTERS JN, Schouest B, Patel A, Reuschel EL, et al
    Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates.
    Vaccine. 2022 Apr 4. pii: S0264-410X(22)00368.
    PubMed     Abstract available


  1088. HASSAN PM, Ali T, Saber E, Asghar A, et al
    Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein.
    Vaccine. 2022 Apr 4. pii: S0264-410X(22)00385.
    PubMed     Abstract available


  1089. MA C, Sun W, Tang T, Jia M, et al
    Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00386.
    PubMed     Abstract available


  1090. SUGHAYER MA, Souan L, Abu Alhowr MM, Al Rimawi D, et al
    Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00387.
    PubMed     Abstract available


  1091. FRISE R, Baillon L, Zhou J, Kugathasan R, et al
    A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model.
    Vaccine. 2022 Apr 1. pii: S0264-410X(22)00383.
    PubMed     Abstract available


    March 2022
  1092. VANDOORN E, Parys A, Chepkwony S, Chiers K, et al
    Efficacy of the NS1-truncated live attenuated influenza virus vaccine for swine against infection with viruses of major North American and European H3N2 lineages.
    Vaccine. 2022 Mar 30. pii: S0264-410X(22)00362.
    PubMed     Abstract available


  1093. MCRAE J, Blyth CC, Cheng AC, Quinn HE, et al
    Preventing severe influenza in Australian infants: Maternal influenza vaccine effectiveness in the PAEDS-FluCAN networks using the test-negative design.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00353.
    PubMed    


  1094. LI K, Yu T, Seabury SA, Dor A, et al
    Trends and disparities in the utilization of influenza vaccines among commercially insured US adults during the COVID-19 pandemic.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00370.
    PubMed     Abstract available


  1095. KATO H, Miyakawa K, Ohtake N, Yamaoka Y, et al
    Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00369.
    PubMed     Abstract available


  1096. ISITT C, Sjoholm D, Hergens MP, Granath F, et al
    The early impact of vaccination against SARS-CoV-2 in Region Stockholm, Sweden.
    Vaccine. 2022 Mar 29. pii: S0264-410X(22)00372.
    PubMed     Abstract available


  1097. FUNK PR, Yogurtcu ON, Forshee RA, Anderson SA, et al
    Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 years.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00329.
    PubMed     Abstract available


  1098. JUDDOO V, Juddoo S, Megarbane B
    Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00363.
    PubMed    


  1099. WELLS K, Moore KL, Bednarczyk R
    Supporting immunization programs to address COVID-19 vaccine hesitancy: Recommendations for national and community-based stakeholders.
    Vaccine. 2022 Mar 28. pii: S0264-410X(22)00339.
    PubMed    


  1100. SIMMONS LA, Whipps MDM, Phipps JE, Satish NS, et al
    Understanding COVID-19 vaccine uptake during pregnancy: 'Hesitance', knowledge, and evidence-based decision-making.
    Vaccine. 2022 Mar 25. pii: S0264-410X(22)00355.
    PubMed     Abstract available


  1101. FARAH W, Breeher L, Shah V, Hainy C, et al
    Disparities in COVID-19 vaccine uptake among health care workers.
    Vaccine. 2022 Mar 25. pii: S0264-410X(22)00356.
    PubMed     Abstract available


  1102. NANTHAPISAL S, Puthanakit T, Jaru-Ampornpan P, Nantanee R, et al
    A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00336.
    PubMed     Abstract available


  1103. ABDEL-QADER DH, Hazza Alkhatatbeh I, Hayajneh W, Annab H, et al
    IgA nephropathy in a pediatric patient after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine.
    Vaccine. 2022 Mar 23. pii: S0264-410X(22)00265.
    PubMed    


  1104. MALTEZOU HC, Medic S, Cassimos DC, Effraimidou E, et al
    Decreasing routine vaccination rates in children in the COVID-19 era.
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00333.
    PubMed    


  1105. FANO V, Crielesi A, Coviello E, Fabiani M, et al
    Effectiveness of the Comirnaty and the Vaxzevria vaccines in preventing SARS-CoV-2 infection among residents in Lazio region (Italy).
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00208.
    PubMed     Abstract available


  1106. SNIDER CJ, Boualam L, Tallis G, Takashima Y, et al
    Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019-2021.
    Vaccine. 2022 Mar 22. pii: S0264-410X(22)00145.
    PubMed     Abstract available


  1107. FERDINANDS JM, Patel M
    Influence of disease attenuation on relative influenza vaccine effectiveness by vaccine type.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00274.
    PubMed     Abstract available


  1108. YUEN WLP, Loh SYJ, Wang DB
    SIRVA (Shoulder Injury Related to Vaccine Administration) following mRNA COVID-19 Vaccination: Case discussion and literature review.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00337.
    PubMed     Abstract available


  1109. JIAN-BIN L, Lau EYH, Chan DKC
    Why do Hong Kong parents have low intention to vaccinate their children against COVID-19? testing health belief model and theory of planned behavior in a large-scale survey.
    Vaccine. 2022 Mar 21. pii: S0264-410X(22)00340.
    PubMed     Abstract available


  1110. PI-ESTOPINAN F, Perez MT, Fraga A, Bergado G, et al
    A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies.
    Vaccine. 2022;40:1958-1967.
    PubMed     Abstract available


  1111. ESPOSITO S, Nauta J, Lapini G, Montomoli E, et al
    Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: A global, multiseasonal, controlled, randomized Phase III study.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00263.
    PubMed     Abstract available


  1112. BILGIN H, Marku M, Yilmaz SS, Karahasan Yagci A, et al
    The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-gamma release by natural killer cells.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00264.
    PubMed     Abstract available


  1113. CALLAGHAN T, Washburn D, Goidel K, Nuzhath T, et al
    Imperfect messengers? An analysis of vaccine confidence among primary care physicians.
    Vaccine. 2022 Mar 18. pii: S0264-410X(22)00302.
    PubMed     Abstract available


  1114. JI C, Piche-Renaud PP, Apajee J, Stephenson E, et al
    Impact of the COVID-19 pandemic on routine immunization coverage in children under 2 years old in Ontario, Canada: A retrospective cohort study.
    Vaccine. 2022;40:1790-1798.
    PubMed     Abstract available


  1115. CAMARA J, Gonzalez-Diaz A, Barrabeig I, Fernandez-Huerta M, et al
    SARS-CoV-2 outbreak in a nursing home after vaccination with BNT162b2: A role for the quantification of circulating antibodies.
    Vaccine. 2022 Mar 15. pii: S0264-410X(22)00303.
    PubMed     Abstract available


  1116. ROTOLO B, Dube E, Vivion M, MacDonald SE, et al
    Hesitancy towards COVID-19 vaccines on social media in Canada.
    Vaccine. 2022 Mar 15. pii: S0264-410X(22)00301.
    PubMed     Abstract available


  1117. MOSCARDINO U, Musso P, Inguglia C, Ceccon C, et al
    Sociodemographic and psychological correlates of COVID-19 vaccine hesitancy and resistance in the young adult population in Italy.
    Vaccine. 2022 Mar 14. pii: S0264-410X(22)00293.
    PubMed     Abstract available


  1118. VAN DEN HOOGEN LL, Smits G, van Hagen CCE, Wong D, et al
    Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?
    Vaccine. 2022 Mar 9. pii: S0264-410X(22)00272.
    PubMed     Abstract available


  1119. THOMAS CM, Searle K, Galvan A, Liebman AK, et al
    Healthcare worker perspectives on COVID-19 vaccines: Implications for increasing vaccine acceptance among healthcare workers and patients.
    Vaccine. 2022 Mar 9. pii: S0264-410X(22)00276.
    PubMed     Abstract available


  1120. YUEN VWH
    Political attitudes and efficacy of health expert communication on the support for COVID-19 vaccination program: Findings from a survey in Hong Kong.
    Vaccine. 2022 Mar 7. pii: S0264-410X(22)00261.
    PubMed     Abstract available


  1121. BANSAL P, Raj A, Mani Shukla D, Sunder N, et al
    COVID-19 vaccine preferences in India.
    Vaccine. 2022 Mar 7. pii: S0264-410X(22)00241.
    PubMed     Abstract available


  1122. MASCHERINI M, Nivakoski S
    Social media use and vaccine hesitancy in the European Union.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00206.
    PubMed     Abstract available


  1123. KLUMPP M, Monfared IG, Vollmer S
    Public opinion on global distribution of COVID-19 vaccines: Evidence from two nationally representative surveys in Germany and the United States.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00259.
    PubMed     Abstract available


  1124. COULAUD PJ, Ablona A, Bolduc N, Fast D, et al
    COVID-19 vaccine intention among young adults: Comparative results from a cross-sectional study in Canada and France.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00260.
    PubMed     Abstract available


  1125. ROBERTSON LJ, Price R, Moore JS, Curry G, et al
    IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational study.
    Vaccine. 2022 Mar 3. pii: S0264-410X(22)00262.
    PubMed     Abstract available


  1126. YU M, Yao X, Liu G, Wu J, et al
    Barriers and facilitators to uptake and promotion of influenza vaccination among health care workers in the community in Beijing, China: A qualitative study.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00207.
    PubMed     Abstract available


  1127. POINTON L, Howe AS, Hobbs M, Paynter J, et al
    Evidence of suboptimal maternal vaccination coverage in pregnant New Zealand women and increasing inequity over time: A nationwide retrospective cohort study.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00243.
    PubMed     Abstract available


  1128. KREPS SE, Kriner DL
    How do COVID-19 vaccine mandates affect attitudes toward the vaccine and participation in mandate-affected activities? Evidence from the United States.
    Vaccine. 2022 Mar 2. pii: S0264-410X(22)00258.
    PubMed     Abstract available


  1129. LAI FTT, Leung MTY, Chan EWW, Huang L, et al
    Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring.
    Vaccine. 2022;40:1390-1396.
    PubMed     Abstract available


  1130. LILLVIS DF, Miller CR, Kuo DZ
    Pediatric primary care immunization policies in New York State.
    Vaccine. 2022;40:1458-1463.
    PubMed     Abstract available


  1131. MOURA C, Truche P, Sousa Salgado L, Meireles T, et al
    The impact of COVID-19 on routine pediatric vaccination delivery in Brazil.
    Vaccine. 2022 Mar 1. pii: S0264-410X(22)00242.
    PubMed     Abstract available


    February 2022
  1132. SINGH JA, Kochhar S, Wolff J, Atuire C, et al
    WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations.
    Vaccine. 2022 Feb 28. pii: S0264-410X(22)00175.
    PubMed     Abstract available


  1133. MCANDREW T, Cambeiro J, Besiroglu T
    Aggregating human judgment probabilistic predictions of the safety, efficacy, and timing of a COVID-19 vaccine.
    Vaccine. 2022 Feb 28. pii: S0264-410X(22)00200.
    PubMed     Abstract available


  1134. SALIOU P, Duteil Q, Plotkin SA, Gentilini M, et al
    The scourge of vaccine falsification.
    Vaccine. 2022 Feb 26. pii: S0264-410X(22)00119.
    PubMed     Abstract available


  1135. MULLER KE, Dohos D, Sipos Z, Kiss S, et al
    Immune response to influenza and pneumococcal vaccines in adults with inflammatory bowel disease: A systematic review and meta-analysis of 1429 patients.
    Vaccine. 2022 Feb 25. pii: S0264-410X(22)00163.
    PubMed     Abstract available


  1136. KAGEYAMA T, Tanaka S, Etori K, Hattori K, et al
    Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2.
    Vaccine. 2022 Feb 25. pii: S0264-410X(22)00192.
    PubMed     Abstract available


  1137. MCGOLDRICK M, Gastineau T, Wilkinson D, Campa C, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation.
    Vaccine. 2022;40:1223-1230.
    PubMed     Abstract available


  1138. MCGOLDRICK M, Gastineau T, Wilkinson D, Campa C, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part I: Initial industry lessons learned and practical overarching proposals leveraging the COVID-19 situation.
    Vaccine. 2022;40:1215-1222.
    PubMed     Abstract available


  1139. HAO F, Shao W
    Understanding the influence of political orientation, social network, and economic recovery on COVID-19 vaccine uptake among Americans.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00219.
    PubMed     Abstract available


  1140. ABBATECOLA AM, Incalzi RA, Malara A, Palmieri A, et al
    Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00217.
    PubMed     Abstract available


  1141. EL-HENEIDY A, Grimwood K, Lambert SB, Sarna M, et al
    Association between vaccination status, symptom identification and healthcare use: Implications for test negative design observational studies.
    Vaccine. 2022 Feb 22. pii: S0264-410X(22)00198.
    PubMed     Abstract available


  1142. TAWINPRAI K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, et al
    Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial
    Vaccine. 2022 Feb 21. pii: S0264-410X(22)00143.
    PubMed     Abstract available


  1143. ISMAIL ALHOSANI F, Eduardo Stanciole A, Aden B, Timoshkin A, et al
    Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
    Vaccine. 2022 Feb 19. pii: S0264-410X(22)00174.
    PubMed     Abstract available


  1144. WINTER T, Riordan BC, Scarf D, Jose PE, et al
    Conspiracy beliefs and distrust of science predicts reluctance of vaccine uptake of politically right-wing citizens.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00074.
    PubMed     Abstract available


  1145. SCHMALING KB
    Couples and COVID-19 vaccination: Frequency and reasons for discordance.
    Vaccine. 2022 Feb 18. pii: S0264-410X(22)00202.
    PubMed     Abstract available


  1146. MERKLEY E, Loewen PJ
    The correlates and dynamics of COVID-19 vaccine-specific hesitancy.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00168.
    PubMed     Abstract available


  1147. KASSTAN B, Mounier-Jack S, Letley L, Gaskell KM, et al
    Localising vaccination services: Qualitative insights on public health and minority group collaborations to co-deliver coronavirus vaccines.
    Vaccine. 2022 Feb 17. pii: S0264-410X(22)00201.
    PubMed     Abstract available


  1148. LAZO L, Bequet-Romero M, Lemos G, Musacchio A, et al
    A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice.
    Vaccine. 2022;40:1162-1169.
    PubMed     Abstract available


  1149. JOG P, Memon IA, Thisyakorn U, Hozbor D, et al
    Pertussis in Asia: Recent country-specific data and recommendations.
    Vaccine. 2022;40:1170-1179.
    PubMed     Abstract available


  1150. STEFANIZZI P, Larocca AMV, Martinelli A, Soldano S, et al
    Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study.
    Vaccine. 2022 Feb 16. pii: S0264-410X(22)00124.
    PubMed     Abstract available


  1151. KALASKA B, Miklosz J, Swieton J, Jakimczuk A, et al
    The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats.
    Vaccine. 2022 Feb 16. pii: S0264-410X(22)00173.
    PubMed     Abstract available


  1152. SALEH OA, Halperin O
    Influenza virus vaccine compliance among pregnant women during the COVID-19 pandemic (pre-vaccine era) in Israel and future intention to uptake BNT162b2 mRNA COVID-19 vaccine.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00160.
    PubMed     Abstract available


  1153. QUITIAN LM, Rodriguez-Martinez CE, Sossa-Briceno MP, Cortes JA, et al
    Disease burden and vaccination priorities in Colombia.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00029.
    PubMed     Abstract available


  1154. AMMETER T, Lang P, Czock A
    Overview of the influenza vaccination activities and legal frameworks in 26 Swiss cantons during the influenza season 2019/20.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00132.
    PubMed     Abstract available


  1155. GAFFNEY KK, Jana Broadhurst M, Brett-Major DM
    Mumps to COVID-19: Vaccinated persons remain vulnerable when community uptake is low.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00193.
    PubMed     Abstract available


  1156. CHAN IL, Mowson R, Alonso JP, Roberti J, et al
    Promoting immunization equity in Latin America and the Caribbean: Case studies, lessons learned, and their implication for COVID-19 vaccine equity.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00197.
    PubMed     Abstract available


  1157. MUCHIRI SK, Muthee R, Kiarie H, Sitienei J, et al
    Unmet need for COVID-19 vaccination coverage in Kenya.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00167.
    PubMed     Abstract available


  1158. UWAMINO Y, Yokoyama T, Shimura T, Nishimura T, et al
    The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00191.
    PubMed     Abstract available


  1159. YAMAMOTO S, Fukunaga A, Tanaka A, Takeuchi JS, et al
    Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00196.
    PubMed     Abstract available


  1160. TANI N, Chong Y, Kurata Y, Gondo K, et al
    Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00158.
    PubMed     Abstract available


  1161. GAO F, An C, Bian L, Wang Y, et al
    Establishment of the first Chinese national standard for protein subunit SARS-CoV-2 vaccine.
    Vaccine. 2022 Feb 14. pii: S0264-410X(22)00194.
    PubMed     Abstract available


  1162. CHRYSI P, Stella M, Marios K, Despo C, et al
    Exploring vaccination coverage and attitudes of health care workers towards influenza vaccine in Cyprus.
    Vaccine. 2022 Feb 12. pii: S0264-410X(22)00141.
    PubMed     Abstract available


  1163. TIBBELS NJ, Dosso A, Fordham C, Benie W, et al
    "On the last day of the last month, I will go": A qualitative exploration of COVID-19 vaccine confidence among Ivoirian adults.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00166.
    PubMed     Abstract available


  1164. HELLER O, Chun Y, Shlomo Y, Gewirtz-Meydan A, et al
    Public perceptions and the willingness to get vaccinated against COVID-19: Lessons from Israel.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00165.
    PubMed     Abstract available


  1165. DIETRICH LG, Luthy A, Lucas Ramanathan P, Baldesberger N, et al
    Healthcare professional and professional stakeholders' perspectives on vaccine mandates in Switzerland: A mixed-methods study.
    Vaccine. 2022 Feb 11. pii: S0264-410X(22)00007.
    PubMed     Abstract available


  1166. ABHILASH KPP, Mathiyalagan P, Krishnaraj VRK, Selvan S, et al
    Impact of prior vaccination with Covishield(TM) and Covaxin(R) on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in South India during April and May 2021: a cohort study.
    Vaccine. 2022 Feb 10. pii: S0264-410X(22)00157.
    PubMed     Abstract available


  1167. DREYER N, Reynolds MW, Albert L, Brinkley E, et al
    How frequent are acute reactions to COVID-19 vaccination and who is at risk?
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00103.
    PubMed     Abstract available


  1168. PRAMOD S, Govindan D, Ramasubramani P, Kar SS, et al
    Effectiveness of Covishield vaccine in preventing Covid-19 - A test-negative case-control study.
    Vaccine. 2022 Feb 9. pii: S0264-410X(22)00138.
    PubMed     Abstract available


  1169. MASUDA T, Murakami K, Sugiura K, Sakui S, et al
    A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
    Vaccine. 2022 Feb 8. pii: S0264-410X(22)00164.
    PubMed     Abstract available


  1170. PEREZ-RODRIGUEZ S, de la Caridad Rodriguez-Gonzalez M, Ochoa-Azze R, Climent-Ruiz Y, et al
    A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
    Vaccine. 2022 Feb 8. pii: S0264-410X(22)00161.
    PubMed     Abstract available


  1171. WALKER B, Anderson A, Stoecker C, Shao Y, et al
    COVID-19 and Routine Childhood and Adolescent Immunizations: Evidence from Louisiana Medicaid.
    Vaccine. 2022;40:837-840.
    PubMed     Abstract available


  1172. DOMNICH A, Orsi A, Sticchi L, Panatto D, et al
    Effect of the 2020/21 season influenza vaccine on SARS-CoV-2 infection in a cohort of Italian healthcare workers.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00137.
    PubMed     Abstract available


  1173. CRUVINEL E, P Richter K, S Scheuermann T, M Machado N, et al
    The impact of COVID-19 on income and employment and willingness to become vaccinated among African Americans enrolled in a smoking cessation randomized trial.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00120.
    PubMed     Abstract available


  1174. MEWHIRTER J, Sagir M, Sanders R
    Towards a predictive model of COVID-19 vaccine hesitancy among American adults.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00134.
    PubMed     Abstract available


  1175. BELLOS I, Karageorgiou V, Viskin D
    Myocarditis following mRNA Covid-19 vaccination: A pooled analysis.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00140.
    PubMed     Abstract available


  1176. WONODI C, Obi-Jeff C, Adewumi F, Keluo-Udeke SC, et al
    Conspiracy theories and misinformation about COVID-19 in Nigeria: Implications for vaccine demand generation communications.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00126.
    PubMed     Abstract available


  1177. WALKER J, Paul P, Dooling K, Oliver S, et al
    Modeling strategies for the allocation of SARS-CoV-2 vaccines in the United States.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00136.
    PubMed     Abstract available


  1178. SPRENGHOLZ P, Korn L, Eitze S, Felgendreff L, et al
    Attitude toward a mandatory COVID-19 vaccination policy and its determinants: Evidence from serial cross-sectional surveys conducted throughout the pandemic in Germany.
    Vaccine. 2022 Feb 7. pii: S0264-410X(22)00130.
    PubMed     Abstract available


  1179. NONVIGNON J, Owusu R, Asare B, Adjagba A, et al
    Estimating the cost of COVID-19 vaccine deployment and introduction in Ghana using the CVIC tool.
    Vaccine. 2022 Feb 4. pii: S0264-410X(22)00070.
    PubMed     Abstract available


  1180. AKGUN O, Kayaalp GK, Demirkan FG, Cakmak F, et al
    Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey.
    Vaccine. 2022 Feb 4. pii: S0264-410X(22)00117.
    PubMed     Abstract available


  1181. GORSE GJ, Grimes S, Buck H, Mulla H, et al
    MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00059.
    PubMed     Abstract available


  1182. GORSE GJ, Grimes S, Buck H, Mulla H, et al
    A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00058.
    PubMed     Abstract available


  1183. OLIANI F, Savoia A, Gallo G, Tiwana N, et al
    Italy's rollout of COVID-19 vaccinations: The crucial contribution of the first experimental mass vaccination site in Lombardy.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00115.
    PubMed     Abstract available


  1184. IRVING SA, Groom HC, Dandamudi P, Daley MF, et al
    A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016.
    Vaccine. 2022 Feb 3. pii: S0264-410X(22)00091.
    PubMed     Abstract available


  1185. ELLITHORPE ME, Alade F, Adams RB, Nowak GJ, et al
    Looking ahead: Caregivers' COVID-19 vaccination intention for children 5 years old and younger using the health belief model.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00097.
    PubMed     Abstract available


  1186. HEYERDAHL LW, Vray M, Lana B, Tvardik N, et al
    Conditionality of COVID-19 vaccine acceptance in European countries.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00099.
    PubMed     Abstract available


  1187. SHAW J, Anderson KB, Fabi RE, Thompson CA, et al
    COVID-19 vaccination intention and behavior in a large, diverse, U.S. refugee population.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00100.
    PubMed     Abstract available


  1188. YOUSAF M, Hassan Raza S, Mahmood N, Core R, et al
    Immunity debt or vaccination crisis? A multi-method evidence on vaccine acceptance and media framing for emerging COVID-19 variants.
    Vaccine. 2022 Feb 1. pii: S0264-410X(22)00101.
    PubMed     Abstract available


    January 2022
  1189. SANDMANN FG, van Leeuwen E, Bernard-Stoecklin S, Casado I, et al
    Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00039.
    PubMed     Abstract available


  1190. JANSSEN YF, Feitsma EA, Boersma HH, Alleva DG, et al
    Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00077.
    PubMed     Abstract available


  1191. PAGET J, Danielle Iuliano A, Taylor RJ, Simonsen L, et al
    Estimates of mortality associated with seasonal influenza for the European Union from the GLaMOR project.
    Vaccine. 2022 Jan 28. pii: S0264-410X(21)01561.
    PubMed     Abstract available


  1192. DING H, Huang J, Ngai CH, Sun Q, et al
    The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00057.
    PubMed     Abstract available


  1193. KALNIN KV, Plitnik T, Kishko M, Huang D, et al
    Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model.
    Vaccine. 2022 Jan 28. pii: S0264-410X(22)00045.
    PubMed     Abstract available


  1194. JAFFE AE, Graupensperger S, Blayney JA, Duckworth JC, et al
    The role of perceived social norms in college student vaccine hesitancy: Implications for COVID-19 prevention strategies.
    Vaccine. 2022 Jan 26. pii: S0264-410X(22)00073.
    PubMed     Abstract available


  1195. BLUNCK BN, Aideyan L, Ye X, Avadhanula V, et al
    Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein.
    Vaccine. 2022;40:536-543.
    PubMed     Abstract available


  1196. TANGUAY M, Boutin M, Laumaea A, Salaciak M, et al
    B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders.
    Vaccine. 2022 Jan 24. pii: S0264-410X(22)00071.
    PubMed     Abstract available


  1197. TRENT MJ, Salmon DA, MacIntyre CR
    Predictors of pneumococcal vaccination among Australian adults at high risk of pneumococcal disease.
    Vaccine. 2022 Jan 22. pii: S0264-410X(22)00026.
    PubMed     Abstract available


  1198. STEBBINGS R, Armour G, Pettis V, Goodman J, et al
    AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice.
    Vaccine. 2022;40:192-195.
    PubMed     Abstract available


  1199. LIAO Q, Cowling BJ, Xiao J, Yuan J, et al
    Priming with social benefit information of vaccination to increase acceptance of COVID-19 vaccines.
    Vaccine. 2022 Jan 20. pii: S0264-410X(22)00055.
    PubMed     Abstract available


  1200. LIU F, Feng C, Xu S, Wu Q, et al
    An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines.
    Vaccine. 2022 Jan 20. pii: S0264-410X(22)00054.
    PubMed     Abstract available


  1201. ZHU D, Lv M, Bai Y, Wu J, et al
    Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in Beijing: A modeling analysis.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00024.
    PubMed     Abstract available


  1202. LI LL, Zheng C, La J, Do NV, et al
    Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00051.
    PubMed     Abstract available


  1203. PITCOVSKI J, Gruzdev N, Abzach A, Katz C, et al
    Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00050.
    PubMed     Abstract available


  1204. PASSARETTI CL, Priem JS, Agner TG, McCurdy L, et al
    Reducing the rates of household transmission: The impact of COVID-19 vaccination in healthcare workers with a known household exposure.
    Vaccine. 2022 Jan 19. pii: S0264-410X(22)00044.
    PubMed     Abstract available


  1205. ROLFES L, Harmark L, Kant A, van Balveren L, et al
    COVID-19 vaccine reactogenicity - A cohort event monitoring study in the Netherlands using patient reported outcomes.
    Vaccine. 2022 Jan 17. pii: S0264-410X(22)00028.
    PubMed     Abstract available


  1206. BEDSTON S, Akbari A, Jarvis CI, Lowthian E, et al
    COVID-19 vaccine uptake, effectiveness, and waning in 82,959 health care workers: A national prospective cohort study in Wales.
    Vaccine. 2022 Jan 15. pii: S0264-410X(21)01535.
    PubMed     Abstract available


  1207. MOYO P, Bosco E, Bardenheier BH, Rivera-Hernandez M, et al
    Variation in influenza vaccine assessment, receipt, and refusal by the concentration of Medicare Advantage enrollees in U.S. nursing homes.
    Vaccine. 2022 Jan 13. pii: S0264-410X(21)01688.
    PubMed     Abstract available


  1208. WONG WHS, Leung D, Chua GT, Duque JSR, et al
    Adolescents' attitudes to the COVID-19 vaccination.
    Vaccine. 2022 Jan 12. pii: S0264-410X(22)00025.
    PubMed     Abstract available


  1209. WOO EJ, Moro PL
    Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
    Vaccine. 2022 Jan 11. pii: S0264-410X(22)00001.
    PubMed     Abstract available


  1210. SHIMIZU S, Tanaka R, Itoh E, Maekawa-Matsuura M, et al
    Performance and usability evaluation of novel intradermal injection device Immucise and reanalysis of intradermal administration trials of influenza vaccine for the elderly.
    Vaccine. 2022 Jan 11. pii: S0264-410X(21)01669.
    PubMed     Abstract available


  1211. BLYTH DM, Liang Z, Williams M, Murray CK, et al
    Immune interference revisited: Impact of live-attenuated influenza vaccine prior to yellow fever vaccination.
    Vaccine. 2022 Jan 11. pii: S0264-410X(21)01637.
    PubMed     Abstract available


  1212. DANIEL CL, Williams J, Legg R, McGowen C, et al
    Factors associated with COVID-19 vaccination intentions among adults in the deep South.
    Vaccine. 2022 Jan 10. pii: S0264-410X(21)01667.
    PubMed     Abstract available


  1213. PENG KW, Carey T, Lech P, Vandergaast R, et al
    Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine.
    Vaccine. 2022 Jan 10. pii: S0264-410X(21)01671.
    PubMed     Abstract available


  1214. OMER I, Rosenberg A, Sefty H, Pando R, et al
    Lineage-matched versus mismatched influenza B vaccine effectiveness following seasons of marginal influenza B circulation.
    Vaccine. 2022 Jan 8. pii: S0264-410X(21)01664.
    PubMed     Abstract available


  1215. FOO D, Sarna M, Pereira G, Moore HC, et al
    Longitudinal, population-based cohort study of prenatal influenza vaccination and influenza infection in childhood.
    Vaccine. 2022 Jan 7. pii: S0264-410X(21)01556.
    PubMed     Abstract available


  1216. UWAMINO Y, Kurafuji T, Sato Y, Tomita Y, et al
    Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and universit
    Vaccine. 2022 Jan 7. pii: S0264-410X(22)00002.
    PubMed     Abstract available


  1217. HSIAO A, Hansen J, Nunley KV, Lewis N, et al
    Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study.
    Vaccine. 2022 Jan 6. pii: S0264-410X(21)01641.
    PubMed     Abstract available


  1218. EUSER S, Kroese FM, Derks M, de Bruin M, et al
    Understanding COVID-19 vaccination willingness among youth: A survey study in the Netherlands.
    Vaccine. 2022 Jan 5. pii: S0264-410X(21)01670.
    PubMed     Abstract available


  1219. THOMAS S, Durrheim D, Islam F, Higgins H, et al
    Improved childhood immunization coverage using the World Health Organization's Tailoring Immunization Programmes guide (TIP) in a regional centre in Australia.
    Vaccine. 2022;40:18-20.
    PubMed     Abstract available


  1220. KUJAWSKI SA, Yao L, Wang HE, Carias C, et al
    Impact of the COVID-19 pandemic on pediatric and adolescent vaccinations and well child visits in the United States: A database analysis.
    Vaccine. 2022 Jan 1. pii: S0264-410X(21)01672.
    PubMed     Abstract available


    December 2021
  1221. GROOM HC, Crane B, Naleway AL, Weintraub E, et al
    Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems.
    Vaccine. 2021 Dec 31. pii: S0264-410X(21)01656.
    PubMed     Abstract available


  1222. PASCHALL AV, Ozdilek A, Briner SL, Brindley MA, et al
    Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice.
    Vaccine. 2021 Dec 31. pii: S0264-410X(21)01666.
    PubMed     Abstract available


  1223. SAELAND E, van der Fits L, Bolder R, Heemskerk-van der Meer M, et al
    Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models.
    Vaccine. 2021 Dec 29. pii: S0264-410X(21)01651.
    PubMed     Abstract available


  1224. SHUKLA S, Fressin F, Un M, Coetzer H, et al
    Optimizing vaccine distribution via mobile clinics: a case study on COVID-19 vaccine distribution to long-term care facilities.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01657.
    PubMed     Abstract available


  1225. RIBEIRO SP, De Moura Mattaraia VG, Almeida RR, Valentine EJG, et al
    A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01550.
    PubMed     Abstract available


  1226. JUNE CHOE Y, Yi S, Hwang I, Kim J, et al
    Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01654.
    PubMed     Abstract available


  1227. THOMAS SJ, Perez JL, Lockhart SP, Hariharan S, et al
    Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01652.
    PubMed     Abstract available


  1228. KIM HJ, Yun HJ, Kim J, Kym S, et al
    Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12 weeks in South Korea: A prospective longitudinal study.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01620.
    PubMed     Abstract available


  1229. ROMAIN-SCELLE N, Elias C, Vanhems P
    COVID-19 vaccine is correlated with favourable epidemiological indicators in the Auvergne-Rhone-Alpes region (France): An ecological study.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01644.
    PubMed     Abstract available


  1230. MANOMAIPIBOON A, Phumisantiphong U, Maneerit J, Chalearmchai Y, et al
    Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis.
    Vaccine. 2021 Dec 22. pii: S0264-410X(21)01632.
    PubMed     Abstract available


  1231. TADAKUMA K, Maruyama T, Mori K, Fujiki N, et al
    Effectiveness of seasonal influenza vaccine in adult Japanese workers, 2017-2020.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01624.
    PubMed     Abstract available


  1232. WILLIAMS KV, Zhai B, Alcorn JF, Patricia Nowalk M, et al
    A randomized controlled trial of antibody response to 2019-20 cell-based inactivated and egg-based live attenuated influenza vaccines in children and young adults.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01643.
    PubMed     Abstract available


  1233. PETERSEN MB, Jorgensen F, Lindholt MF
    Did the European suspension of the AstraZeneca vaccine decrease vaccine acceptance during the COVID-19 pandemic?
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01631.
    PubMed     Abstract available


  1234. SHAPIRO GK, Gottfredson N, Leask J, Wiley K, et al
    COVID-19 and missed or delayed vaccination in 26 middle- and high-income countries: An observational survey.
    Vaccine. 2021 Dec 21. pii: S0264-410X(21)01649.
    PubMed     Abstract available


  1235. BLANCO S, Salome Konigheim B, Diaz A, Spinsanti L, et al
    Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort.
    Vaccine. 2021 Dec 20. pii: S0264-410X(21)01634.
    PubMed     Abstract available


  1236. POUKKA E, Baum U, Palmu AA, Lehtonen TO, et al
    Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01640.
    PubMed     Abstract available


  1237. HERRING WL, Zhang Y, Shinde V, Stoddard J, et al
    Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01609.
    PubMed     Abstract available


  1238. CHUNG NH, Chen YC, Yang SJ, Lin YC, et al
    Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein.
    Vaccine. 2021 Dec 17. pii: S0264-410X(21)01635.
    PubMed     Abstract available


  1239. CARLSON SJ, McKenzie L, Roberts L, Blyth CC, et al
    Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation.
    Vaccine. 2021 Dec 16. pii: S0264-410X(21)01629.
    PubMed     Abstract available


  1240. GOLDBLATT D, Fiore-Gartland A, Johnson M, Hunt A, et al
    Towards a population-based threshold of protection for COVID-19 vaccines.
    Vaccine. 2021 Dec 15. pii: S0264-410X(21)01615.
    PubMed     Abstract available


  1241. YU Y, Jia W, Lau MMC, Lau JTF, et al
    Levels and factors derived from the Health Action Process Approach of behavioral intentions to take up COVID-19 vaccination: A random population-based study.
    Vaccine. 2021 Dec 15. pii: S0264-410X(21)01628.
    PubMed     Abstract available


  1242. CHEN X, Wang H
    On the rise of the new B.1.1.529 variant: Five dimensions of access to a COVID-19 vaccine.
    Vaccine. 2021 Dec 14. pii: S0264-410X(21)01596.
    PubMed     Abstract available


  1243. ALMOHAYA AM, Alsubie H, Alqarni B, Alzayad B, et al
    Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data.
    Vaccine. 2021 Dec 13. pii: S0264-410X(21)01610.
    PubMed     Abstract available


  1244. BOTTON J, Dray-Spira R, Baricault B, Drouin J, et al
    Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01617.
    PubMed     Abstract available


  1245. LUTRICK K, Groom H, Fowlkes AL, Groover KD, et al
    COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01593.
    PubMed     Abstract available


  1246. HSIEH YL, Rak S, SteelFisher GK, Bauhoff S, et al
    Effect of the suspension of the J&J COVID-19 vaccine on vaccine hesitancy in the United States.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01559.
    PubMed     Abstract available


  1247. OLIVEIRA-SILVA J, Reis T, Lopes C, Batista-Silva R, et al
    Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers.
    Vaccine. 2021 Dec 11. pii: S0264-410X(21)01621.
    PubMed     Abstract available


  1248. ZHAO AR, Bishai DM
    Public health spending, primary care, and perceived risk promoted vaccination against H1N1.
    Vaccine. 2021 Dec 10. pii: S0264-410X(21)01538.
    PubMed     Abstract available


  1249. KATZ MA, Harlev EB, Chazan B, Chowers M, et al
    Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI).
    Vaccine. 2021 Dec 10. pii: S0264-410X(21)01580.
    PubMed     Abstract available


  1250. KADKHODA K
    Post RNA-based COVID vaccines myocarditis: Proposed mechanisms.
    Vaccine. 2021 Dec 9. pii: S0264-410X(21)01594.
    PubMed    


  1251. ZHAO H, Li Y, Wang Z
    Adverse event of Sinovac Coronavirus vaccine: Deafness.
    Vaccine. 2021 Dec 9. pii: S0264-410X(21)01576.
    PubMed     Abstract available


  1252. PEPIN J, Labbe AC, Carignan A, Parent ME, et al
    Does BCG provide long-term protection against SARS-CoV-2 infection? A case-control study in Quebec, Canada.
    Vaccine. 2021;39:7300-7307.
    PubMed     Abstract available


  1253. HOOK SA, Hansen AP, Niesobecki SA, Meek JI, et al
    Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States.
    Vaccine. 2021 Dec 8. pii: S0264-410X(21)01540.
    PubMed     Abstract available


  1254. LENNON RP, Block R Jr, Schneider EC, Zephrin L, et al
    Underserved population acceptance of combination influenza-COVID-19 booster vaccines.
    Vaccine. 2021 Dec 7. pii: S0264-410X(21)01597.
    PubMed     Abstract available


  1255. SULIS G, Basta NE, Wolfson C, Kirkland SA, et al
    Influenza vaccination uptake among Canadian adults before and during the COVID-19 pandemic: An analysis of the Canadian Longitudinal study on Aging (CLSA).
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01579.
    PubMed     Abstract available


  1256. RAW RK, Rees J, Kelly CA, Wroe C, et al
    Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine.
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01577.
    PubMed     Abstract available


  1257. BRONSTEIN MV, Kummerfeld E, MacDonald A 3rd, Vinogradov S, et al
    Willingness to vaccinate against SARS-CoV-2: The role of reasoning biases and conspiracist ideation.
    Vaccine. 2021 Dec 4. pii: S0264-410X(21)01553.
    PubMed     Abstract available


  1258. NGUYEN AT, Arnold BF, Kennedy CJ, Mishra K, et al
    Evaluation of a city-wide school-located influenza vaccination program in Oakland, California with respect to race and ethnicity: A matched cohort study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01547.
    PubMed     Abstract available


  1259. HILL R
    COVID-19 from a polio perspective.
    Vaccine. 2021;39:7117-7118.
    PubMed    


  1260. IZAK M, Stoyanov E, Dezuraev K, Shinar E, et al
    Correlation of Anti-SARS-CoV-2 S1-specificIgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01557.
    PubMed     Abstract available


  1261. HERZBERG J, Vollmer T, Fischer B, Becher H, et al
    SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01555.
    PubMed     Abstract available


  1262. YORSAENG R, Suntronwong N, Phowatthanasathian H, Assawakosri S, et al
    Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01560.
    PubMed     Abstract available


  1263. HELLE F, Moyet J, Demey B, Francois C, et al
    Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01558.
    PubMed     Abstract available


  1264. VALCKX S, Crevecoeur J, Verelst F, Vranckx M, et al
    Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July-December 2020).
    Vaccine. 2021 Dec 1. pii: S0264-410X(21)01414.
    PubMed     Abstract available


    November 2021
  1265. ATTWELL K, Rizzi M, McKenzie L, Carlson SJ, et al
    COVID-19 vaccine Mandates: An Australian attitudinal study.
    Vaccine. 2021 Nov 30. pii: S0264-410X(21)01530.
    PubMed     Abstract available


  1266. SUGISHITA Y, Sugawara T
    Effectiveness and cost-effectiveness of influenza vaccination for elderly people.
    Vaccine. 2021 Nov 29. pii: S0264-410X(21)01257.
    PubMed     Abstract available


  1267. CASTRO F, Pascale JM, Slocum Hewitt I, Calvo A, et al
    Mass vaccination campaign during the 2016 influenza outbreak in Panama: Challenges and implications for COVID-19 vaccination efforts.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01504.
    PubMed    


  1268. SCHMITZ M, Luminet O, Klein O, Morbee S, et al
    Predicting vaccine uptake during COVID-19 crisis: A motivational approach.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01542.
    PubMed     Abstract available


  1269. MALTEZOU HC, Anastassopoulou C, Hatziantoniou S, Poland GA, et al
    Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.
    Vaccine. 2021 Nov 27. pii: S0264-410X(21)01539.
    PubMed     Abstract available


  1270. GULPINAR G, Uzun MB
    Examining community pharmacists' intention to provide pharmacist-driven vaccination services: A structural equation modelling.
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01499.
    PubMed     Abstract available


  1271. ROBERTSON JS, Loizides U, Adisa A, Lopez de la Rica Manjavacas A, et al
    International Nonproprietary Names (INN) for novel vaccine substances: A matter of safety.
    Vaccine. 2021 Nov 26. pii: S0264-410X(21)01528.
    PubMed     Abstract available


  1272. BUCHMAN TG, Simpson SQ, Sciarretta KL, Finne KP, et al
    Seasonal influenza vaccination is associated with reduced risk of death among Medicare beneficiaries().
    Vaccine. 2021 Nov 23. pii: S0264-410X(21)01461.
    PubMed     Abstract available


  1273. LENTZEN MP, Huebenthal V, Kaiser R, Kreppel M, et al
    A retrospective analysis of social media posts pertaining to COVID-19 vaccination side effects.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01526.
    PubMed     Abstract available


  1274. DINC HO, Saltoglu N, Can G, Balkan II, et al
    Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection.
    Vaccine. 2021 Nov 22. pii: S0264-410X(21)01507.
    PubMed     Abstract available


  1275. LIN C, Tu P, Terry TC
    Moving the needle on racial disparity: COVID-19 vaccine trust and hesitancy.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01444.
    PubMed     Abstract available


  1276. MUSCATELLO DJ, Nazareno AL, Turner RM, Newall AT, et al
    Influenza-associated mortality in Australia, 2010 through 2019: High modelled estimates in 2017.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01464.
    PubMed     Abstract available


  1277. CHEN T, Dai M, Xia S
    Perceived facilitators and barriers to intentions of receiving the COVID-19 vaccines among elderly Chinese adults.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01484.
    PubMed     Abstract available


  1278. CAMBON L, Schwarzinger M, Alla F
    Increasing acceptance of a vaccination program for coronavirus disease 2019 in France: A challenge for one of the world's most vaccine-hesitant countries.
    Vaccine. 2021 Nov 19. pii: S0264-410X(21)01467.
    PubMed     Abstract available


  1279. ORTEGA-SANCHEZ IR, Mott JA, Kittikraisak W, Khanthamaly V, et al
    Cost-effectiveness of seasonal influenza vaccination in pregnant women, healthcare workers and adults >= 60 years of age in Lao People's Democratic Republic.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01445.
    PubMed     Abstract available


  1280. IRVING SA, Ball SW, Booth SM, Regan AK, et al
    A multi-country investigation of influenza vaccine coverage in pregnant individuals, 2010-2016.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01463.
    PubMed     Abstract available


  1281. NGUYEN KH, Anneser E, Toppo A, Allen JD, et al
    Disparities in national and state estimates of COVID-19 vaccination receipt and intent to vaccinate by race/ethnicity, income, and age group among adults >/= 18 years, United States.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01485.
    PubMed     Abstract available


  1282. BELLIZZI S, Aidyralieva C, Al-Shaikh A, Muthu N, et al
    Inclusiveness of prisons in COVID-19 vaccination deployment: Evidence from Jordan.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01468.
    PubMed    


  1283. KITRO A, Sirikul W, Piankusol C, Rirermsoonthorn P, et al
    Acceptance, attitude, and factors affecting the intention to accept COVID-19 vaccine among Thai people and expatriates living in Thailand.
    Vaccine. 2021 Nov 17. pii: S0264-410X(21)01476.
    PubMed     Abstract available


  1284. VOSS G, Jacquet JM, Tornieporth N, Kampmann B, et al
    Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12-13 February 2020.
    Vaccine. 2021 Nov 16. pii: S0264-410X(21)01382.
    PubMed     Abstract available


  1285. BRAKEL KA, Binjawadagi B, French-Kim K, Watts M, et al
    Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model.
    Vaccine. 2021;39:6817-6828.
    PubMed     Abstract available


  1286. MURPHY RP, Taaffe C, Ahern E, McMahon G, et al
    A meta-analysis of influenza vaccination following correspondence: Considerations for COVID-19.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01470.
    PubMed     Abstract available


  1287. ROGERS JH, Cox SN, Hughes JP, Link AC, et al
    Trends in COVID-19 vaccination intent and factors associated with deliberation and reluctance among adult homeless shelter residents and staff, 1 November 2020 to 28 February 2021 - King County, Washington.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01471.
    PubMed     Abstract available


  1288. SILAS J, Jones A, Weiss-Cohen L, Ayton P, et al
    The seductive allure of technical language and its effect on covid-19 vaccine beliefs and intentions.
    Vaccine. 2021 Nov 15. pii: S0264-410X(21)01472.
    PubMed     Abstract available


  1289. ROSENTHAL S, Cummings CL
    Influence of rapid COVID-19 vaccine development on vaccine hesitancy.
    Vaccine. 2021 Nov 13. pii: S0264-410X(21)01448.
    PubMed     Abstract available


  1290. VIZCARRA P, Haemmerle J, Velasco H, Velasco T, et al
    BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity.
    Vaccine. 2021 Nov 11. pii: S0264-410X(21)01417.
    PubMed     Abstract available


  1291. CHHABRIA S, Stanford FC
    A long shot: The importance of needle length in vaccinating patients with obesity against COVID-19.
    Vaccine. 2021 Nov 11. pii: S0264-410X(21)01442.
    PubMed    


  1292. MCLEAN HQ, Levine MZ, King JP, Flannery B, et al
    Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01415.
    PubMed     Abstract available


  1293. RODRIGUES CMC, Plotkin SA
    The influence of interval between doses on response to vaccines.
    Vaccine. 2021 Nov 10. pii: S0264-410X(21)01381.
    PubMed    


  1294. WU K, Choi A, Koch M, Elbashir S, et al
    Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01435.
    PubMed     Abstract available


  1295. MCKINNON B, Quach C, Dube E, Tuong Nguyen C, et al
    Social inequalities in COVID-19 vaccine acceptance and uptake for children and adolescents in Montreal, Canada.
    Vaccine. 2021 Nov 8. pii: S0264-410X(21)01426.
    PubMed     Abstract available


  1296. SHARUN K, Tiwari R, Saied AA, Dhama K, et al
    SARS-CoV-2 vaccine for domestic and captive animals: An effort to counter COVID-19 pandemic at the human-animal interface.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01386.
    PubMed     Abstract available


  1297. GOODE JR, Cook P, Cuttino S, Gatewood SBS, et al
    Early experience with COVID-19 vaccine in a Federally-Qualified Healthcare Center for the homeless.
    Vaccine. 2021 Nov 6. pii: S0264-410X(21)01388.
    PubMed    


  1298. DE HAAS TDJ, Yeung KHT, Hutubessy R, van der Putten IM, et al
    Programme costs for introducing age/gestation-based universal influenza vaccine schedules for young children and pregnant women in Hong Kong.
    Vaccine. 2021;39:6762-6780.
    PubMed     Abstract available


  1299. LAU CL, Mayfield HJ, Sinclair JE, Brown SJ, et al
    Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework.
    Vaccine. 2021 Nov 4. pii: S0264-410X(21)01428.
    PubMed     Abstract available


  1300. SANZ-ROJO S, Jimenez-Garcia R, Lopez-de-Andres A, de Miguel-Diez J, et al
    Influenza vaccination uptake among high-risk target groups and health care workers in Spain and change from 2017 to 2020.
    Vaccine. 2021 Nov 3. pii: S0264-410X(21)01392.
    PubMed     Abstract available


  1301. RIBERA-CANO A, Dupont M, Houze-Cerfon CH, Houze-Cerfon V, et al
    Evaluation of a prototype decontamination mobile unit (UMDEO) for COVID-19 vaccination: A cross-sectional survey in France.
    Vaccine. 2021 Nov 3. pii: S0264-410X(21)01429.
    PubMed     Abstract available


  1302. MALTEZOU HC
    Vaccination of healthcare personnel in the COVID-19 era: A call for actions.
    Vaccine. 2021 Nov 2. pii: S0264-410X(21)01427.
    PubMed    


  1303. CASSONE A, Cauda R
    Multicomponent vaccines to fight SARS-CoV-2 variants of concern.
    Vaccine. 2021 Nov 1. pii: S0264-410X(21)01402.
    PubMed    


  1304. WAGNER A, Jasinska J, Tomosel E, Zielinski CC, et al
    Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments.
    Vaccine. 2021 Nov 1. pii: S0264-410X(21)01401.
    PubMed     Abstract available


    October 2021
  1305. KHOURY J, Najjar-Debbiny R, Hanna A, Jabbour A, et al
    COVID-19 vaccine - Long term immune decline and breakthrough infections.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01370.
    PubMed     Abstract available


  1306. LIU H, Zhou C, An J, Song Y, et al
    Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01399.
    PubMed     Abstract available


  1307. MALTEZOU HC, Panagopoulos P, Sourri F, Giannouchos TV, et al
    COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01387.
    PubMed     Abstract available


  1308. GORDON SF, Clothier HJ, Morgan H, Buttery JP, et al
    Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia.
    Vaccine. 2021 Oct 29. pii: S0264-410X(21)01350.
    PubMed     Abstract available


  1309. GARCIA-GRIMSHAW M, Ceballos-Liceaga SE, Michel-Chavez A, Garcia-Alanis M, et al
    Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study.
    Vaccine. 2021 Oct 29. pii: S0264-410X(21)01391.
    PubMed     Abstract available


  1310. MAZUR A, Benitez S, Chuffart-Finsterwald S, La Rotta R, et al
    COVAX no fault compensation program for COVID-19 vaccine injuries in 92 low and middle income countries.
    Vaccine. 2021 Oct 28. pii: S0264-410X(21)01380.
    PubMed    


  1311. MARTIN S, Vanderslott S
    "Any idea how fast 'It's just a mask!' can turn into 'It's just a vaccine!'": From mask mandates to vaccine mandates during the COVID-19 pandemic.
    Vaccine. 2021 Oct 28. pii: S0264-410X(21)01351.
    PubMed     Abstract available


  1312. NOWALK MP, D'Agostino HEA, Zimmerman RK, Saul SG, et al
    Agreement among sources of adult influenza vaccination in the age of immunization information systems.
    Vaccine. 2021 Oct 26. pii: S0264-410X(21)01372.
    PubMed     Abstract available


  1313. CHANTHAVANICH P, Versage E, Van Twuijver E, Hohenboken M, et al
    Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture-derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects.
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01317.
    PubMed     Abstract available


  1314. OLANIPEKUN T, Abe T, Effoe V, Westney G, et al
    Changes in COVID-19 vaccine acceptance rate among recovered critically Ill patients: A 12-month follow-up study.
    Vaccine. 2021 Oct 25. pii: S0264-410X(21)01324.
    PubMed     Abstract available


  1315. LOEB M, Russell ML, Kelly-Stradiotto C, Fuller N, et al
    Adjuvanted trivalent influenza vaccine versus quadrivalent inactivated influenza vaccine in Hutterite Children: A randomized clinical trial.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01355.
    PubMed     Abstract available


  1316. SHACHOR-MEYOUHAS Y, Hussein K, Szwarcwort-Cohen M, Weissman A, et al
    Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort.
    Vaccine. 2021 Oct 23. pii: S0264-410X(21)01327.
    PubMed     Abstract available


  1317. TRAN VN, Nguyen HA, Le TTA, Truong TT, et al
    Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.
    Vaccine. 2021;39:6485-6491.
    PubMed     Abstract available


  1318. ANDRADE G
    Covid-19 vaccine hesitancy, conspiracist beliefs, paranoid ideation and perceived ethnic discrimination in a sample of University students in Venezuela.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01371.
    PubMed     Abstract available


  1319. MAKOVITZKI A, Lerer E, Kafri Y, Adar Y, et al
    Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01376.
    PubMed     Abstract available


  1320. FAN S, Li D, Zhao H, Yu L, et al
    Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01375.
    PubMed     Abstract available


  1321. JAMES EK, Bokemper SE, Gerber AS, Omer SB, et al
    Persuasive messaging to increase COVID-19 vaccine uptake intentions.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01368.
    PubMed     Abstract available


  1322. WANG J, Wagner AL, Chen Y, Jaime E, et al
    Would COVID-19 vaccination willingness increase if mobile technologies prohibit unvaccinated individuals from public spaces? A nationwide discrete choice experiment from China.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01340.
    PubMed     Abstract available


  1323. DANG TKNS, Rivero Cabrera R, Yeung KHT, van der Putten IM, et al
    Feasibility of age- and gestation-based routine universal influenza vaccines schedules for children aged 6 months - 2 years and pregnant women.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01291.
    PubMed     Abstract available


  1324. CHEN AT, Stacey HD, Marzok A, Singh P, et al
    Effect of inactivated influenza vaccination on human coronavirus infection: Secondary analysis of a randomized trial in Hutterite colonies.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01341.
    PubMed     Abstract available


  1325. KIM D, Pekgun P, Yildirim I, Keskinocak P, et al
    Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach.
    Vaccine. 2021 Oct 18. pii: S0264-410X(21)01346.
    PubMed     Abstract available


  1326. CHAPIN-BARDALES J, Myers T, Gee J, Shay DK, et al
    Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system.
    Vaccine. 2021 Oct 16. pii: S0264-410X(21)01339.
    PubMed     Abstract available


  1327. ALI SAHRAIAN M, Ghadiri F, Azimi A, Naser Moghadasi A, et al
    Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV.
    Vaccine. 2021;39:6347-6350.
    PubMed     Abstract available


  1328. YAMAMOTO N, Takahashi Y, Hayashi S
    Legal and regulatory processes for Japan's COVID-19 immunization program.
    Vaccine. 2021;39:6449-6450.
    PubMed    


  1329. AYAZ S, Dibben O, Chapman D
    Presence of defective viral genes in H1N1 live attenuated influenza vaccine strains is not associated with reduced human cell fitness or vaccine effectiveness.
    Vaccine. 2021 Oct 15. pii: S0264-410X(21)01320.
    PubMed     Abstract available


  1330. MOGHNIEH R, Mekdashi R, El-Hassan S, Abdallah D, et al
    Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
    Vaccine. 2021 Oct 13. pii: S0264-410X(21)01314.
    PubMed     Abstract available


  1331. MCNAY LA, Arnoczy G, Martell M, Mock P, et al
    Community-based hospitals: New partners for government-sponsored clinical research during public health emergencies.
    Vaccine. 2021;39:6183-6185.
    PubMed     Abstract available


  1332. HART P, Farrar J
    The influenza vaccines roadmap - A better future through improved influenza vaccines.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01286.
    PubMed    


  1333. MOTTELSON A, Vandeweerdt C, Atchapero M, Luong T, et al
    A self-administered virtual reality intervention increases COVID-19 vaccination intention.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01311.
    PubMed     Abstract available


  1334. BYRNE T, Patel P, Shrotri M, Beale S, et al
    Trends, patterns and psychological influences on COVID-19 vaccination intention: Findings from a large prospective community cohort study in England and Wales (Virus Watch).
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01281.
    PubMed     Abstract available


  1335. HUMBLE RM, Sell H, Dube E, MacDonald NE, et al
    Canadian parents' perceptions of COVID-19 vaccination and intention to vaccinate their children: Results from a cross-sectional national survey.
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01309.
    PubMed     Abstract available


  1336. MULLER-PEBODY B, Sinnathamby MA, Warburton F, Rooney G, et al
    Impact of the childhood influenza vaccine programme on antibiotic prescribing rates in primary care in England.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01284.
    PubMed     Abstract available


  1337. REIDENBERG BE, Hirsch K, Costello CM, Russo M, et al
    Drive through COVID19 vaccination for developmentally disabled persons.
    Vaccine. 2021 Oct 6. pii: S0264-410X(21)01279.
    PubMed    


  1338. ALLEVA DG, Delpero AR, Scully MM, Murikipudi S, et al
    Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01294.
    PubMed     Abstract available


  1339. LAZAROS G, Anastassopoulou C, Hatziantoniou S, Kalos T, et al
    A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States.
    Vaccine. 2021 Oct 5. pii: S0264-410X(21)01295.
    PubMed     Abstract available


  1340. CORCORAN KE, Scheitle CP, DiGregorio BD
    Christian nationalism and COVID-19 vaccine hesitancy and uptake.
    Vaccine. 2021 Oct 2. pii: S0264-410X(21)01289.
    PubMed     Abstract available


  1341. PALLIKKUTH S, Williams E, Pahwa R, Hoffer M, et al
    Association of Flu specific and SARS-CoV-2 specific CD4 T cell responses in SARS-CoV-2 infected asymptomatic heath care workers.
    Vaccine. 2021;39:6019-6024.
    PubMed     Abstract available


  1342. BOZORGI A, Fahimnia B
    Micro array patch (MAP) for the delivery of thermostable vaccines in Australia: A cost/benefit analysis.
    Vaccine. 2021;39:6166-6173.
    PubMed     Abstract available


  1343. BOZORGI A, Fahimnia B
    Transforming the vaccine supply chain in Australia: Opportunities and challenges.
    Vaccine. 2021;39:6157-6165.
    PubMed     Abstract available


    September 2021
  1344. ROMANO CJ, Hall C, Khodr ZG, Bukowinski AT, et al
    History of pandemic H1N1-containing influenza vaccination and risk for spontaneous abortion and birth defects.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01171.
    PubMed     Abstract available


  1345. FRANCIS-OLIVIERO F, Bozoki S, Micsik A, Kieny MP, et al
    Research priorities to increase vaccination coverage in Europe (EU joint action on vaccination).
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01224.
    PubMed     Abstract available


  1346. YACOUB MR, Cucca V, Asperti C, Ramirez GA, et al
    Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine.
    Vaccine. 2021 Sep 28. pii: S0264-410X(21)01239.
    PubMed     Abstract available


  1347. VIEIRA REZENDE RP, Braz AS, Guimaraes MFB, Ribeiro SLE, et al
    Characteristics associated with COVID-19 vaccine hesitancy: A nationwide survey of 1000 patients with immune-mediated inflammatory diseases.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01260.
    PubMed     Abstract available


  1348. BLEICHER I, Kadour-Peero E, Sagi-Dain L, Sagi S, et al
    Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: interim descriptive data from a prospective observational study.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01234.
    PubMed     Abstract available


  1349. SHEVZOV-ZEBRUN N, Caplan A
    Parental consent for vaccination of minors against COVID-19.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01250.
    PubMed    


  1350. FISHER KA, Nguyen N, Crawford S, Fouayzi H, et al
    Preferences for COVID-19 vaccination information and location: Associations with vaccine hesitancy, race and ethnicity.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01261.
    PubMed     Abstract available


  1351. MOLODECKY NA, Jafari H, Safdar RM, Ahmed JA, et al
    Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic.
    Vaccine. 2021 Sep 25. pii: S0264-410X(21)01228.
    PubMed     Abstract available


  1352. LAW JLM, Logan M, Joyce MA, Landi A, et al
    SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1.
    Vaccine. 2021;39:5769-5779.
    PubMed     Abstract available


  1353. LI L, Honda-Okubo Y, Huang Y, Jang H, et al
    Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection.
    Vaccine. 2021;39:5940-5953.
    PubMed     Abstract available


  1354. FADLYANA E, Rusmil K, Tarigan R, Rahmadi AR, et al
    A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01255.
    PubMed     Abstract available


  1355. SINGH AK, Phatak SR, Singh R, Bhattacharjee K, et al
    Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield(TM)(R)) and BBV-152 (Covaxin(TM)(R)) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study.
    Vaccine. 2021 Sep 24. pii: S0264-410X(21)01258.
    PubMed     Abstract available


  1356. MOORE KA, Ostrowsky JT, Kraigsley AM, Mehr AJ, et al
    A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future.
    Vaccine. 2021 Sep 23. pii: S0264-410X(21)01028.
    PubMed     Abstract available


  1357. PARK SJ, Kang YM, Cho HK, Kim DY, et al
    Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice.
    Vaccine. 2021 Sep 20. pii: S0264-410X(21)01207.
    PubMed     Abstract available


  1358. MANSUY JM, Sagna AS, Laurent M, Izopet J, et al
    COVID-19 diagnosis in a Senegalese company: A model for COVID-19 vaccination?
    Vaccine. 2021 Sep 17. pii: S0264-410X(21)01227.
    PubMed    


  1359. RAINA MACINTYRE C, Costantino V, Chanmugam A
    The use of face masks during vaccine roll-out in New YorkCity and impact on epidemic control.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)01164.
    PubMed     Abstract available


  1360. MOSINA L, Kulper-Schiek W, Jacques-Carroll L, Earnshaw A, et al
    Supporting National Immunization Technical Advisory Groups in the WHO European Region in developing national COVID-19 vaccination recommendations through online communication platform.
    Vaccine. 2021 Sep 16. pii: S0264-410X(21)01225.
    PubMed     Abstract available


  1361. SELL H, Assi A, Driedger SM, Dube E, et al
    Continuity of routine immunization programs in Canada during the COVID-19 pandemic.
    Vaccine. 2021;39:5532-5537.
    PubMed     Abstract available


  1362. SULIMAN S, Pelzer PT, Shaku M, Rozot V, et al
    Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20-22 April 2021.
    Vaccine. 2021 Sep 15. pii: S0264-410X(21)01154.
    PubMed     Abstract available


  1363. LIU D, Leung K, Jit M, Wu JT, et al
    Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities.
    Vaccine. 2021;39:5490-5498.
    PubMed     Abstract available


  1364. KOHL-HECKL WK, Schroter M, Dobos G, Cramer H, et al
    Complementary medicine use and flu vaccination - A nationally representative survey of US adults.
    Vaccine. 2021;39:5635-5640.
    PubMed     Abstract available


  1365. KIM DY, Kang YM, Cho HK, Park SJ, et al
    Development of a recombinant H9N2 influenza vaccine candidate against the Y280 lineage field virus and its protective efficacy.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01149.
    PubMed     Abstract available


  1366. VAN HOOSTE WLC
    Influenza vaccination at the workplace.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01188.
    PubMed    


  1367. BENJAMIN-CHUNG J, Arnold BF, Mishra K, Kennedy CJ, et al
    City-wide school-located influenza vaccination: A retrospective cohort study.
    Vaccine. 2021 Sep 14. pii: S0264-410X(21)01161.
    PubMed     Abstract available


  1368. PALACHE A, Rockman S, Taylor B, Akcay M, et al
    Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use.
    Vaccine. 2021 Sep 11. pii: S0264-410X(21)01157.
    PubMed     Abstract available


  1369. THOMPSON MG, Soto G, Perez A, Newes-Adeyim G, et al
    Influenza vaccine effectiveness within prospective cohorts of healthcare personnel in Israel and Peru 2016-2019.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)00982.
    PubMed     Abstract available


  1370. PERRY M, Akbari A, Cottrell S, Gravenor MB, et al
    Inequalities in coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales, UK.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)01198.
    PubMed     Abstract available


  1371. JOGI P, Soeorg H, Ingerainen D, Soots M, et al
    Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).
    Vaccine. 2021;39:5376-5384.
    PubMed     Abstract available


  1372. WAINSTOCK T, Yoles I, Sergienko R, Sheiner E, et al
    Prenatal maternal COVID-19 vaccination and pregnancy outcomes.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01191.
    PubMed     Abstract available


  1373. MOORE DCBC, Nehab MF, Camacho KG, Reis AT, et al
    Low COVID-19 vaccine hesitancy in Brazil.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01192.
    PubMed     Abstract available


  1374. EBERHARDT J, Ling J
    Predicting COVID-19 vaccination intention using protection motivation theory and conspiracy beliefs.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01189.
    PubMed     Abstract available


  1375. SULIMAN DM, Nawaz FA, Mohanan P, Modber MAKA, et al
    UAE efforts in promoting COVID-19 vaccination and building vaccine confidence.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01194.
    PubMed     Abstract available


  1376. JACOBI CJ, Vaidyanathan B
    Racial differences in anticipated COVID-19 vaccine acceptance among religious populations in the US.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01184.
    PubMed     Abstract available


  1377. SCHLEISS MR, John CC, Permar SR
    Children are the key to the Endgame: A case for routine pediatric COVID vaccination.
    Vaccine. 2021;39:5333-5336.
    PubMed    


  1378. LEVIN D, Shimon G, Fadlon-Derai M, Gershovitz L, et al
    Myocarditis following COVID-19 vaccination - A case series.
    Vaccine. 2021 Sep 4. pii: S0264-410X(21)01172.
    PubMed     Abstract available


  1379. ZHOU Z, Zhang X, Li Q, Fu L, et al
    Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19.
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)01165.
    PubMed     Abstract available


  1380. ALI A, Dwyer D, Wu Q, Wang Q, et al
    Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01126.
    PubMed     Abstract available


  1381. DRUEDAHL LC, Minssen T, Price WN
    Collaboration in times of crisis: A study on COVID-19 vaccine R&D partnerships.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01163.
    PubMed     Abstract available


  1382. BARRY M, Temsah MH, Aljamaan F, Saddik B, et al
    COVID-19 vaccine uptake among healthcare workers in the fourth country to authorize BNT162b2 during the first month of rollout.
    Vaccine. 2021 Sep 1. pii: S0264-410X(21)01131.
    PubMed     Abstract available


    August 2021
  1383. PRIVOR-DUMM LA, Poland GA, Barratt J, Durrheim DN, et al
    A global agenda for older adult immunization in the COVID-19 era: A roadmap for action.
    Vaccine. 2021;39:5240-5250.
    PubMed     Abstract available


  1384. CANTARELLI P, Belle N, Quattrone F
    Nudging influenza vaccination among health care workers.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01073.
    PubMed     Abstract available


  1385. TROGSTAD L, Robertson AH, Mjaaland S, Magnus P, et al
    Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: Large population-based cohort study.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01103.
    PubMed     Abstract available


  1386. ALBANI VVL, Loria J, Massad E, Zubelli JP, et al
    The impact of COVID-19 vaccination delay: A data-driven modeling analysis for Chicago and New York City.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01158.
    PubMed     Abstract available


  1387. DRISCOLL AJ, Ortiz JR, Hartert TV, Riddell CA, et al
    Recalibrating public health expectations of respiratory syncytial virus lower respiratory tract illness prevention on chronic respiratory disease.
    Vaccine. 2021;39:5257-5258.
    PubMed    


  1388. BROSH-NISSIMOV T, Sorek N, Yeshayahu M, Zherebovich I, et al
    Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19.
    Vaccine. 2021 Aug 30. pii: S0264-410X(21)01148.
    PubMed     Abstract available


  1389. O'LORCAIN P, Cotter S, Walsh C
    Influenza vaccine uptake among healthcare workers and residents in public health care facilities in Ireland over nine influenza seasons (2011-2012 to 2019-2020).
    Vaccine. 2021 Aug 27. pii: S0264-410X(21)00987.
    PubMed     Abstract available


  1390. XU X, Rodgers MD, Guo WG
    A hub-and-spoke design for ultra-cold COVID-19 vaccine distribution.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01117.
    PubMed     Abstract available


  1391. HARPAZ R
    COVID-19 vaccine safety monitoring: Might differential healthcare seeking introduce detection bias into rates of medical events and cause false safety signals?
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)00712.
    PubMed    


  1392. ROTENBERG S, Downer MB, Cooper J
    Making COVID-19 vaccinations accessible for people with disabilities.
    Vaccine. 2021 Aug 24. pii: S0264-410X(21)01110.
    PubMed    


  1393. PIERCE-RUIZ C, Santana WI, Sutton WJH, Fischler DA, et al
    Quantification of SARS-CoV-2 spike and nucleocapsid proteins using isotope dilution tandem mass spectrometry.
    Vaccine. 2021;39:5106-5115.
    PubMed     Abstract available


  1394. WIEMKEN TL, Salas J, Hoft DF, Jacobs C, et al
    Dementia risk following influenza vaccination in a large veteran cohort running head: Influenza vaccination and dementia.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01079.
    PubMed     Abstract available


  1395. BRAEYE T, Cornelissen L, Catteau L, Haarhuis F, et al
    Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01108.
    PubMed     Abstract available


  1396. DUDLEY MZ, Bernier R, Brewer J, Salmon DA, et al
    Walking the Tightrope: Reevaluating science communication in the era of COVID-19 vaccines.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01070.
    PubMed     Abstract available


  1397. PENG HK, Dombkowski KJ, Freed GL, Creary SE, et al
    Influenza immunization coverage of children with sickle cell disease.
    Vaccine. 2021 Aug 17. pii: S0264-410X(21)01072.
    PubMed     Abstract available


  1398. LIU S, Liu J
    Public attitudes toward COVID-19 vaccines on English-language Twitter: A sentiment analysis.
    Vaccine. 2021 Aug 17. pii: S0264-410X(21)01106.
    PubMed     Abstract available


  1399. LAUFER RS, Driscoll AJ, Baral R, Buchwald AG, et al
    Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions.
    Vaccine. 2021;39:5037-5045.
    PubMed     Abstract available


  1400. HAGAN LM, Dusseau C, Crockett M, Rodriguez T, et al
    COVID-19 vaccination in the Federal Bureau of Prisons, December 2020-April 2021.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)01078.
    PubMed     Abstract available


  1401. LAIGLE V, Postma MJ, Pavlovic M, Cadeddu C, et al
    Vaccine market access pathways in the EU27 and the United Kingdom-analysis and recommendations for improvements.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)00918.
    PubMed     Abstract available


  1402. CIAPPONI A, Bardach A, Mazzoni A, Alconada T, et al
    Safety of components and platforms of COVID-19 vaccines considered for use in pregnancy: A rapid review.
    Vaccine. 2021 Aug 13. pii: S0264-410X(21)01067.
    PubMed     Abstract available


  1403. PALLADINO G, Ferrari A, Music N, Settembre EC, et al
    Improved immunologic responses to heterologous influenza strains in children with low preexisting antibody response vaccinated with MF59-adjuvanted influenza vaccine.
    Vaccine. 2021 Aug 12. pii: S0264-410X(21)01041.
    PubMed     Abstract available


  1404. STINSON JA, Boopathy AV, Cieslewicz BM, Zhang Y, et al
    Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)00957.
    PubMed     Abstract available


  1405. GRUPEL D, Gazit S, Schreiber L, Nadler V, et al
    Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01045.
    PubMed     Abstract available


  1406. KANJI JN, Bailey A, Fenton J, Ling SH, et al
    Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01042.
    PubMed     Abstract available


  1407. OKAMURA S, Ebina H
    Could live attenuated vaccines better control COVID-19?
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01038.
    PubMed     Abstract available


  1408. RIZK JG, Barr CE, Rizk Y, Lewin JC, et al
    The next frontier in vaccine safety and VAERS: Lessons from COVID-19 and ten recommendations for action.
    Vaccine. 2021 Aug 10. pii: S0264-410X(21)01006.
    PubMed    


  1409. PETRIE JG, Fligiel H, Lamerato L, Martin ET, et al
    Agreement between state registry, health record, and self-report of influenza vaccination.
    Vaccine. 2021 Aug 9. pii: S0264-410X(21)00995.
    PubMed     Abstract available


  1410. LYTLE KL, Collins SP, Feldstein LR, Baughman AH, et al
    Influenza vaccine acceptance and hesitancy among adults hospitalized with severe acute respiratory illnesses, United States 2019-2020.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00948.
    PubMed     Abstract available


  1411. YOSHIKAWA T
    Implementing vaccination policies based upon scientific evidence in Japan.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00968.
    PubMed     Abstract available


  1412. PHILLIPS A, Carlson S, Danchin M, Beard F, et al
    From program suspension to the pandemic: A qualitative examination of Australia's vaccine pharmacovigilance system over 10 years.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00950.
    PubMed     Abstract available


  1413. FENG J, Li Q
    How to ensure vaccine safety: An evaluation of China's vaccine regulation system.
    Vaccine. 2021 Aug 6. pii: S0264-410X(21)00986.
    PubMed     Abstract available


  1414. TAYLOR SC, Hurst B, Martiszus I, Hausman MS, et al
    Semi-quantitative, high throughput analysis of SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune response antibodies post infection/vaccination.
    Vaccine. 2021 Aug 6. pii: S0264-410X(21)01013.
    PubMed     Abstract available


  1415. D'SOUZA MP, Palin AC, Calder T, Golding H, et al
    Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)00964.
    PubMed     Abstract available


  1416. FRIEDENSOHN L, Zur M, Timofeyev M, Burshtein S, et al
    Sub-cutaneous Pfizer/BioNTech COVID-19 vaccine administration results in seroconversion among young adults.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)01010.
    PubMed     Abstract available


  1417. DODD RH, Pickles K, Cvejic E, Cornell S, et al
    Perceived public health threat a key factor for willingness to get the COVID-19 vaccine in Australia.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)01008.
    PubMed     Abstract available


  1418. HAUPT RE, Harberts EM, Kitz RJ, Strohmeier S, et al
    Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00847.
    PubMed     Abstract available


  1419. SAKALA IG, Honda-Okubo Y, Li L, Baldwin J, et al
    A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00914.
    PubMed     Abstract available


  1420. HAYMAN B, Dennehy M
    Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00922.
    PubMed     Abstract available


    July 2021
  1421. REDONDO E, Drago G, Lopez-Belmonte JL, Guillen JM, et al
    Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00926.
    PubMed     Abstract available


  1422. KONTOPOULOU K, Ainatzoglou A, Nakas CT, Ifantidou A, et al
    Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00958.
    PubMed     Abstract available


  1423. SIDDIQUI A, Ahmed A, Tanveer M, Saqlain M, et al
    An overview of procurement, pricing, and uptake of COVID-19 vaccines in Pakistan.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00965.
    PubMed    


  1424. MAHAJAN A, Kaur J, Sidana C, Shivam S, et al
    Geo-prioritization framework for COVID-19 vaccine allocation in India.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00989.
    PubMed     Abstract available


  1425. RAGHUNANDAN R, Higgins D, Hosken N
    RSV neutralization assays - Use in immune response assessment.
    Vaccine. 2021;39:4591-4597.
    PubMed     Abstract available


  1426. DIACO M, Yin K, Seet B, Samson S, et al
    Author response to a Letter to the Editor on "Introductory paper: High dose influenza vaccine".
    Vaccine. 2021 Jul 28. pii: S0264-410X(21)00917.
    PubMed    


  1427. YU VG, Lasco G, David CC
    Fear, mistrust, and vaccine hesitancy: Narratives of the dengue vaccine controversy in the Philippines.
    Vaccine. 2021 Jul 27. pii: S0264-410X(21)00929.
    PubMed     Abstract available


  1428. GEORGIADIS GP, Georgiadis MC
    Optimal planning of the COVID-19 vaccine supply chain.
    Vaccine. 2021 Jul 27. pii: S0264-410X(21)00961.
    PubMed     Abstract available


  1429. RAJAN S, Akhtar N, Sharma S, Chakrabarti D, et al
    COVID-19 vaccination for cancer patients: Evidence, priority, and practice.
    Vaccine. 2021 Jul 24. pii: S0264-410X(21)00956.
    PubMed